{"schemaVersion":"peptidescanner-fda-regulatory-history-object/v1","objectId":"fda-regulatory-history:current","canonicalUrl":"https://peptidescanner.com/regulatory/fda/history/","publishedAt":"2026-08-24","sourceObservedAt":"2026-08-24T21:23:49.000Z","sourceObservationSha256":"6166fd223ef126a19e8ebfdaafe1fbf7c330a4cf7153cef00fb6c52c45ef757b","reportingBoundary":"This history reports exact Drugs@FDA submission status dates, source-defined action labels, and official document metadata for applications already selected by PeptideScanner. FDA's AP code and action labels are source metadata; this page does not interpret approval scope, reproduce document text, establish safety or effectiveness, or provide medical guidance.","archive":{"bytes":6071716,"lastModified":"2026-08-24T12:32:50.000Z","sha256":"d6a5fe5ae6834d4ffa421948a56cd423f489d4c5b0c2849ca3e240439e70d3a0","sourceDatasetDate":"2026-08-24","sourceUrl":"https://www.fda.gov/media/89850/download?attachment"},"coverage":{"actionAssignmentCount":1116,"applicationCount":110,"documentCount":1317,"mappedPeptideCount":22,"newestDocumentDate":"2026-08-19","newestStatusDate":"2026-08-03","oldestDocumentDate":"1997-05-30","oldestStatusDate":"1960-11-14","submissionCount":1094},"submissions":[{"actionTypes":[],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-08-04","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4b5c75d9d0537f7a01196df783204c62a77254e908b8dc1427b5a26f4c2b2a9b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-11-18","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fabc1c27841bfee3f1eb2ad4a51f002a3ede80140ee5e5862f82736f9a1758a8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-03-28","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3ad134ec9a2319bfa61dde042c159c96bf23f85f86e6a62a18675e2cb32bec40","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-09-27","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a899bfcdf06de6a5d4dded02651584e2ce183fbae5c30f5b8acb0ba9903f96c5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-11-17","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"57cd74e75947bfeee5582c7308f97d873da122d73e4ba4b6b33797588facf83e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4537a10ab1453d7fa8872a1c5fbd1a0033988a85dab7c23aeb077563c34c232","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e92ed4ed6e340ea708cff47001827f89ed24775ff9deb56c167afbe1ad378515","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Microbiology-Processing","level1Code":"MANUF (CMC)","level2Code":"MICRO-PROC","lookupId":39}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-04-03","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a0f41ffeb56b061d914943a4ad754161d796de220ded795ddcdd857f49da035","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-02-01","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"427b099569da6478dad7a51a44286547348b13c71cadf5fe9873372fd0aa7cd9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-02-01","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f9c138b8ae6a81673272524278dfe86c3feda7fb6e82fa4e3dcb9272afb64fd0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b5f1910e5eb500e81dc12b9bcf2f5397210c0e5e586118e766aac1a637d291a3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-04-30","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c75fca5f1b372cf8bb3e66d50c71c8a1d74537b9f021b37bba00f006ee613488","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1559120f0d1ffabf32086d60e35c0d08ee87349c6cc5a5950670d3c02f4a84c0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-09-13","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1be67d86addbf8e661a03d11511d89d96e9d290ea5a02bf1d8a13868ca45fd98","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"ANDA074728","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-07-06","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84da7c6d6cc162f0055b35b91290faddf421073dfeaed0d4225e315efcabd7df","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-10-25","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7ec70b557be97cd31aff220ef638dc8f31e2e02eb7be7ec9ae850caefdee0476","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-09-20","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"34a6210277238f8cc5f7dafa36de8ed8908269dd1d7e61a76c99337495378357","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-03-28","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dcf13151a2089ea67ae02f791648ace37b7329ff7fc88c5081f137537d4706e9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-08-09","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0067c8ff5f27e23ee446871f27a5e63c47ab8b15c6dec4e740ee4a3480b99dca","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-01-31","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1f4b3fa545bffa72a2cf9dc4ea3cfc5427c03712ed6c9ef486661ba8fc6b2eef","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b511a4ee0b801b36dfceb7d314bcc06aa4f5c3196a529e2309a0854ba6c7db7d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6efe507c2fa2c6e6e99148d290ce9dc5c1ab45fe15b73322deef747fae6b6fcb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2536f532302591fa5f1609d4bbaa6e8e7ca68d101ab0de533a7693411e757dc2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-19","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d2e0665fac2dc3718f3fa12929442be062aff6502821ce35bebb0ba065cde420","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-19","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"89e3d38cbf4aa83647293de761c6ec819b76be93ff4f5d33dbab2af13ded7132","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"932c9b5fb5cd6f14e39eadada7d90212ea89beb2aa675fb6cbfd3c70c306ab06","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"12cef0b5536a3cafe42f9946f90b29665b82930497c7b601a518ae3a721a09e3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"ANDA075471","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-05-27","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7de7c8a9618cc22feeb1c6f99c9707c7751575bd2a51807ddc7e2925206effb1","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA075721","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-11-29","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35a33512b87bc310dec247ad9365151d4edb5b7c9d4c77fee064a65a731523eb","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-10-03","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d79d1d8875177267553277677e83f7cd00a73f28d34809a07bf66d014b886c55","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-06-28","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bd85df6f8f555708f7baa320c5b661fc14c665a753a5e6e488333962304d8511","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-06-28","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dcd392c7f424e122c3167bcde0d7e0c42516c3da5195ac92ab60257434c0d0ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-06-27","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"60c6ded7c5b2bf8eae60333fe98e567d741afa7571a33fd697bc8ed8f4e1f99e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-11-04","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2b43f8b99be6083dea255d3264fadf25882c773000a344fff8f9d548b1995a42","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-08-08","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd99fc0cc13a94de33309ae9915800ad76edf654376e3c847bad1b984c0f0b99","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-08-08","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"17417ee78fdca1f295db03d78659d083e4b9c35c5c43a788c6cdc6f082446c03","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075957","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-08-08","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8580b61048abb195c8a5c96ea83a840946ba2f3c9cf6bbfd841b10aef405bd88","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-11-21","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"155de6eefde8d730a0d98ea9a052854c628e01a02cdc8ea8212d9694dd6cd170","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-07-12","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3a99ef3f4768efa8b986b82624fdd66a9ffacf6d62b9321a42a4158955c2c8e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-07-12","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f8cf549184bb47092c30240882af6cb9ab6166dd4186993d66d8503795850fb9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-06-27","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"430e8757966401dfa1f158a7c4e3a0348d385b0e8c26516ce9c7b77d2a6d76c5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-11-04","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"41b1a2a4ac80967aad1b2b2893b1f574d571ccc837277fd05e6034b882357430","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-08-08","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30f2787a8a905be1c4a87ed4c9c5dbb8ec723cfd9b3cbd2e13c3eb00383190dc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-08-08","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"39b23a339ec822ca20065ffee63ea9345dbd9797e74e6564ce37409e7a986718","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA075959","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-08-08","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c4cce142d2959de1dc6fccd073e34207d27826676e955974b937d4a77235ace","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-03-28","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d26ac650d5abb05c43373b1de2afe2139630c9cea5391f1904d76a2a0c1f419f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-08-27","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f44efb372368193e6bdf34ec2fe3c44cf053255019df0340f8f04c8d0f91e995","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-08-27","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"234ccc630e4decb54739296e46940934b62bf7635596470d05fc5727c2415321","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-09-16","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2871948c2fdaaf825e615dec5afca2818f2d4e0ef0f4ed850a1dda47e3651ca6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-09-16","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e5076ce020017b04aa1da0cb9b9df33c2cec093993da9ff69794979664545239","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-09-16","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"31eedcd9dc1b68ce31ce472d5c8aa05d8ff92a4a9073cebb8337f35826f44353","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-03-03","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1b917572612eee5002494c9c09e5d87781e5e5b5d83a6dab9ee9372dc197c768","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA076313","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-01-02","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75428ed34ca465f901f2dac83636ee0ae81454d27a4dfe7edd7606f5db93c959","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA076330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-04-08","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"05745ffef90b3fb8ae5cb3fc340e3bcc5c83666a9c4e89867cc10ad24a90cba6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-08-27","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bf3668fe3305f530b0621fa815168bda9ca78a61b1a5d26beda9ddc1ab2d9ad1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-09-16","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3652138bce0da889bb1e65531da95fa36d8e3ba90c535845bc9c7a8d8ad5e958","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-09-16","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"58f620000ef48765432f8d536523906a71d77b84b6fec0a392a3e1650fe46338","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA076330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-09-16","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1608be13216da99853cd705037e41e0d91fdd287f671bb1bd0c29d8b64b87f62","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"ANDA076330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-03-03","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"59695e53933986de89e0c7027db868f30c623dee55bd41a6c0ab4908ba8f5a83","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA076330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-09-12","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2c6b146345468aefc5201ae2f94febe58fe99c556a87a0f55e199eb39de1d886","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA077329","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-03-04","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"822aa0fcc7095e69bbcb5d99587df794973c655e2e1477fe8e0c78509c07d531","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA077330","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-03-04","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"abcf3034390f50d907cad4db16259278cb39873872f3d30aa69dfa7ea13e7ae9","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA077331","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-03-04","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9fedf6e4cf982aac394b02a57b45d45e62008a283efd6664e3789ba1315842a7","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA077372","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-08-14","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5e4f92cd41edadd08c744c158c7b21aeb670b2f4d46db0c95f44065f8b839d68","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"ANDA077372","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-06-28","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"96ab9d78233a915947ce1015945d248e04464d4fc2c4957f6b85bd9025b3c5ac","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":15}],"applicationNumber":"ANDA077372","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-11-30","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cca24c0218305d1a2a979ba5743f8a25201905b6ed67d079489789d3f79ee95a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"ANDA077372","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-01-31","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"511dd532e680645c05e962deee809c5b306136192692774dcd1189cbc254c3f2","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA077373","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-08-14","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1799607e47003461b082ffcffa8254262ea4978afb92d37dd33707a83ae80935","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA077373","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-01-31","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a24c5c554de937ebb7f051b4b1e8eb18725233d95713e3de8d33a30e47de2d81","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"ANDA077373","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-06-28","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"768c0d54974ea38cca6154c9b0fcdfdfc61af9821fe45c8d6ac0976536e6313a","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-02-10","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"167e017fd3cbac7e0f1f3c40f9ab1fda3f1a9fde2876909ee958ea40a05a3d0d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e9264f15e121f97dbd67e4f837ec83340f16c8a4cae581f090414d3f836b9e54","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"910fd4928039e2504e4eccd2ee18d1a89bf3e4da113956c230225c1a8a8fd1b1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"106c11de5f7c0bdd1535b413d1a6c8715fe67aaa9e8bbb08fb987beb560f5add","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-09-25","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed76a56a7acb65470479ea45f35636b3e27b4c15420a481a5973cbcdb4106012","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-09-25","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c083d591d3636ad6c49b315b6afb8a6eeddf1e77bf02d7622c1be922877f4c4f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-11-30","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a4703dc8863916b6a4482cfd981517886491c10c90711c1a754e0d936fca87c7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-03-09","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"14036e78853521154d791d84ef81997ec065e40dda1cddad526579e6442185d7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-03-09","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2c014c906e15a885a920f9f82c5d5ad0d0f410c5c1a8e16d350b6f4edca0edd0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA077450","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b5a7b134be054dd1f3ac2be84f7570ff14248c60910ed2fa3ff6a1f65324a56","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-02-10","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c5ea68562dae82b16fc4d2a4093db322713d9e7fb307e3c48c369d5c9a9e4770","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cf028f1c185e9fbc29c590d99792b90b04951d594dad95055a56d5f4bc01a424","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0e57204dc3dd12bc8a2a1267ba415e07191b5c11c9b902c47a5744c8c9c58d34","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4121d0dee8b22132bbffa2443bb2c0e2bd90023aa7e722fe7ff576b2b97492c8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-30","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6485889332bebd7ee9db97eca69e605ecc523e0ddf7eed577fdcf6e0d945b0e6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-09-25","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ad3baf491d7721cf4ecdf3de266f939f95808f52bc2e56a708ef9e137d4ccaa","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-09-25","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8395dc6a8784eba57e9afc598cc8a2f45bfe89d9dc0ff0ea520ad55f0b9fe62a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-11-30","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a8fe2e73acbaa77bea88afc69877115f468c7316fe7d9a9ab840f97f4ade3316","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-03-09","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b1b647f39053c8dd956e02c94507425495d4d30158f4b34120e14a7e919a2637","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA077457","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-03-09","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"98e9a9d7051ca3788f9ff2fbde8598403d9f6463e172289c22d4488a29ffe36f","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-03-09","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f698bd61d29f90e3f3142e2a0ceeb92dda8002d35c36bd02c3f05d968a648254","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-05-08","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"552527cc6ba14328a8641a138d36cf304bf1ff7066f321dd2bed3b7d7e74d6bf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bd498e3ebd73810279fa9028892a27d9218c83f84beee3f2f9b0a3392bd6f3e1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b19f90aa931c028ce7fa190b8d74a7389bc7fa330a5fdf139dfb5541ab7a0e98","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-11-20","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea476407cd98d13552b44246bef5b9340611fbbd5b6aaf913dab20548e037a10","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-11-20","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ba4c7c76d3bfa068c3164892efb41f204bb9958ca29f4e66e6e4295c6f9b6f5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-03-28","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"73d57e0a8ce4baa077888b7f14230a8dc81e4e013ed25f19c4e930759a34eaec","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-19","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c2c556f3c3638c3d3a66508c64578016e1dc722f96b94c9a0ee109388c4c2867","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"80aea09f8a0204630ff26e39049ff7465428008b47dfae953184509e270436af","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6da9de11ee0774c71517fa8b01698acd600cb72b301f3003c5ed27ccb466709f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA078885","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-04-26","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8397be2424fac5639e288606206f42aabf836184aca893766824087763eaa12b","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-02-10","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"afa4d746e1d07c8e1af1d5d20ef9ca0e244001325995d16d7dbbfccaf0df70c2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-07-14","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c831c46736d215154e11fa473d96641ec7d401d9bc207327aa2ff00fc6b8227b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-21","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f6dddc05428b4e0b67cb097a289dd3aaaa9c952ba579e23424cb9c7ceb030e37","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-21","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d47ac582a0cc953eb97e93227bcb60d05edef290e6db1c65544d5035db808c13","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-21","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"093f3de194940a085b80edfa5b5ae50b294ad94043a23a1ff8232d42501bd03a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-12-02","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"99288950ec3e0694e0792a1e273661dbcf2e665c67f621bc8fcb8824c1b53851","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-05-23","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9fb5a219bdac5c9e0ced1d9bde0098d4063a25bb2228a3b6b18048155b37949d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-07-07","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"60b24c0c3e54a09cde411cc9b56ffbdfe09835c7a2a945e6bd9881b49af90acb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-07-07","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"261e3fcd50acd2212cba1d163a60862f8fca5b44f0e928384f0edb8f76c53930","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA079198","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-09-05","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e22702864e1116eb7c22befb2969072377f4122bd1cdeaba7112f82ea7417d82","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA090834","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-11-12","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1a0fe4a63fb2790da4ee72b67288527b0c752f5008188ae8bd241e6f4e3c1b9a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA090834","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-07-10","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a53b8811b72945cae14de469c59c18043ff4d2d3a3231e088455054b736bf20c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA090834","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-08-27","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61a62281d39ae2ffd0d4305c71d6ced8cd13532b568313ae5e235b5a53ba0d1d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA090985","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-05-11","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a7f5a7aaaedc87b567b3ed045f7ac348f97fe258fc855de7d78777af36e73c89","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA090986","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-05-11","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bc332f7d3fbdaa10c22c7ec945afd45590aa2b04a771066f94bf544ddc45480d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA091041","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-11-12","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ee49cea687f9b4049de8f67f806fa4780d530c64a27d887c52ef75ab4b119a2c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24}],"applicationNumber":"ANDA091041","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-07-10","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fb0fdb5ac86393b385690356035092a91fd1bbde96060e5a27b8ee95836c1707","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA091041","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-08-27","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0163ef9a946dad3178591f8bcc48106a90a3335190df0e887bab86e03e16d326","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA203765","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-09-07","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cb44106edb61ba8fc32178b57d8a6d69144bf8e932a21b82cf90964f1d1cc4a7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA203765","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-02-03","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c0ddc9dbfdaa015a66507b4c07d2e011d802bdd4160f40bfa1682b39540abd1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA203765","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-21","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"05b13301648ce1c5bb1f31a2e6b87e1294e71e73dbfb6b101e06ae441414ce6c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA203765","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-21","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5d8db856745e4b640174c7e5f7b1f3d6953f86611d027c83c72491b88aeae800","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA203765","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-09","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"82d3a12c1eec21794466cc84fc4e37e65478b1a4454fefb6eab8c6ee600f3a32","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA204468","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-12-12","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ca59d28b40d5bb30fb392b413fd6bf02db3445a90fb1aef0ef5b4f9b4246ed60","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA204669","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-27","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"af23312732e0449dc1b1d714ff78c816960fb032852deb33a118207610f1ab93","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA204669","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-02-03","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"06656467192a5e54ac1f6bfe4724aa58faa8fe076e73037a929786abacdc5443","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA204669","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-21","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"27eafcc5ed41f6c23eaa0896d276f3db3a964a1e4f98b6a1426e4520dd207583","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA204669","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-21","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"319773223c455382039194ee1970f167173dccb3cea400851395d8cd51458195","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA204669","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-09","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"89c0acb86b0e4a032c649b0a80c943f67de8f41d130be1770dda434d54af4b5f","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA206697","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-19","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8814ac3f0c98f29010bf08fd460106c96a566cf1c614a24d5990eb5eb2f6c6f3","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA208086","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-12-28","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e645e7dce47a0f84d42a1c261b7614bdad639f7cd1628e4ebc13832b05a2ace6","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA208569","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-11-16","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1f4394eeacdfe87fc3c49a67535f6db87191d1d93d18bc58a0b3d521c94bfb48","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA208569","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-06","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"66ec3f359dbbc4be72507482fef4b17abab5227eb03748b47ee37f676c0455a3","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA209564","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-02-09","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cad801b59064a0eddcd7958048b2cc21da6d42ef18c08b90047105383c04e309","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA209564","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-05-18","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"257881fdaa042d93b1a0bff2cf9d948611135dbc8f74ab5f79e72125bc30dbe5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA209564","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-05-18","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"74eded8bd898bd9d12c926bfafcb17d7ad1d8d91e17c8fdb37583de46775f860","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA209564","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-03","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8cfc2d98c4826882bcda5e0f92d71f16fa9f1b5ded8a3eda09b309cd0e7d3419","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA209611","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-07","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eb1af64352528465e11fe73c9de4f7f41f4c61e47902ad2211b440f2f498146d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA210317","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-12-05","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0d6604c809d8c4b1a30cbdfba2f3ccfd9f364a96a77a84f64f4163ba84d871b7","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA211097","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-11-16","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a6770b5dc1e20f63e936de530054f1eb992af8f417177bee0e3c2b0c372ae323","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA211097","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-07","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c3f2681de57e16e0fa4f8f21d502b435807fd43594b0dbfd1d14ccf06298aa36","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA212552","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-03-30","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9558a81d9ec5057a1961d33e6639a8133739d21d2c7f47dd37553925c099536f","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA212963","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-06","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"642077a4e07bf81a5837d462e1e1a2df34549d443c0f3c62d5c7493155c3c4b4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"ANDA212963","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f493cc0dad91600f973d06575ad4f2f213f264291d86b08f1eef5c9667db515","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":24},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"ANDA212963","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-04-30","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0fc9837f9e3c2827b36ea26d01b28871e45198c991cedcebed4338b56a26b227","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"ANDA212963","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9e4f43c1ec145d354c7dfa7d881e0e8d9022df20fec7393f3404afc4adebadc8","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA212972","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-07-01","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"72529051e8d04b5bc57915d6190d0bfe4363dbbe3f1aa070979d3e602996b913","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA213155","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-06-15","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d2402e787fee145c5fef3b80c60b134e8d34d02303d4b6bf0a8d7f2a4ae92dd3","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA213641","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-12-12","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"79899972aceb4884e8a358a3021501e21f5fc5bebaa32d44dc8cae954d5e32e7","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA213829","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-08-13","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b4ec8c942bcc560f5356b7da082d1c1d14807a33f37d2a6de830ac4c95bd9d2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA213829","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5562db9f475ea9a25ed5b3d5260c02025b0230c326eaf64ef4b0203f65e179e3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA213829","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-04-30","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6653c19aa14c6af75df7e64360ec1bfeb9654e242ceb07283fcdaadcb22ac2f8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA213829","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6f7741f57204c02f37078152aca35706e6aa3f1ff28f757f5bb8020dbe45dccf","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA214457","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-07-22","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0c478cef27630e885630fc6c12d2a1ae179e43f345f08b839329cd263b8b91a2","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA214568","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-08-27","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bfc09824c95d174a4a515b81ba197e348b5ae4faed1aa8357637b47f60f0b365","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA215245","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-03-11","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"496b39e384c5d056ded4421157cf355796c5c21853dd854290adea0dc8448a2a","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA215336","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-10-28","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5b39e449e15ed3d44b1cb78e3add9691025e356986637641608da297b27854e4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA215336","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-04-30","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7c746884bccee62cdaff615e029152110f921b568cf94a451aaa3a15f5e0adab","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA215336","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e7fb79ed011c6704ea81769ebbff026cd0c0fbd463a1bd5945fe2b03c34ab100","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA215336","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9842fb55aa7a07210213d9d88a1fffa4da1de7639324f4cf7e320ce0183d9160","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA215421","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-07-22","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5130e4c1799f162c5e17d8f3b2a8f0747efd031a07c5408f0c631ddacd65be42","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA215503","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-12-23","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2477c6e58e5444be66e5e058c069d8333fce0e96df97889c25beaed495106624","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA215826","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-11-13","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9090c133a0a72c0abf0d1d769e5a3e22b3bee12255356044f9cfdf7dab31cd5f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA215826","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2680558c88f0ae8d98d60a18e1b30d1b1e87c56312adb9ab9cba9d1a592b10ac","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA216589","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-12-12","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6a8a4795f360aca81b8e92e079e32720c52df9b7c9311419b7e950f59ff80fb","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA216807","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-13","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bfd83b328de4b0e6c4035d76b378c628b403122d222854ca4c73ed4fd11b0214","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA216807","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-06-14","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8a1c3ee85dc09af60f45f2d624ee8fee24149b600e7e9220467662ec2d58486b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA216807","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-09-30","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d4fefccd7c1bdf7390d802b6637a306bec07bd0b15c96b59abbc437c2e0737b","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA216839","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-22","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6fb509b69d3fe7755462e6f551caa8347d8162478d4a20c6d1d68de9cbea982f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA216839","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-06-14","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3302045ad6dd4ae2ba4f2db59c834d5764114a53c2a38fe446d05bbb37faf7c2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA216839","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-25","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e89722cf1548f17daa7cbd679405f0751c3667afb63bbbe412bff9f4967a4294","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA217063","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-02-24","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccb40664036149db6d5ce17a8d778f712e86d46e237a6f31153c2b56c8369410","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA217193","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-05-21","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d2e7b340c7dd4c7f04eb24511c4de847bb3f22e33d6fb1281719197a2e03d749","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA217234","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-02-24","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bf77b244175270a5c11f28ecb0f76df5acc5fef5fc877881d34feaaf97c632b9","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA217437","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-06-09","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c57301196f464607037973f7278c765c707a7b809e3dc3be5f5b3937e3a52eb5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"ANDA217437","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"76a1fde66d2fb1f56e7b94f8d00f0ff79ff0ab45266ef5c81ee99b3a0766f29a","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA217590","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-14","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97ee37f291805347bcb5e4b11e4efba68ee4bcc48e596e0c6bd6fe1508edc66c","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA217860","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-05-02","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84fd19f0500ce6712cf46779948a1a153c09be4f458e62bff2d31b4f00b3cac1","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA217957","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-17","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"abbba7831d1f05c3497be577c005d9a415e2f2da0c6a34518be6c36114d5d76b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA217957","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fa57049113b49fc1d9dc08b31ae817cafebd6c9838f8069a9c9cd8e6b6544cf8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA217957","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-04-30","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"45422be0c55ad4da8a8675c379707163a05794a958a4ecf8bbc3e78a1002c49a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA217957","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4f16e9bf1d466fddda4ec7df9e47aa9e7ce94fda4b0ba6c01ecf498a9d2968d9","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA218115","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-04-02","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fddccc7781a4be17e66a3034d0304660b58e040e4e29761ffb8fa712da3376ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"ANDA218115","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-15","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fbb470eebed9c5f5f746006f48528fd5ac80c96ba7e08373ba54ca524306257d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"ANDA218813","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-15","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84bcc97fb690f7198e963828689aaca61d161c0a891a3328e8d1d619862374d0","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-11-10","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e3f2dde65bac6c5ceae19d81c039edf64fcf9f477383c97bf46d34f87ecd5e7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-11-29","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5b3725d181a7f1389e70ab6a32be3d2547940bf3d9bc159fbdcac1b2d98ee094","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-01-18","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0a838d9de691adab7d2f778c0403e721f9032dbcba6b064834827d06db7d8d2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":15},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28},{"description":"Labeling-Proprietary Name Change","level1Code":"LABELING","level2Code":"PROP NAME","lookupId":29}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-05","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e5c4b811ec1896e2f12f32b071200d80fa81f687735a7d8b08aca3822873a560","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":15},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-05","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fbbab2b97ed498b26ff1e1e8a7b78ea19f4d05d2127e2871ff5703a2d0e6da03","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-02-27","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a318cd0015c69bbaeeb8e7b9e68023d10851be906d2c57b472fba58f2b16f908","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-03-25","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2036f3251a22daf80294bf4fdd26a968c7d382baf5830ae688e3242822189cf9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-11-29","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aed8be22e052577f5afb3d4a051415329440f91a6411e14159cfa29e60f50de7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-01-07","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"12e1f25b6b38bfda1874b7765ac85d3660f329b4c9e079b6dfa616c436f26046","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-12-15","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9817306e59872bc94a1a0f78f6dafab061ec11d055efeb1f2da73f4becb925cf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-02-09","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a0852de3215c3d95857b6c5a82d12fb7a0e361f3a7d05f448cfbda258bc8a66","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA022505","peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-06-08","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d77e5e428e0e04bdb7b3498bcf75cfb20759b237036fc7981914113a2a8e6a9b","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-09-18","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"24edeab042d1ae60a233421454d802f22fed162976d0b10ec4bbf54a0896e04f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-03-09","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1d16e51150bf9e6ea2b9cc397bb879b651f891d064624d3894f2ae52a369d06c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-08-01","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8cf188269f4844bcc5410becf0ce5aae8e413993beda819cab4a3e24a8229784","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-08-01","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eab1d772d250108d9a39220bb5beecb2f882c93c09c66179546d78a559886025","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Accelerated Approval Confirmatory Study","level1Code":"EFFICACY","level2Code":"COMP EFF","lookupId":4}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-06-29","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0fc3bb1a46dc855d8d1b2584e15c32ceaaca3666740c0a1508f77b67884101e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-12-19","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4ab3aa6b0ed60fe5743a608d23c6e6b1454575a7c73c39339da3bae877d38b1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS - MODIFIED - D-N-A","level1Code":"REMS","level2Code":"MODIFIED","lookupId":55}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-12-12","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"254cc49056f13a278d7bcb64ecfaf56bcce9b98b815112b010cbbad96ca84e02","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-01-15","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"95b16efa31b77c4c69df6b66bf30721cdbe50ef5fea9dd9b5d48d19f0ca5642c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-09-21","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e88a828af16b2b49470146a461db185d83a8ba15c9bd0006ae6aea63917af785","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-02-21","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"90d0fa6f3afaa8d46b5c14e45acbb7f95c6cfe4b99a71e1978422606b6c9495c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-09-03","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a35db1158c58a7ab944baee0a6fc4eff7cd09f0716feca05909e2475f7d83486","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-07-27","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f621fb5f25ef51235ebbcbfcd7bdbed9c190a3ef7dd7ac0f93ffa13938e4062c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-09-30","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"569c0fe3f633f4c6f9239586f323560433d3ea96aa3768bbb86b66e9359b00ed","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f7cefc790b85f71feb8b8a8fd0a817b906c022e72dbcd9beead9d7329b7500aa","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-11-17","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"348e30fd8918f8d2a65e3e4a2388a550af5bb26da5293ea9ef6ce89525fedbf1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"075e37fdfa81f83fb887a626f17e891ec05dc3f737f94f27670cdbea3e772ed7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":61,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3b8c63bf0de16dc6dd830009dc3aad55ffadbae61a481fe628defd2617c3cd2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c1b48c65d6c56e28ad3d78e6094b7fc898e46a43d49fcf310439ca1964a575a0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":63,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2cf9f8ab50ccf6a61aed9f554a7ddcc871359a5d37d98c095d199fb42a29b3db","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-03-12","submissionNumber":65,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"24745353cc54aa7de1e26bd79079448c2e1c59201ffabb5cb6399f0b9368d1f7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-01-27","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"47f995411707e8ae9575e1cfe465425cf6a13c757c2be3aa969fa91deaecb0c9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"BLA125469","peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-01-27","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ec36d61616711909a018c358ae9b45061616309b5aa8b2ee15a0aac2d3a084ae","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"BLA208471","peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-07-27","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84568e2675f2e7c3ba5967836153fff09a28f0f8f79947b77ca0000e15665402","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA208471","peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5cb65508fde6ac3f17a17e8aee86e921ef4ff29fa905a1c0da2fd61e23381ba4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA208471","peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-03-12","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9248bf88d36a16982a9037e8e9ebb56d6b8f93bb43d7c5181708bef6872b2924","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"BLA208471","peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-07-30","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"821f2d803a657ea7dad40fa3556b5a63bf3105db905cc5b393f54951c46b3aa2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"BLA208471","peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5b8e1f0c680f01e5d0b34cf5b75120f9b6943e002c6af7a3045ff3e72c669d01","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA208471","peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-09-28","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c10c3631ef8107bcf195b6c9c692f4d6dce77a83999bbb8af0b5e13e7b00fee","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"BLA208471","peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3adb3be5200732550d69e48394bfdcbd790cbf982bfb6b9e8b2cca41fd1399b9","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"BLA761412","peptideSlugs":["insulin-glargine-aldy"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-04-29","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"843af8c57c51a7025c2251a9d81e44d2f5292b9a9b1eed47804bed24e84bcfce","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1960-11-14","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a8291deb2cafe1155137825943e0698a85b3d0674b2e06a0889bfed5fe8cee3f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1975-12-31","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8132f4c88544c30f117428d33a74e87032c11e7ee3d6393108f7ec57d1e443e5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy","level1Code":"EFFICACY","level2Code":"NOT APPLICABLE","lookupId":2}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1979-11-27","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a85a68cf78f4f53d778a895964f711c61c943332f52b5a579c3f178826cb3e63","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy","level1Code":"EFFICACY","level2Code":"NOT APPLICABLE","lookupId":2}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1980-02-21","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4d306044adcec5fe461c4e3d4112181e4e575772da0109e5e1712b2f5f287196","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy","level1Code":"EFFICACY","level2Code":"NOT APPLICABLE","lookupId":2}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1981-06-15","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3afdd7ce1be5e788b83f7e43bd2c8c1d4e55e4430fa374205a1383a9eb2ee25","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1981-10-09","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a962c303bf71266ff3f31df21820be5a241183096981f3b56a52b379a99bdbd4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1983-07-21","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1a41758415adcae86e5b4f391a58437612ad56cd224dd6439d37a916edf3229c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1984-08-02","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4118671b1d942826b62e919f36aceff0eb5dc27905f7239b026e6ca93c76615","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1984-08-09","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"95af08b85575d70e5ee3e52dba65ff2b36a4fb60285ee6831ca5a6ea3ceab79c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1984-12-13","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"db689c25aaa0241ddd3b22784397d0aab91391da725f898db3ddd0cadc924210","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1986-09-30","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"45b604b151fc3ddcb46b609876240974f427fc6a9498299c9dad497aa7838328","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1991-04-03","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fb78e9b0bbf843a26e8f132d02b5896de6621d4e3c38edb4b7d3276069c94927","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1988-01-05","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"876fcd23a67a9ea1571e0c9e47ce70d3b41cfc6972158877ab07c64726b898ce","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1988-09-30","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4cfd489703f5ef12ae6d7024d652b120a0b79c06277c3ca3ba7d01ec566782ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1988-12-02","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20e49df17e8e807c46d03b30232eee19a0415e976cf77751fde46fb796f8fa84","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1990-10-04","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e5d2c6ca2adfa012e7ea4f1b40d5280b8d8385c380915c4f01a4daf870b856d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1990-10-11","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0633063b241a42052ecfbaff79aeaeecd231ab0d97e091e7f0af217cf2dd075d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1990-10-01","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4aa34993f40094fb4fcc0219c129cac2caaa5d0b3ac6823cca9a3a05dc21a12c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1991-11-19","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"216ff34d3fe42966d8de6e1586d652083bc5334978956e86994aae05bb04dadb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1993-04-28","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8d6fcfa2aff70e792af33fc111a6587f8c156f0ea9fdff8c1b137c0e25cf9d89","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-04-19","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"98f7662e5c53cc6227ad1019c0449e813f3aa8f05b3b108324794c57e61b21b3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-12-15","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a5a7918431eb84ff6698f8fe52998768ae4319aff09410e15dc6b8ccde8d3ad7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-12-13","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0cc032e633bdc2a36f4637ee99a0957749d417ebf912d8393ed8ab312f83d1c9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-11-07","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"383aac4a4839ba1055f9812415eacd18f82a5d5fbe3eb70d8ccc7d0c8494b077","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-05-12","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f21091533df6a6624d5fc890af301dac650faddbb81b6e22a1daf5ac872d1436","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-04-18","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4e260565a32b4e8786b18a13c3082d8a09d2a8327ef2d63f3cf28e1c83ed3d0a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-01-08","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"491c33af4a8ccedba3e76e5ec2d6fc42a7175ec8b55e47355d974c9668b48607","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-09-23","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"55f0422fa2b60754614b54ba96c40e9722b626fbfa55d8d6f26487a3d64ad727","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-06-26","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9274e149e9d79eb96c0ebeb781420907128a5e3405813cec86ef18ab855029ad","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1975-05-20","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a678446e33e5b8d393a418c71ff8fdd3a74453e64c0fde4e1d385a5c700c4ba","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA012122","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1975-01-27","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8291df503c6b482b472116a7c2eb5a25018809ccbe0bbae358ead5d3d7b6c163","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1985-04-09","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42635a8864542dfddddeb50e51c3d9573ce1c858da134f562af710d46eb3da91","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1993-06-09","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"15b7b4c39cd9d794fd4477ad88e677f78cc0ae2bf3841afc1c444327834f6520","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-05-09","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"79ce90c19b034fa2b54cd59a146cc1a46bddb13b4819cceeee348434d2b1547d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-05-09","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bdb78a8214c3a736877db53bd296ae4ccf5a832661ab4063b677b02e3be03be6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-04-24","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c7be7332b91db1f3f952d6ae0935a783a974df430d7e5adb0b2d0b5c8ad2af92","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-05-28","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd97da02d0202a94703ebbc54515548b0cff0f9c29db3e359439171958a98f2f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-07-07","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"325f436b942efecd1f5169e21be4f225411fb4a107b6d353fb25acd6b33d35e5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-07-07","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8d6932da620b5259dc3d0a916f7b8832a8c53c55d3dd27b7273626c25d79fa4b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-01-08","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7fd9fce3aae54087f2a334abe30dc3c51b483866826979c701f45b45dbaea54e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1986-07-10","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d425161f826cc10c22b6e5101daf9507f9d8a0016caf8a41b1d8632000bf6a3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-09-25","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6dc6a651c14f55f66f79121beb52a5845e8dbaf1605620ac12364ba556553c10","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-11-22","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"90725806ef5f5bc1e2215b887a7f01552a683ce55d89541b56cc55b634960ee8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-12-21","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1bc771b10997e86bb2deb843795a5913ff15127cdb112a343f0d4e31a91357a2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-16","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b7f0b13bde32ff103965c7446ded7b766b0bca3a4ea1b3c151933d250aa191ef","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-16","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed6f22302376920a48f54ad40e7eae41ad7b4a6d88bd77ca18186ebcf11d87d9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-11-25","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b58777c3450ef0d71d15471e0ea704ebf29931d1ba0588a505d51acd8172e6e1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-10-18","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91d523ef0dda639286b295d93411b658b7768f4855caadd1298b0161b75ec8d8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1988-01-19","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"44a490bda72ff0cb970e967b6da4c57fc621fa408ee340ab47084f1a0564ca2a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"944e7d9d35dda117b9a94ec8121d21ebc82bf6f2f5a4b36cb528834a701546ba","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-09-14","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"028b8c2b1f472c108550ed1728dad7004c1f611f49bb8ee49735161859e256df","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-04-28","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"927f48d7f122eb98321885b54129e54df4a9b2f73e4d1e84f0ee5a702d40b24d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-03-21","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d726c1570da67db54fc6a749edf0925063014d8032be5a8dae7908e90622070","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d5073aeaa8a65eb744b6ec7d758658fd5d50554d1b11c60d1191b67c93a8cfb6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-10","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"50dc2d26185bc1d8220552d217b55ad0c420a0096a701daff1deb4efaf2e4a58","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f1280bf031672f8f4e7a31c370fddf606812571face0124327a6d0d53458346a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-07-11","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"53050a3c3b102600613ca8bea6a3e99a1c00c5c94aada763a17bd9ab0e21f7e6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1987-03-12","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ec729bffcff040a96e5e0caf8286f0880939b456743e1c404587729c5450248","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-10","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9dac6522035ebc397107b7535139aa3e09196141c5346905372a00c41d19d64e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-30","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3cb99ef37f53ecce07c1d43595d3c8665d59f065a935b55aac1fd63c6dfdb70a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c23c88ade5b0fd43f7d376edbf006722fc93233b54eca2b17ac083f9132932b0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4f930166dd56148b659aad149b297b1f751f2e3721c94f9a332457f6b3d7b983","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1987-01-14","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f409fb140d4a6e6d359a192c65848dcfc44efd4a474fa08055ed33b53f065dfe","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Formulation","level1Code":"MANUF (CMC)","level2Code":"FORMULATION","lookupId":37}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1988-05-09","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dab9fa6196f7c389fae0ba8328d51ce6daf8d01115faef2cc1778e83a5fe7afc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1991-10-21","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4607f6f7c63e431214c8998edcbf158de8c1484f224566beb725717a40dec3ed","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019010","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1992-07-07","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6dab35f164a41a5b06cec8d1b65a51673bbe7bcadf6859d21965c0478b1fa8e7","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1988-10-21","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb7ee09a373aadd223c40e41d04eab9232935abc28ad9cca73897ddff5977dbc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1992-02-28","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"729bc7773f5871fae95e6a3379daef65b39bfa76b215f06adf61cab52d98f2d3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-11-07","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2895fc9fafac9e6c865eb6f1f85bfb43be2eba3d377ade6e502417c99adaa0ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-10-10","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"15d2201baad63bf688ddaae5f6768e3e70b1e91f98fb405e6dc980904ad6a754","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1992-07-31","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1ea3ef36a600683a04032f275eecd3c0f1d57679e32d95153f84198471496cb0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1992-09-30","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ec3c74044eb81f4b2e4df544e68ac73deb3131165b6122563489cb4ff2d9fa47","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1993-01-12","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"72984392f03b41f524cc055141c264cda56aff33dd2bee4d0c523b4a8ba55c2e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-05-03","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"db0326c5c143a5d4c1336a24e3e4c5f550359a8ee93b35cf47de2f0306b84f2a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-02-06","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c9ed66da9f03bf6e9d47a2421ef411048243d1b53fbe9c03f2b347242c1d218","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Formulation","level1Code":"MANUF (CMC)","level2Code":"FORMULATION","lookupId":37}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-12-18","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b5c29da9797757590ec6dd211196343e5737e2da8104b691f011d8c2b67ccdec","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Formulation","level1Code":"MANUF (CMC)","level2Code":"FORMULATION","lookupId":37}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-12-06","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8dabda9ff9e8e479b077fc51a73493f62e51cb27577281d6498c628c050d5f8f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-02-16","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9985f3825ab8b74a67d411cce9e2e3d25ac40c47e488d9eac4259da33c21b00c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-06-12","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"82e01559bf872d8db24e6be6ca00c6a8be903bf8d7b8638af8c76a6f967c2bc6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-07-16","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ddd75724741da7140ed70debba03b0a724ea747ce1b2b8f0c35ff2a0d2318bf7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-08-14","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a76d0a49c7b6737fa9b32f4d4e3b387e0026c45b22101086d1e1881265535b78","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-10-21","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6609c04ad46b2577a3bdf213f5afea6fc0fa8149028a01db265444a02bc4fd93","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-10-24","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a29103cb5d9e93f80ad68c91d4990312f7ce4db7805b42e8acf83d8b33b3125d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-07-24","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7e5503477160317e11bee1c5913a46327d3357e557c2844118dfa62b43204d56","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-10-24","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"88923afc4b8f6c35347fb4d3159448fa823d4af0e4e9bb36ab773023d7017ced","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1989-06-23","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"88a95e488af331e37eb03779516cb2ec1f1c4aad9851bd95f9243c5573ab2688","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-10-24","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7556bc4b951d22cf655e3303468d0db4ba39c746bf2664f148e99f1dbdeadbae","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Expiration Date","level1Code":"MANUF (CMC)","level2Code":"EXPIRATION","lookupId":34}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-10-24","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0d1332285e24cee982c9b345057ac7f018b4e94ba9ee894fe8d1709b38bf9da5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-07-24","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"308c40b67f9e7e76f6743e3b3450fcf183d1eaf02b3c011c0b55f03f60a66973","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-12-17","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cf8ec85f1d0a367d78594d4d90a09ea7cb7f3d853f4278ef51126ee341f86aa8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-07-31","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bf23c5ebf13242bf5d32c24ff910260b3c223fce0703e6adda7e3b72a0c3f783","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-02-17","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"34fac4ceafc08ea3efcca6afe0346430ee08a4d2f366408dd0e2356816effe4b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-02-17","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e2da3fd134380bb04519c0f10528d0138d0840d718b80330d67d94ce306c5cef","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-07-02","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c3601206593e859485dce345fe7be16c7c9ab16d2f4af21b434f943fa5af5ce","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-06-21","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"510e36ebaa14aa6630a625273cc82854edfd55ae744bd23a54fdf65a92257dd5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1991-06-12","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b9a1154a47f7e66f247262594f7e0e27abca07b31d7678795ef4f10eadc346a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-01-03","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d74079da72f9b711c19e196c3613391755dd2ed6f5005168b02389fadf2c0451","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-13","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fe6a43f59d2f2f0a410e40f4fab8893666592aecbc5e1f23a00ee0cb80793e5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-02-10","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aee13abc2eb738597b5975c08ab32d5ffdedf0cd6227e9a2bccc31f3a269db1d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-28","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"51caa229d74957b4febb93023c86bee8603863edb017a41aa338acd0c371d965","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-01-17","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"67b3242be891fb83cd2f9accfd1fd1c21babe062fdbce02ac5ae92ca6d1802b2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1990-04-16","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7e3f04bd01757ad43a39dc73938c1c004b8c219485f13e682b7ba6ef11d89571","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-02","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30f649b6670bec831fc259cc5dcd7e24623ab1e36b1e6935d8895141b78708f6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-08-26","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed4d18d9be20e8d7dbc16bb707a5c5f0acb60f2ed6ebef26969d22d43888f2d4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-01-25","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"662f008ead490c9345f6aa30739f32f09e40cb0680aa247be8b24d78b0cf719a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-02-04","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f122524f0414f3efd5f1ee269b5dd2cbaf545efca97317928f3174fa9b889458","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-03-23","submissionNumber":61,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bd41c9ac9568093fb47a6bb0e534ed4ffb28818ef9aedea090703b1116fdbaa0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-02-21","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d6c45a53f77c99c8644a1a68b65e8241119740a3f2de9c04530c7a1bb33763df","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-04-11","submissionNumber":67,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c1718ddaa0f59cdda6650319d1c5b6bdcfbc20a5c886900c32f8cd7886e14a38","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1991-07-03","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e174d97c74f9df61b47c61e51377a165150703af3d0913b928fa5b25b3cd1502","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-05-25","submissionNumber":70,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"31c4b07f237e18ef78e71fcb3fba0bf89e76262c71b44543afe1c39996dfa975","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-10-20","submissionNumber":71,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f72db53ead60324fa702d13bad65e55bd7ab3978ea5a93524c53ea3ef8e89a06","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-10-04","submissionNumber":73,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"db01aa23f5dc3494395c4eda93ea17463da0f36b4f3fa85b45d6ff8a76f08c79","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-11-03","submissionNumber":76,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c329fc21c50e6b3b19fec11f48e14796677afe06f37db3603b7209db617531ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-11","submissionNumber":78,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9879bf0cfe83e7caa5116f68ddb1b660ebe79876677d6f6f9625666524c0a3bc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019667","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1991-10-04","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c290b96d48e72fffda6a2c04a948ee749b2c28ef0153819e1a753dd9f8a4d784","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1989-01-26","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6156b5f116e952805ae33fed0638a820456b2421f78f26bc7beff6225984dcff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-09-22","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"794179fc71fa518c05270fb695f01c86f7cd6f429ce923c2ce154fad0a19c219","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-08-11","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0c8a4a36601c0105c7d31bad079b61676e915d8b1a78d6fb3d04a9cb317d91ce","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-01-09","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42da10e548c0452d393b920cba5ec6e7c4429183db747496b7d445eacf24861e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-06-27","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eac09447a353291e29b989c03a5a8cdea3be890eb96eb14f1f04c9bb5a711c4d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-06-30","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a55a1a49d67fbe55e8883e57ffa85693c041952f41ceabc97a55de99f1e59c7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-10-04","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e953113b0eb58b73476fceb3ad8d151ea7135e5d9a12689a7e5c6b8ea340391e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-08-13","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0eeff8c76271286ded1ed48ba1c5c64ed10816d41d141dcfe908da64c6a87ee6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-11","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e6f98aad143b369e9d624792211f9240d52c0c4ad441e74c49dbdf228f317439","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-12","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"05a279929683f3fd539d899ff6f81c02222109336c7917e1aa4bff4972d13114","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-01-24","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"38f60a4029fece5062f4ec379cae6968357d7d9f41b6ca88e24b48a80f2eed3d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1990-12-14","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3a5df165c51e4f14114397b1d5f857b079efef43c2333af23abdffffda43101c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-03-01","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"092b07382db1dec517a5e2d5169d9f9384ff53a34223e447a1c6e3d19dd009a1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-02-21","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d309a8d4e71774574226184dea9803ccecd108d84f9b9659cd0490fedbd1269c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-23","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f6e688999ea305138fb3355ff0420a1f36c68f3d568d0d63be87a6af850ebb3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-09-09","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8037b0870a154b243e8a90b433dc255bb6eca37d3a3136e047cf74ce4dad13e7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-09-20","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8542ba6c24607d797f430b45d1b3ee3319f7166f6ead7147b0419ab0e7ded663","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3cc9c33f1739d444aa6c1206e8a35d1adbf94be96c428fddc63d472663e908cf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"03f0b6ad8a1cbf49d993f88fd5313da06d12c2e8774fd57175d866fee76abe35","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c4735c216722e0185e6a7af8cc9f5f40c70b9c34a2aa899c7abe4e89aa30e8f6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1992-03-26","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"284a7ceaba961dce7666a26ea2a77c68c48a99c254edaa365a09a049a10fca0a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-04-28","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20b6c0fdda20639cedcced50afd9ac4d53023d442fc18b10afbd8f2883b94b8a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-04-28","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e8ee822b8734c0a4d7f73b579cc77c53914dcfdcda5672698a84d8b81957b1d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-04-28","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eb7c01b1969d0a6df8240da6e7a5b66e177870d0656ec5e8a0bf3205af33c7b5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c2a50aa2b2c0fd313cbe91f2bf31e55605c555a31c4a7027f66afe3be68ef85a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-02-17","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"312af1f9534162a8c3cc1dd8604a73550671430830670cdac18cb3acc254668e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-07-10","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"71c3cde1d9a2c0abf008b0bd98a914d5b6ffb9e56e816e48c6723c95c64e91af","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-06-27","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6e4d9ba8893dcbf47bb94ccaea2f75e55d1ef81ba16ca0b2573c0a00754175e4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-06-06","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1f513d1e325664feb06d119d93295746a266022fc67232636322403637da7a23","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-10","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a3b15e1bdb75c207c0ac0ea825628cf0faaaa48aa087acf7a3320f1d8985c01c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-03-04","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1cf766655cf9c2cd07d2499aec84d28f8227c65efb3271d69182471ce939c052","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-04-18","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"71351aa0bbf1e7b666c012093ee99ae984425bc232b95e2370623be0d2fa1b2c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-12-04","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2145b539fdf3a090c9b991b6015c839afc9da315b560bdabd5ef41437f268ddd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-03-21","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6cfcd9a72ca6419fe54e4e1fd883177cc6ce7f579a8c6571c61b60a729d0068e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-08-18","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a798fb66d2f8757a93ee0548fe79e5ef016ea36c0abcfd911d864ceef7e57b5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-04-26","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c1ec99f6aba7a9b8f294f5235ee43fedc2ac33c9a4b23f42b17aa5a6dbbca724","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Expiration Date","level1Code":"MANUF (CMC)","level2Code":"EXPIRATION","lookupId":34}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-02-14","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a47e1851e6201250d6e24c2399d90c4e7e62111a519dcbfdab55900e22615bd5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-11-08","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3f7beaf31ea9ba05671928e400b938609db0dd6f561f9519110f92d0851d200","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA019732","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-10-26","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"de6ecc276f9dcaf9881d4e2b1dbfa1266a06c0cd57cea4e1a6d3efcb95d0a0f6","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-03-30","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bf962a753ced15e2d0d9879e63c619f4a814d578b660e70300a39b5b6dd3d4e0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-09-22","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"43e57628ed033ecdbc6bc1ec92c308694aa692a3ec8236b8a404bf2f49d587ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-08-13","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6d1d1eafd3ee6c21e3a412beed0e656d449bdd45ef99ee99a60095db74abb547","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-11","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"661d4bb4ebc9697524ca72e7a2ed947509a541de3dedba4d59925cdcdea94d68","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-12","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1e6e84415a43577ba875fa31895a2389512f9a0d7814d32e7b2787c1760f5589","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-01-24","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c59e20bab82b1d6110cb8444c73cdee48e043d9964472e20ebcd3b4da2940e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-03-01","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37c5a12c8742ebd7e606bf504275999164900f50b5c076513549026a0f5eba1e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-11-14","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c2a3614c26dace3eca101919493b80e43f102eaa64c0fd13cae17c8b307da3f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-02-21","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"25e6484858b4bd853d3a2635c546baa052b244db2f3fdec27f2ffccc6e3647f4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-23","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d2fc5f93b57bcb8425f624f66a04bbe3463ba55f04eba679cdb042b127758c58","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-15","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"08ba77bbf9c85f7c9613f28c2e5bd433f3a6d1ed4d619d4ec9592820e9dff062","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-09-20","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f19a36ccb58fc325270a9902a800034310983680f7a1dea96fd755a422c0cccc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-12-12","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a14bd7a7a18188c2cca7daf5b40a0443b667f9d1d114ef2c263bf3dc021a8834","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"882907b5e2b9b495e1a0bf442c2cc694af0a3373acbe44917df1ef1c71c200ae","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7987a5fc4e218c879f56099dc3fd243a30ef2116f0c19f199f72509670d3d81c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"447edad3cdaac4bf5bc974aad92a101a0e8b617fed8f5641110b2ed3652b6dcd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-10-31","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"47a53da274fd9659cfa246e0c5fcfddf1db4a5413f4ee01a23550a9d11da5490","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-06-02","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0405940a5555d336e65b4e84ecdf3a2525b75d873a2ff370bc6b9b7e71908c1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-10-26","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d3867b9316356641af28bc4866b74bde6dc7c1f15638ae936e0035ce10082b20","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-10-29","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"15334ddf29c00fec491546fc1c4acd05ac32534487a600d5c511b68fa564b83a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-03-28","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd86f682167d8305f1020587ed4bf54b0eeef3c20d80cfbc6ed17785d5151c51","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-06-14","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fe3e374703d7aad3a6b9a18eb76a2296561150babcddee9d2ab1439de5d66da1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-01-23","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b774bc622ac4e99200ddd614d6d5420115125f00023b5ae34c8b11e1501cb916","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-10-30","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a7c215c147ffc3d94cde212b3765a5ed61f34594bf4928bd8e3d855d89c161f9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-02-12","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ab8645862b0912a8691921470812e661b20ae8537b556437f5828936e5360c68","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-01-27","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e0bdf9c37e210686a5474b3296730d9da09ce263d7afb9802c06d6da79d78a89","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-08-11","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8826bede90d6994156cd35d1df34921d7a5279232a181b84226a6da66d53da1c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-10","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7fc4b0368090dad207ed0e0ba265ccbf53e617c41d9ea3c2bc8fec067e516391","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-10","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f4bfe047d8c5f00a1fe0e8821d43f187cc095decabd5c879c957bb1ccfafbce6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-09-12","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ab4b9289f761b0cc898435074f65a2977dfb237028424e77675a1c6991a63be2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-06-27","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"29feecb367908f5374c1a4f751a581346b917e49029ce32c280cf7c7691213ab","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA019943","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-06-30","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"09a099276ca10f05f40cd0e3b85bf32269a35543281601962ecb05a13e32a337","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1990-10-22","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ec58e9e61c80c4b8a6b72c4316465b48981bb32a85422f71a52c81abbbeae78","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-09-12","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cd0af99681150242f7f215ad2ba189d0d3e8c53e42581bb2af148ccd81d7dba3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-06-27","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"034c8bb5857bcb25da1513e49191b814a203ca0c0b928003e65953bd241dd1e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-04-09","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4c6678a003ca38a90ef6141751f3168d0432c8ceca2869a7d32cd4d0f717d85a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-06-30","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"04ac4c488ec2dcf5d67c58abb4d9ee326b4ec7fcb5ae769f81b9f38870001025","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-08-13","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1464875958c7604f3c4fae7819137ae7a01702b6ba3efbd2d6e784b744a52c7d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-11","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a66ce705871f006ef16cfd7defa7ca595282cfea9420c4d43c3694737344bec5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-12","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cb938bd22a6b741972f565a49f5701866eccddbac29aeec491dbff62af6e8a4a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-01-24","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32e0b709eb10dbbbe0e23812ce19b8f304f16d926f226e2e8cb43519b7b91261","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-04-26","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3a855cdd0efe865e0c31366f329849d4013e368f7227f7645a36bee006a567a2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-03-01","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccb9b61c5cfc39cf6b31db2afa3d38c30905edfe99be6e6c43122e16fa424362","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-09-21","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c3e2e28a7655849985849656444d077020c27039b0adb295e6a0d9bb9f7ab23f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-11-14","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a4b50a30095a6baa7044102a095e6c75090c4363d00b39b749e9bb091c0c8bbf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-02-21","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a27adbf28e6531411c6d8539170db432f380b37423095e5f5b5911220cbd1417","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-23","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"81fda1249f3f71bde8cb238d78b6e111bf92114de91986c218ba4da092ede8cc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-15","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9310e05ae51309c11d84eeb88ef9c51f1aba4296d2bb5a14dbaf7bc60fe4109a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-09-20","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0cce4a65f3fd1305f21f1a6900de5059edd8a500bda9031d4d1344fa549b8b01","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a66a003eb0c9e5802f5ecaf058c9803d85d7b7338f5ea610cca83b0c0b0e9fde","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f774cb45d6a8054b691cadc5434d73b74bc227504be22f0dc2f043ecb0c1ca4c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Expiration Date","level1Code":"MANUF (CMC)","level2Code":"EXPIRATION","lookupId":34}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-02-14","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d82af523508f331cb60b264ac09d4b2e8419dfd15d2794118c4749943b6b71c3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b9aa6c6292e15270388208a89c8f8f7d8c3d55e4a8d6219fb5bccd191f36cb68","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-10-31","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5892e0f4a25c54640683370d940a7346fe376fc4556d4bd5e384451b485e5760","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-06-02","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f274fef1c4ac42685b2dcb261126e10362568ebd2b04632db4a7e7862bf24bcf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-10-29","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"133e3c87544cb0b22e5ccc7158da1da36fb24b7387c93f94b69b945a64de6582","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-03-28","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fbf16b7749bcaed179a5b52884f6ffc57200fa06b39b67f6864b0abce1ab44b2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-06-14","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"128eff9cec67fb4279a9820b5bd29afb42f0ecad76123020d58ce76fc3a29fe1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-11-07","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b292e8684164cca07ae38d12d0e65fe9ffc9b0bf086557274d7e7b97368832c8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-01-23","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aad9d53196bcde368b043676bb64261e2e69cc710a97ef64eab6d4b843641632","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-10-30","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32ec9ef0dd7c4365d9832051f69204eabef2cc2ee2631b003221ed6babfe9d66","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-02-12","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ec575d8c2223c96dc39b9beb93f0a4be1bccc13acaa376851d84bf4dfd835c94","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-01-27","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c3aa6cbaf6693a0ee08b7136ef2bce5f0c658e62f8598f5523b9645ada1beda5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-10","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a43aed5eab89b9f83f8ed96b388611aec5754d08f92950ac32c84fddca3e65d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-10","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"38bd58b8dc3e375b6c6d26b72dfd9268a32238c7148d590567dcd84ce32b0528","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-07-21","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7a8fe88d8501c92dfd2aab3a8aae222d492c1e83f03650dfc21721bb1353b2d9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-10-26","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8b07c6c84ad605797cc1aae2245212d7a47ff4f31eb2a729340f4ad44839e2da","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-09-22","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"44a8b4c51a19d203d1c4667c718e25e99ae3954c9ae1472bc4a571fa3b95fde5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020011","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-08-11","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"810e1743ea5e7059e513c51dfa74ac4490c00c3d06baa013530fc0f9ead5fb74","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1993-04-16","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7bccfbe25a6b2131ede9393111a71a63ebc99567a4e06fd26e641222448e9830","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-01-21","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ffd94f332c54b955948b8e895766e8b3e7be2a9c2dbbc823d9af81d62f7ede6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-06-27","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d1032ae04193e7224ab71051aee6a549d3d6fc5da332e9661f5b37f8cf3c5a1d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-06-30","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"242b091f3bc1baef3f307e0cee345a75ea2fd9e5ccff881a0bbee91c0e7b353a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-08-13","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5dd46fc5658dc2d87f71deaa7b87c97de64575bf04a9dd42282aa78459f75070","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-11","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"45b9697226ecba777eb461054fb7c040743e996e78d5398dd045ebe979d6809b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-12","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"122f0d6087d1383526d9acd344939c6bb46b1bc7f5748ec2cf3bd6235b47b123","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-01-26","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9e17238a48333419d73fc4a1d1b837baafaa0fa4216b96c8b986eb4e85119e28","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-08-06","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8009265d047270fa7cc0d7118983d07bb96786d05f3861a8f8bea187fa08b2f1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-03-08","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ff87732bc7f3a1741e763d025ea5fe66e8bc7323814a04b759f33a04f9cf6aec","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-16","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e95aea572515851ac5c92e4d6848949611e330475979857de82eef04ad92c34d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-09-24","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4c8370ec82eea99dedd60108f9f15f4c4dfc40fea128e7db0c38ce4e8547973e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-10-28","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a548834d9f163b7b8504537dbc7a045fc71e053c8e5161f3fbb075bcf60f7df","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-12-23","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0224dd9b0265d73348b9597ac033c63dff2317c6440f19ed3948ccdaaedff84e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-03-02","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"64950217ee8088490d3394250b74e6c124aca04254c8c4db1cdf27b22230f13e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-11-09","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"06952ab3e77835aaaba1d3a40050f74a63b9878cd618c62a507e1c274e2ec17d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-02-16","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aa42a93db21ca34e3fc29828706135b87464578ff9baec288c722b62b74c1859","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Expiration Date","level1Code":"MANUF (CMC)","level2Code":"EXPIRATION","lookupId":34}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-02-14","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"acdefd92ceb8a978b4787f202f1b2daf4f34ea7b04e65efca552424e2ad26ade","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-07-31","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4d74a8f89b887cac8ba6c2469955c1e54592fbfeed179c60f32b1b138a78f480","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-06-24","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1d4b65ef892098964b5ebae88e2c53b15a3254cb7b4b52bf4bf78e21bc648fe5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-08-30","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aecc7a6ddbf6cd078f89eb773917afd7683ca9dd87d26300fd59885ed53be5c6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-08-15","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2a86db93e7817b7fb32e7eefae32b22bdb28ce806c87f09a7479c49e8a2c694b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-10-08","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"405a77746ccec6859b6cf9a3c76381ca38f74ca7495841e98873bb8fda8cf728","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-05-14","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c17a1a7c6fb6bd7e3ce5e781f23929660f1812c3a995b8814fca08f0ef34cd4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1994-11-07","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e4f505dab53de3352e2782df12a4a1f0bde05a78237651007c108493ffc8aa7c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-19","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a05364cb1cb3db5ea73851e1e9fdc29a74ceee10d1d17e8bd3b75874efabc1cb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-03-11","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dba8c5c518597e1882935a7e7d691b3e9a02a4abf4215a96170cb2229d398efc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-04-07","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2300eea0eb5f67ff25e35272028de378c9f02f11b9aa9f75bd4366f63dd2afab","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-03-11","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cdafe6a53128068e7e5e04343590e1d3b5b37d328d37655613d411c710a5c59f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-11-12","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"23b662aa5636730bc1f3cb7ea8728190253d75b21c389dc649caf2b2c01d277e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-03-24","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49c3d18ac807b3587ad20ce40187db65d4df28532d8e929e6c6b1b2b470224e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-04-22","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42f36b9ab313363b40ba499a78e02aaf6fbc65a3088ddd4ed748f41f3732eb3d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-04-14","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ba33ed8e8cacf5d2392d31c1aaba0b04251f934e9328ace14c7fb2924aac84da","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-12-04","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fffd51f8d81c763c5f74abf288f1c3e4fdb98d637f459523411423deeaf493e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-22","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d878d627df185fc9b672e85b1c2bc4223fe8f58c6d263a615ed763ce39378af1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-11-14","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b801813ac2dacd9da3afda7e8de14f1c29b0180a301e6366280bbc77361b1cc9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"47efd6b86216296da781b13e5a0a47a08be8f1cc1f8bd5901fd9620c7ddde885","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-10-26","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37b054202ed301b4f52d4133acc47065cee851775caaeddb12924f049dc1420b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-09-22","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"63d4b2f4fcf12b100abcf593e1b03bdad530e3c3ffe24f67d75ff6aab0698d27","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-08-11","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9fe627e49b3008ea35d11e67d924e95c6f8ca3a5391c1bf2fdeee01fb477f30c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020263","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-01-10","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f61e59e0cbf356ef51e5f0421b7cb979300d7ff7c7b9f525ff5132b3bf449bf","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1995-12-22","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a07c389c38ba3a72aca7a0355c7b42fef42110c5579c83401899b0a997dcea3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1996-12-03","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a7770bfc68ca9e51e27fa866ff9613e7cd85da6dacaa1d4a5d8d6d04591bd900","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-03-01","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b0bec23e3a6b59a3064c8308baddf466f013dd5e44351de740c3d2b6ad25347","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-07-23","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b28ec1805ac69b81e1a0b33291079106be6f6eab8d1c96f3d929fd9035df680","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-23","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a69a471f336652d49367d95a3600a20e66d108c76de514cd385d2d6285c185b2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-09-09","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c3a554b43587c454ca6088b44eb9af2fa6a94fb63fe686ecbded3055a69ad3bb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-09-20","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b461bb70b6c1a4c1304ac19b0c1268178cffb6d9732391d188b7e0bd5e25593d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e3f34c19b8f3d6f6aa8e2d909b2ab87cde67bce415a0af2fce9195ca7c7548d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3dd8a030a6ca59ac1a9c45a4bcd76eeccb74c635e3eec5bb72c2b784a35808dd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"09097d5ca99d542581c999ac03d0f54704ac9ed853e3db38d9de93dda97bd1aa","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-05-30","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e89659cd9f6d0adb43e028ebe881acc3b94a2ca4aa3401c7ce60b40219a773a1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-04-28","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f4ca8824150f6dcd7db70dcdc885f0d2cfcf9efa113b090d1f5c2ba5be595ffd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-06-17","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61b6d904fced69d239651b1862a4350dc39ff5aa1d1747a2aaf0951bfdc6058e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-04-28","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ad40ebb95312004a226f7c87d52bee68449175c08c046c3891c3fc13338a5405","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-04-28","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"08557859849c7cee056957f68e2fd5fd8808ebd7f1da80b95bd29db8e854274a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-06-17","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d3c3f7729adc204de556f806d1f0a71de01adf63b7944b8ad4aa94c1a050a18b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"860f1f5f7330f2e2a8ece8c2bbe2d5c65718d7b5ac025fe67cbf54578510ba1c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-06-17","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8201d17b6ad74417cecafb4bf394825e9ca04c851bf72c2cc62f3ff6d713bb9a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-07-18","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"92cd8101ab4283ff7d2b123121f702cd0500a12af82b538e69ccb79dda382203","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-11-08","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ad5db6927f2f5933091b4994ade55318efb3b57fe0985069be460a537cb1d375","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-07-10","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"98da72007803f1465d11d53a2f1778dd614543236c6f03f7db9f515b55b41c49","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-06-27","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"83b9d0fc6b5712601d1c9bbc79ffa504ab57599b3c66737303de72b5da95148c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-02-11","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e37fda7da71ca174d9ec67b947c065d0eda513fba06d4a38a4292d6bca7a4f9d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-06-06","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"62990509d6243e454dde227aa05d3dff5841b5c50cc9db5f87143c6d5d5ba547","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-12-23","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1ac44119042c7f6ca79beebbc3da8274aaaee0b5cc251d9cb359ac55b45b18bc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-10","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1ba58bd3de80dc385d91f9677a6e6b292f77c32f18080bd8be41e2a8598ab3c2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-03-04","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dc5b439b6dcb9fc541007d0a3e998a48a0efae5f0eed83c11f0cd3c03b2e8057","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-04-18","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20d3477b24a307d8a3833829dfd9140dae3a154f7b77b7b93773028f5d5015d0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-12-04","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"10343a9134c0e757fbd2975d6933df98ae8df1cb765254ae6a777b6e75c1f3b0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-03-21","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b97510b6405a502c6f9e91180ca6571e995b99c01626f70f632a244b6a7cabc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-08-18","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a451a4d4d4e0e3452e3ef1d9cd85fb43bcff2df228b3e676cd2063233eeea0bc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-07-29","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5c12e05d51b43dfb569fedfecef2d8ac6949bee89125609f1429c84d1ee1faee","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-08-13","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6366cf8060b2246174984cec0a57746067c9ae5b880a37f2707ce7d44f4b63a2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-11","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0bb31702eac811a4ad87bf06f42d8b2d3cafb86403d4abd3fa806efb7e8c9fe5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-12","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3703c7f312c044fd4bab5a0b2540aca74c949bfee5d2f167a45c969b9d86febe","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020517","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-01-24","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bce8f4e473926a1160f3687a0cfce7992827aa2dd41988b65e8a22f8aa264fcf","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-03-07","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6b023c5344dd859ed0c498001e1ec37251f035f9943ae48c3b1a204092ce29ee","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-09-04","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2f7b8b998383d3bd60c1f7e62614574e3c40bc1cb605106237db16be39a2a241","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-03-01","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4e3b78f9dcecfd90d0161402704eef3133ba1ba2c0e41d502966b770b37ef7b6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-09-21","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5abaf5e3139cef16b3e196caa6b597192f3c0cb6e41647e76f327236a6a0122a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-07-23","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"12a0a7386c1740d7a84630dab1bf7bb8c6da1bddd0515e9b683dd18784ac5a58","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-11-14","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1290e58461b2be1f5e77e31b5799b0f6c23cb44c8749c9d327ef080893a8f0fa","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-23","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"05359c535b837970d4dd1f33eba3b3f13478ed544468eb1fe91c731a8952c185","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-15","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1bc019766575ca7f1c4d6732fe6e209b2a5abd69061ae14316d7686f173deb18","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-09-20","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7bb6611e46eb4edadfd768706a009d28d067bddfe5ed0ae292a48e25b7854c86","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ff42d3f40be6f883f7d180f47941f39006caeba9ced6fe51f71c0b6706e9b83","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1997-12-23","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33e799da58a63fce84b8d763a81d4009177e426c7b96c0da5c26622597cfe19d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"458dfc52c59bf214a15f87a5538ce804982c96d128eaec44c67389d0c504d7f7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cf0e27ce5bf85dc722c1dd362e6f75a3545c2d2e8f48f8dccd3f5a1880ea537e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-10-31","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f0ab5de50c6a8090de0f52dead49baef299d726db1d105487de67d06f39b1e72","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-06-02","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"820cf5bf40950a3f15fd8899de5461b154af00c08ad2500c60d01f3ada3d2c37","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-04-09","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3336bae949e982205999036b0e4d3574b14f4bcb45f8f8d4d8092974c4f3e3b7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-10-29","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5704df3ed52fbeaed5488277703fcb8d3b98dc3c4d9ffa5f20184a3668402a42","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-03-28","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eaf057b672cd1ab1b04d13e1855d241070f000b7a64c8f1ec133f939f7691319","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-06-14","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c7f453f4308ae7ab3c3e771261872288b43ff03cb6a3bc5964b1cb4df941dbe0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-01-23","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c7f5d88d34fe6ed972aae3132fbf09e9b0f4990c1430add51a3be5c5555b8ef7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-10-30","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a21e12002b2854c3c7b0984b818f8c66f87ca78410bb7ef5600b207948f92421","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-04-18","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f330b6fb6bbb066349a4ee1f5388fec92544d4384ebfc6f9f13475a812c0b06","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-03-18","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1eb8c6f6e4fd486e36cc42f11b009efbb2a766a050e9e58ca36e19e56b67644a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-07-29","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df193664e57f5726a266d813d149f03f209a57d9e5d9d0a19b4934c948fbc9a3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-10","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a709e41576678644ba61c4a3f3ea76d903427dcb8bd5a847339840c402aff5bb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-10","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0d42b49ed0ef7fe0e36eb555747e9c095abf7b45b767fc6b303ee117facdc57","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-02-11","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"27ba377d48a4632d7b5214bea959bc75585b0ca85e8eb99d57e15e70ec5bb019","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-08-13","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bed46c3892997833f0ab111b788c1e8c5f135b7c3ff8ce7917d3409dc44ee37c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-11","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e8218068efcd74e63724fe2c918709a6243c9fcbc9543c598b58b0bdc6df16ce","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-12","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5bdcd84811a06a6ce4845b707c5c9fc7e1ac06f381cbdc671b053d8e0576ffb8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020708","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-01-24","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5462da525636d55d10d1a222d0e6b541ba78ca2f750d64c72478b2da86ae5402","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-06-22","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e9972cee540fdc54fef8a7674977540e763cb6007a01fb5162b9eea4ad6bc14c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-05-30","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1717970aef38b40aff216272b7ffb57e58f7b49e150aade2e0d0e9dede68d459","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-12-23","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9d0499152165cabea8d03d6bcb15a0b0b2347bf6640a348823de9e0c31b5b91e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-11-14","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da526701f7b58bcb758d0920fc7327caf2c9df0eae9550611db2950f9957c112","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-08-18","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33bacd69a46e72ac32b55b6691232108ef30b634b5edd860afcbc4b02afd46ac","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-06-28","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1514fabeb0ec5b283bea448a1dd7d6cb3d91cffd9620038415e2643a5c9d91ed","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-07-11","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9c0e4649fe606153256695ffa36f42d0f5cf6343fe1ead8e42532c52ea29e167","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-12-15","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"edb9ab0a05fcbd359f854071cde19cb91679967fc27b5e8d6d4a6a59ba93b63f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-12-29","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"58577e1324f3fdf3372ca4766a860bd81d9e9b9b7eeb162ea86bef743f7b426f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-01-16","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a3883dae84cb5e0501bf83385fc70719585d3f3fae369538ef956e6330c302d4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-04-26","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a14188881ce1429405c8afdb606473ea07265d6061205c5ecbb8efbd071c4f81","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-04-01","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d158e5c6f2147a9daa250fbda66c3847a746805ea5dfaef61cf33ddda7668786","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-04-26","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c7f56ffe97e88114c2fdefc7304295f88c97a8f2530fc3bdbafde94469c4e535","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-03-14","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1a06fda4338cee0523c91720548fb9511ee09a801af97bba145e1a853e2b3af4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-12-10","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"23881d7e9fec153cde55f18582e6a031fda9f5281218227e4d7744b89cbdbf4b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-10-08","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1042f5c98d207fc84da34311f330e0c50a85d392d873c289b3fb544b76687ad0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-02-11","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20fcc419154964c96b444776437d74e723a4e5238a34b9d93fc2beaef2490657","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-04-18","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccc080ce73097622c1b6ad3b5691ce2ba6826a5a89f2603813bd0d68ce7adcac","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-08-05","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cc725021e247a822a176d5e34aa396986f827d5d4704e36e22985532a60e5412","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-07-06","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c8e13291e90727440889884ad539dd44890bf375675583d1059fc6c92cc680d6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-09-03","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"900bd3987960286bcb5b60ded0254dafa49647dc336a5ae3eb236ef8c9164f87","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-03-11","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"55697023a4d6fde394a6fd71e4e5af92e18161d5540979ef2badcb0a6a0ff046","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-07-20","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e7f13124a68567ad122f15faaf48294c334b6c9e4db5a932c26e47e52ca7618b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020918","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-03-01","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8af54d8b4e19c747b6ba20f5ae52c359c5b536b68dec45522665460b3fb3cb91","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-09-11","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"71170b6d5266b66a5902398da94106bfb6db1d28c5458366a848df5d7baff93d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-07-19","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a6e7617029cbce1c0f5a2764a8f72d642be0e710b997edc978d92ab12f22d10","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-02-24","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"444b9cf0c0a54a9027910308d0fe8d5cccbe91f88dc01f1264d2df1c3363f329","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-09-13","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"223f341f7f65862aa412431e33dec83a9614f19ea66f4b24e1142a5cf4aeb5e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-01-16","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"512cb4582d9ac6cfa98375e740e64badf1a66f99deec5540f0e66544f6802eb2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-11-12","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eda0c4f85cb96da244291faf9c6dae6e1368916981ef30cc6606aaadb82351ed","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-09-27","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7a2f6b5fa649020a2274bf37ff77b4b9b545e49c003399e1ff82c1296a1a96ce","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-03-27","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a95d1f3d8ffa0047a61f9c6c21b4d9e996204ef89f612c08c630d33aacf1f768","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-08-11","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f1977f8064d2edb2d98cd02c69f84e669e8f440e7706aa35728ab1dafe0006ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-11-15","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8470dd76c3e7d177efed1071e38d2ee3ee4cc770ebee226268b5919a26d726aa","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-07-21","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"51216856653c4580e6830ad7bb3fad8a0653542c37bc8be4da4bcb1f943dac5f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-12-18","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b1b7201396468af8c950c5565f321f6d47fd9d9e0f914f4ee76091dd4ca90ada","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-04-18","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"16e175d122fb00cf3a15b72fb16bdfd637a1309454938dabd0b12f785458a1b9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-07-06","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"67f96891932601c948013cb33f853c530eee7eff99cad07bb605ac86c9976e5a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-20","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b96c2441a9c51ba06a6ec317fdaaf09c742204037efc9711aed78df5e3ba96f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA020928","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-01-26","submissionNumber":60,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1f745fcecd2bfac69f1bbdf9559e44b157bfdc3c4fd2a74243b539651aa51192","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1998-11-25","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"28e53759dc2b679b75eb044d65b6c21f10dd514154a7a4e714ef6d30c462adc8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-05-17","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bdcd14da41db8390b668302a67a4e174a6b8bc0aa40b2ccff2000c3f1bedd119","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-04-19","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"040cc02865808e93a75510db836582aed4f78169b9c09fd5280dd6bab949126a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-10-14","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"074ab06ef872277cf5d45c880edb34aa076870e0cae6816bdec592339020ae5e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-05-10","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1603704c9bbfbdc02c4e4464a4c6d6bf7579da1a61c5f366a134b786aa30d5f9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-05-10","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b2770659b42151eab8affd9599c1c9099735031251f5d56a334bfee54992ed5b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"1999-07-13","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fa52861db55ad0d122793eb861c0f142eebbe90bb97bece92d04e91da4c7dcc5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-03-03","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"375b4db58ad0910ea4d6ecadd698c74d401ca644db90bb7e967f4b829ae96258","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-01-25","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f0c1bb3ea5f1db54275fb64e69e554da0fa3be1d10e595551316743175cee01c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-09-30","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bd0961b45936bf5c81335c3b9ab2aeb1d84e1f052fa9d1937bb60c989ca05067","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-11-30","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7af2a239173ac45540c31a3446d29139e8d075cb525c84bb576681c052b95f1d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-05-19","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d4685838ba8c74fec38a88ff32f3c63c54f39479bcfd1ccb32ed65b08b87f28","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-01-30","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7bbd1bd9afc239e8ffdd203b79b6b889d13085b9287d6e38f16a169730e01ec9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-07-02","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61295d78609871d7858048caee56e51fdbe2b5ad765bc50bdf05ff88f7305911","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-17","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"576f0e33003c9905dcb55b5f9830feb75654f0fa8301e9d310629520da94cfa4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-08-21","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e86f3d86cd998f51bd98675117eea7f5936dcc451b0a2d792dad3e5ba60b61ad","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-05-18","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8058495dfb46114466faf5426c809cbeea50942bc8bace80d070ab1164bd8e7b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-05-20","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ba2adf96aba7a57eb6268efc905e6e25da0b3ecd4a89c1e24ad9d87727a483eb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-07-22","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ce8268ab1c2a0ad233ea3729b68801d31748ff5d8e899cb5afdcd1dacbfaf269","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-21","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c5385c43f008f0eb10c43cfce12b7b22c6633c4379282f88dd85cbd83c4098f9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-01-03","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"76a49d9b1bff15761830b104cde7dee866c50e6063d9ad35be8b0e1b92ac320b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-03-30","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d735343b289411281ef975180d249ce0e5e317c9f140b05c88ab865091b0c17","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-04-11","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d0f9fb598823122089d84888993386a8affb68bb291a77400bdcc4c616962669","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Facility","level1Code":"MANUF (CMC)","level2Code":"FACILITY","lookupId":36}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-09","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"436b1537a951340c9dba26b7da0bc56e9f10f4ead6711f3247751c9940d6b7c8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-01-05","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"806b92a694f5fa6fdde7ac14c264bd4e3fd19b035d7f9d9dcc52d7048332af4d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-11","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4844ad68c65b47e39db200a3c6d6fcbaaec100bf4aa1ae4b9a269daf8d2d8ef","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-13","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f1b3785728121f2356a69e3b0c669aef0f89efd1c2f184f22ae25de0d13e895a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-04-19","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e11d2d1286a425210144adfa16453297ba0b1490a97c6763b4fd77b05a0c2bed","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021008","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-12-18","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f304c8d9c2b92dccd0adddbcc9ac73c3091064eeeb2135b24a869c040a891dfd","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021060","peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-12-28","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"68f290efbe21f9f19a4c9f7140e1e2897b36cb35d56b5756ebd78ac4c8ffca1e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021060","peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-05-26","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d23726e638d169e149ce092dd5ba9bf1eb3d7f70c5d6157cf55a541e2bcb0a08","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021060","peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-12-19","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2b374594295b872552bbe33d5434a563a57c924fbdb769ab6ba8970fabb75430","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA021060","peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-03-16","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3e5f46e58f25fa0f0ab959c7db02a1940905689db80e2c861a7c684ecb865d2d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021060","peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-04-18","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7b3287a26ec4f16bb7df6f915bcd06168572274b42a5ef4ff385868ffda525af","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA021060","peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-09-01","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f4275242edd4b789a5787a1b3959dbcac39a85981179fb84425c01cd9f0908d7","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-03-03","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e9a42a7db8892524a81136792286adc267a6c1d2be400c455ede189b273da8ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-09-18","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c71d2eb949e3c7e477a5ab8ff70f2cf8952dba6e96b0d801b334233b701500b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-17","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42d06925b1ab990c1c2d161b0749468f2ec58af0e6040ce19e59a9688b8f46ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-23","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"77d901ab88d9fad190bda153831f7fbb04491b30a443813a0c232b1439a3eb01","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-08-23","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f7e0a57e127c6214c4a0dbc4a454bace71a814333ef61478c8d6a2c45ccfc16","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-05-23","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"674c5770215a07dd06d0c0175be2d1643251e8903fed5d41f6733a7fdd1ea5bd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-08-01","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ec948757d2ad936e1f1642083fa0780af5d08e1cf0bba6842e465ce13de296ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-10-21","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6552ef49c4d6d1565cc6b6af1facd9cc8c9ec12d2e76b2b5860f710643625bdb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-09-28","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"68db0f80bef486b64f3eccb7cdb0757c86141f08e159e1de4d7590d65d2ff079","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-15","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"437babb97c02c29b0dbe8546b8cab0dacb69d898b8c9e563cd35fa49a591d1f1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3b5e0e8588db882e8682dafdd5faa417ebbdfd5ae0a3f1ea699b5f47366cd7bd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2000-10-16","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"74030225e2bae05631d406889c5712fa5574ffea2229de2adef66588123b6f42","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-01-24","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c41842fe3cf48f4a0807fdd7462a394845a22102eb1aa67082aa2acb10c1c348","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-06-08","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75839dcc2406150b991c1510bd80f394016ab09a6a66dcd46a82463b8b4580fb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-07-05","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e351b9362b84a957f77eeb91f4d076f61b8dff76777bca14d92cd7e73e86fb16","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-09-08","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3a29926720948aab504fd1244989f840c185446e43a9103511155df03ff64b97","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-08-13","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1cd3cd01119dec64ade9da22c9d157ef983b74f153f444c62abf620ad4058a9e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021088","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2001-08-08","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7cb6c945b14890f033d70da109b2ee7a4dc3499b8dda1e46aba5c0b2d91390c0","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-11-26","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"17ee559fb45a7848327d48b6a263054973e4a1b23a875b5168cb6d8b3cf05709","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8},{"description":"REMS-Proposal","level1Code":"REMS","level2Code":"PROPOSAL","lookupId":53}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-07-22","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b212d29ede666ad06df0cf903057c596ed5891c0ae9034869445bef18565305f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-02-28","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1118e280bb7e1d78eb497122ce0684c4d7ce1eb25502d0e0566a2d09cf9d8cc5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-06-25","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"96a67dce32b07497f2106a064d08b8561b8466f3a83f1ac2e655d44300df8b24","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-06-02","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2800ba3d543cef7e2658cf2a907a2adf2f398abf8fb485687d4fe176b60b6cb4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-08-10","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49ec33e709f6704e1e155424ee0e13be2229bedaae1ce405f0f8ebb8d1262fe7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-03-13","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"93f48862d53022cd5708d11f41ccdbb225e1aab5d1daaed4f0852a094ee0c9b6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-02-15","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8f2682df780b4a295adc7a840493be0c4136fcd56a940e4d0d05c2acff72c66e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-03-13","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9a51760982e8bf3a6f06591ceb7f6760552dda5e7523ae33a8f064a7e52144c8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-08-02","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed9a2022b4af8d5611bae627270cd9668a7799dbddc940056fb56e670b0c3a40","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-08-30","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5aca1c689fc2b6eeedfd05a1b1ea5bd4957eadc59b09935498dd4bf23708fd58","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-03-05","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d2fc3485f3da28e083e0b9c98c67b196d28f2fa0104fe39932424862c49208d6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-01-24","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"40d0518092041dfab00c9000e3f51d9d75d293d9e1fa5930f056b510446bb0f1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-04-11","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b6664dc008e12c49078d07a3dc2a0ec7db5e6f490f93cb4104fef040a58e02d4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-09-03","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2f13adfc49e284432c8203530704125a26e7dd01563529243767a7dd372ed828","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-08-13","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d726783a7c3be873ac7e356dee077fc019aea07c6cd66b7909e11b366b242464","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-09-12","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49cb6975ff69011e757b5fbf90ced3ec929f35f30edb13db71b009711e6a6bef","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-11-23","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3461cb21f4540b80602496b558c96deecbcd6039e0bfbb3b4e5e4a2aebb33db1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS - MODIFIED - D-N-A","level1Code":"REMS","level2Code":"MODIFIED","lookupId":55}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-04-28","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c8d4990dc4b5f3f9f9bba5e94d6c5a7162faac7f445474f46610b0e6e97b4151","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-10-03","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8a35e2a662be44076bd93951b9837f103134de2950675457ba43df684b935598","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-04-06","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9c97d9f072bb10565b63d5909f828bf1cee83b687278a8f7359d383123dbed80","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-11-16","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"959f697978af0c5e285dd86576cf93045bd4d99f9fa3322cb99fd44af3bae995","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-09-07","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"65b568a475620cab8b6b4cd5e032c5c1a751d4b187e5da4e13bac3d9ec04ee70","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-24","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42a59345a8c3ae7127aa058ebc30d9fe0dc65ecb22872bf3f7e835349e9b9650","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-08-03","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea1dee1931d3ebcd073d601005b2b35a02dbb1aa6a67d1f1158dc0818cf90b19","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021318","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-05-19","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8dbb262d59f895832fdcde4b3db86746c0a13136e876aa223b0f51f8fefe4bf6","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-03-16","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e8ec3a293e5c4a1ad3f7e1989036144763f6a71968843da1d628bcf4fe723d36","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-08-04","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"be3ee2dceb945cbfb645a3e41d238bdfc99e33e59f30297e100d1432bc51e3be","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-06-27","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1398f97177f49e9a876734887b517892759a53f62bef4046e4c09a4725cbed17","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":15}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-01-03","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"362c78abbd545d9390f77ee98d0c6bfb8518abbd092745810b5f6d4fcfffd5a9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-02-25","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a2f3d7f43677fd47275894dc678dbed2931366634b304d1a9e789fb19871d6c7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-08-07","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"88d45db28db94e77c65caec8a3c8eb5cfe8f716077686e3149fd5d2a340af4f8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-03-20","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b263d78baf14b940c4ceb36d29098d6985cfb69b051b7f115dc89e83f8bce841","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS - MODIFIED - D-N-A","level1Code":"REMS","level2Code":"MODIFIED","lookupId":55}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-03-08","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7606be75f2dee1807679fa57feca8d12262368876a62b39808aa16f735fbb309","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":48}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-12-18","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"de816c25065e394e48fa4c0f2484d4aa22959dd6c839c6ca76b2814cf28a783d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-09-25","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a18fbbe2700f59f3c31059fde03c1f7e38888c181950b932433542540a783ba","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021332","peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-06-27","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"74e383ea37bdcd04dcc5def0f7a92b884f8d8cbe1c1a11d65fb7623487df0f5d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-01-23","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d62ff469415f3c543bb7f59bf07db1e3d5dc5ab037cb0a3243b1d29568906e06","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-04-01","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"60b412fc551fbd7d53260a2dc1f93e816d6d7a3c3d4fba2efaf82cb8338776a3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-11-08","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d4eb8e470d92aa509933430e2ea535d61ae45e56c24c830f9bb1cf40a19ec94e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-10-05","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4962a8e91fe64c55b43a8dcb784f443bc87b18f403fcf4e7330bb3815b8b2946","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b93ff31159f883d82eaee52b1bc38182ae6d4f9a9ae1d372f0645dcb9b93279c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-07-03","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"50a074fd6d771711c1c8e636378f0a500fca6dcaa8c4df001e259ba8d5aa58bf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-04-08","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1ae99010621daf3021becee9331ee4499111e70353e17ad10cd9836921625a7c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-04-09","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"69e2bbb2ee05a1fa31fa22147acdc3bd6d5c819e39b7a639eae8349c100c2f12","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-02-27","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a3d2f559a065b46209404ec9dad9ee14dc5baf38d848a957a5dc1506c391b029","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-18","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d531637ee79abe503f0d1d45ad938aaae9cf748288561c5485e1d3baf8153a9e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-05-30","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7a09417caa2dfe5b82f1e8b267d3379ef2f511414fa58d25738e49cf37f4cb9d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-10-10","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"541a959a9f7fded0f75d432f4f58b4c611b0ed52d37e69396f3e267e29ab8841","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-10-10","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"92862e1a4f8a64f72945b89aa78a955e3c8bc0a31d8f9a2f422efa8acf4d8d09","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-10-26","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9bbfa266521a71b052f23cd68ab1812ced21450c4598092c46a17b0b113a0fb4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-02-29","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fd759879dc3f1178ce1b96cfe237534c90a2ecfb6fa9bc86d2d364045051dfb2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-01-13","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0a38dba49ad99eec2509b85f64be3174a61be256a59ae9efa5288343ed3d9fe","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-02-15","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"47cdb68efeeeb432966d9dbb3f0aa199733187df99f4e097e66c2540266f446d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"db753ee4e680694f5e1a67b9408ef63c46e62499d1533d61a7ba2df639ba63e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"50f7023684524c3f60dec2eaf0663e2c1ced7b19ecef152753edbf6218c504c1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"017762c6e5a0d1f22d53c044ce99b179ed103fcc465a16e412a976d1a914189b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-01-23","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9cf5ee09a181f4c426c2118eb20ba1ef60419165a3b607ad550237c15482d573","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-05-21","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0bef576f50a83ea921fd0fd6d46a034932caf893fddf38b3f2110069880ca2ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-04","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2c0de5b304452463435435b93e99dcbfa537549e1954a8ab7e4976ae985e2a97","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-24","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"492733af3e74217eaf1e176ecb1186078fd5e0b8fe6fb4714c775f9fe793b9b0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021343","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":60,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75eb697070d1847e8768dddd8851d644accfe26025bf2f51c103056d201c014d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2002-07-24","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c58f8ceed501eeb719e1c2151456e4d22ef645691b925935449542570bdf89da","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-11-08","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c851b0219e6c960c6c88ae2946b3875338a412f63bf33b69527afd0341c3a617","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":27}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-10-05","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"73a9192439368a03b8bdc083e3402c8cd6aed82e2c1a8e30efc9725f010a7359","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e84765ffeb581360c2833a77d3183018c24f8d3518801c5781462bdbdd5e3fa6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-04-08","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1f3b77d383bee2713b4c97f05fd388d28664bb33f651ee6d258a0b367f83520e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d6a53175ee30572ab61f63bcfd62c9704cb28b0b40ba72495b055a9e8d7ab650","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-01-25","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2723577cd22a4bfcd9bdf0d6570861c7662eb7b51fd92989c5bc7bd4bbc0b7fd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-02-08","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d8323fd6747e2863504d9423016708c9ebe006fd3f53f0cac82796ebde8feb17","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-02-27","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fa02c87ea34320d944feb764ca4a9a496e6a9ad1607d610c99637df121e3c984","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-18","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ce493c33b8d6aaa70daac93cba8502442cdcca276f027c01c743302b9cda14d2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-02-03","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0b6b2a234b90261e1c633634680b75441ef86921891f9f4fa845d5170c5d574","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-04-15","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7f7adc01e755cba3a54a3303cde9b350d104e6abe1c172424dd09cc8c4179e61","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-10-10","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"02a54328472f62736824b168f8de09a06f6e1b70d20183490c728a5774846f81","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-02-29","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a0bfcf44c38a63fa24fb87a0ffc856b082017dfe9e50168e45e93fddf242ce14","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-02-15","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a2f5f06072a456d1b1f054d5e576dea6b95e5987f2cdf3e872a4cf35953fd2e0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6b9f3653ef86e29c03d248926ed35138769d5d2ad3e879b03e848e5eaff5efed","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b85bf2758f7faa331d7a194f1fe36138d10838eb3d6f5bf5819bfd4ed1620942","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-01-23","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"188a2eb2de2fdcc90c73ffe9b737f8a928ce1dc03b65a45999b5e00a2d083af9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-05-21","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7edbe866338259ba62fc8763d801ac7851b6903beb9290cba5e34924579ae79b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-04","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49b9b3123c5a0ae6bebfa39aec3d9509adb0a56ad7c5eaa8ec409ad6fd146286","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-24","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"51d7b8662a9d75c378b6761ad13ff38f79d6cd207bfc2c7389c294d8cf1c3e90","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021379","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":65,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"41f21aaeb16a6cce573f2e183f5b4cc768a99795f753dfb56cf9fc253bcdaa2a","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2003-02-13","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ce0dbc8be66f3f52c0adf607daa946fa6052e844fddd2e394e37d3696f45d49","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-11-08","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f192e037c9ac79277941ae205b85f4eadfcf378137efca30b6c446d70843c14","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-10-05","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"80b34c6d79c4baabe0a1301494c4c7dd46b564e4fec702381bf4ea80a39f4b2c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3e0dbe047b8315810b4c66976cce9b980bcf472a8d2cde5299070d6b20d3a5c2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-04-08","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"978ee85fb456204f979ce32e2ba801868bcaa94a20cdb22971b573cf241e568d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-01-12","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c6fbebd7c9952479370fed99b902a97bf3844e4b50703d1bc9fcd9e53955989","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-02-27","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c762b51e7f2e5244643f3ee62cb9666bc93850892990cd5230ed46a012400818","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-10-10","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"40b2afe9e5ddaf1b783ee9360062cabf7025b056220abfe4d719ba2ea07ef0ba","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-02-29","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"baff50f555f653943cde9f54b1911e4a0450de449c075bab43f9f158708f3c41","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-02-15","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a301077a3be6d45b7acea124e574c0fc7e4a9c3221c34c42e3ade333d47a0c4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"77b47f1145ef5cd747e0556efddd0849dda66673bd0eb1d819acd2b1d74b096e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"80298ffb4b39f16fea55e233c460da0083208574c1dce536b77eebbe82e9793f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-01-23","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccf7152d3244b4df4e3b344e31118fc1f133302e49fe66a5ccbdf02464023836","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-05-21","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f4339af407f55e6fde9be2873b740487a9b51b0662de99d21db1c8646aec450d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-04","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"74a2fd21f36547f473d16c2cdc8032062a16d640bad27f94cea70ac6496623a3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-24","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8a56195439df5ec13b54a896fbcd4c7f12b2074c73e70c76565ce2cfd07ddb57","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021488","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ad224005d6f96f4c6d6a44d918286d03a5e4e58d27c38fbbb6f521ff45b90c22","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2004-12-14","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cb0ad1a214e75b4e71633ab95fb0e682f029648c4088752486c6bf2faf4b7576","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-10-05","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0ea8a2efe5b8466d7bad94a6c9203c87500bc6807eba9049aacc05e9021b2c64","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-01-14","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f8db075979477c9096b18c21bac83d8e57dea4eebb358f1671d22d1f4b668c40","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-04-08","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f3c4a21d3cfa2d3ba4f5216c690ab1456ed82bb33fbd10084e79b5e49dfa7346","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-04-03","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9221addc66fed5f981bc96cd8968c6b27d8f2adcfb7457fb1780f4ea6b45cd5e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-02-27","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0c993b4edca935cf360df71785cd199226ac1348259ceec26791cd74fd3af74e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-18","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"be697c64e6a5a0f654e94f41b75bcf5af3f998ee6c9d769b3fb245078e8e37cd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-10-10","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0866b0874fdd138ffcc0f9d660b336a9af4f4e9183040240238b3a81ce2732af","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-02-29","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"73a9bac9837cfc9b97036e9f1e02396f635380a67c130f00ba454c51f2d1c490","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-02-15","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e262854cc979504c29af0d1bea1a1f3efb21ef7e7a8b2cb1f9e600c2359062b1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-09-29","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c56c2adf8d8317907e4a8dad2ac6e370a18e5a39f4d21602f67087cc3d648367","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-11-25","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"48a3aa63a8efae5dbca5649e131ba06646b5da6db93e7c630d46e0b29c3f2c2b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"974ae2cf5c3af0a7ed84e532699ad63b72c372c9a9cf16a8c7a35d9e4c34a6ba","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-20","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ca451d8255be8ec1bc0629a902e3f8b6c5e718b3ceba0ab23146ed9d7e6df89","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-11-08","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"50e2e68d92fb45501326c39453a4866c62a5330b59d20a96efb434cd6f1a86e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-01-23","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"00572e5c85afcfdece2e81fccb67dde3c2e47d799d9e8abff00dc5168d42aa64","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-05-21","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f2f0e6743f2ac8070cc4021cd59f27cb729454fee8b21e802180c4e9a92b811f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-04","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df20fc436aac6aa038438a948560ee038ca4549643fa87d223e442bbdd73662f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-24","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8384d70ae493c96e98a4391c3c95c228343dbba16c16e97c0115fe4e70960b79","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021731","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-06","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30b950054734bd70f2cb72cd174b2ecf2bb21cd669c8c9167141cd22be0d2d27","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2005-04-28","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61c92d6e54e33b476adf95c18529c9bddc48abbd169ceaf72036cddcc3d3b9ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-06-17","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"066ba2c22352066da6995f4decef97ff9ad55d3675f6b0a4f836e1d39703fe92","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-10-30","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0008266de849a06f7cfac39b55aa7a06d12b7104647b7d9d749599c99444629c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2008-01-11","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75a8463eea9984d68c9f8e6565648e2467593dac4dab01943bf97b005ba4a3ae","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-10-30","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9883939b7fcca511db41f52e3633f2bde93b12c4876baa306a424aef513c1dae","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-10-30","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e90efac746ac1e88d1ded859d85933fb04b0faac376498381e1c756b2f57291c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-12-22","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f90f8d7bf70a1d926751d57690d5185273532ebeeb9d5ecbb52b8edcbced9ba2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-10-30","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"19e952e22e42553a254a8b7c4de87ca5320b2a916861229a67faab126692840e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Proposal","level1Code":"REMS","level2Code":"PROPOSAL","lookupId":53}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-10-30","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5db6de203f7924e0028f2bd7aa5e0667a42b698dd9617cf1d7ba16af46ae1ef4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-08-13","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d10ff0a57902d5e76c7d15a34b392e1b155873916e7a663683968ef9f17c4b65","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-11-12","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3654aa739714451fbc1c7d25554abb991088daa8505b4ebf7a887c36d2e51270","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-10-19","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1cf5ff9d3ba04c109a23dfdde38ad92ed75651a47bc2084f841ef02056ce3c67","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-10-19","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dcfe05144823d0bd5c3126da5470f96ba33366ae8afe85880c8751e8fc84f4fb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Assessment","level1Code":"REMS","level2Code":"ASSESSMENT","lookupId":50}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-08-05","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8cc050c4d7955f89e470a6bda3e8ff4f91418b26442f7725f70ddf5df9efed15","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-01-30","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0fd4cf3795b1955a5e6a01c88655df52c511e48107a48915547c5ba2f9e6a62","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-04-23","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b9a2a25a2b491abd293d2647401135e0f9df99dff7d1945f61262df859563794","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-11-24","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bf1d3ba0239e6e178546f65bfa16a0160cb112ecfa6c8ac15ffecc7264f2260c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-06-04","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"63fc67f8f0ac703b36d406f823cdb3831f47da406ee0c5b6de2af788838e44ad","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-06-04","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6010bcfa964793accc7dafca3e70bf612f8f680c418faac205bf5ccf3ed9c82b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-08-12","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"187ded64e7dc909e3b46394c68edf707056806a135c2a086f32f249b1d33f67a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-10-12","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c602b366ebec926ac76f8c1d6ea26f7a6cd338c40ab4a683778c7e198a0d82bf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-02-25","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a5dd6017171ad907afbdf11e2076386f5ffab10c78525ce9b3263ebf9e6237c4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-20","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"80068bc100ae66d2c5427ab51714cd489472006625d0167f4c5c89fe5ae7ff34","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-02-28","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97ec5a9ac1cfb18edc166a6b29ee4442bd9bc1cd857943f2eafdcd1132a8d3bc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-06-17","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91237e95363a284a52d1daf2226eb6b1e75f3e3feeef6e6ce3495e87d55f9ffc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-11-04","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c609529448f566bfa2f1f72395f9e932e2c293a7cec00701068552f54bde72bf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d7329035950c54166cc52fe4753c8fa38dc634d242636c2940f2f141496bcfb7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8386ea9d0da73f839ffb25194cd5f79ff544e70026610580e39595fd0a79fb6a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-12-21","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9c266c91b1dedda8f8ce50ef3547ab101b96acc5a75ff2cf1aa538fe5ef8383f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fdb11d8a879636e772d9e1e19e25e3bfe8ec343a0a1b48d2078b6bbb77576e4c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-11-01","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0134ef6ee82b50a4dedd05af991a3529ba7ac36d494945402ba972a729d0ab93","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bade16da68edffe249ed1af410918ec1082b33aa677b3ecdddae6dcbc67c61d9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-02","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"580aaf38b80a85e649ac5b05606d85573c3fdcc5acbf8feb620e077922f1f56a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2006-12-22","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3ecd9eb1e1f56dc78cd49fbf5c212972ef530c3c5f5c61af8dbab63dc39ed2e0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-02-10","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b7ac637d0379db6f27dc7c3c011f780beeab4f4b81d9197290e508977ee243e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling","level1Code":"LABELING","level2Code":"NOT APPLICABLE","lookupId":13}],"applicationNumber":"NDA021773","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-10-30","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97983165542f772a68789d0c48a52d01c36ca114b3d88c7f3594d01af53afea6","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA021919","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2009-10-30","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f244afc71cdcb1e5d43d505b5c37019dc7ffb6cc440f436a6b86a601c8fc1b24","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2007-08-30","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"01439c50fe654db35ae732f3313dae35a8394239cda166fa1cf2fe72fdea5562","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-12-22","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1329147f57bbacc5f40c7524a1fea74ed870d7850af68765136b169806940a1b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-12-16","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30fedf86bfc756900146fddc1c2da7391bcaab942fe13249c8057f52d6aef16b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-06-01","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"81204a2ec84c2f6dcb992b48f31d491d804919c5306c67639e1025307efc18a2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-06-01","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f22b62189f316906ca35282543364bf2588372f54d731521b0c8e0ede175deec","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-11-02","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e066a8040c639b5f3732b4e6d46dc007502bbeba9dc27f90019ae97d8330eef3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-12-11","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ff4ef326ff738f7ce66eada90a7a14500d6bfa4d07f3191c4d5ea59f81970c0c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-09-15","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"771578c68ee39dda1d884ecbf46988cd4db1a14e5a5b2b8e6500d1494cd53189","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-02-22","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d76b7f5e425020b03fbf78be900d9301bce8fa9afe57ee18da60eab8079537ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Control","level1Code":"MANUF (CMC)","level2Code":"CONTROL","lookupId":33}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-10-23","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f9561dc0ff83f8ac389e08c598f854468b862b31f943876d76c8c440b55be0ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-06-14","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"109cac09ac7489dcdd611978b4bcb6ca98853c1aa4363bcf9d43ec3b26912bd2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-12","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"41b8a8e220c2aae5a32e6767591daa56d94edb0cbc73d7f197f7e2cdbf36eaa2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-04-11","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"989bb8b2d08f8ee47a1fccb7fe714e9b3074e72ffbdb7c833edf1720c28f0d30","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-24","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1e9f5c0f1d64aff5035503cd69501f21f5ad294b76c04965520e6637190f4d05","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-03-04","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"885a9fa349ef5a35e4b84ece902401681957d99ba2319f34c920d4deae1ba244","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-11","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"646e545e8c7f1eba4379b56262aa0d09ea02a29be150f00e8da282fedd96f005","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-10-28","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b48cf25cc025a804c5dcf24123a85772e81de02af62ca83ea33607d55bdead3c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-11-27","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33d718aefae16da639aaa32141fd0782db0ad9c08691ee7514e4f5f431467ace","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-02-21","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"94fd42182e6a823673c8c3f40ed5917b7047e08e9f038ac3010d9c256fe5bc33","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022074","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-10-23","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bfa89af27f06abb964edc9ed509732be866f14ed4b4e84e935643baf766a24dd","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-01-27","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1af0a07a35534279114119cb136c127facf58db2ef4e7d321b855f932ba4c012","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Assessment","level1Code":"REMS","level2Code":"ASSESSMENT","lookupId":50},{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-04-29","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7baaa8ccf451768013ee7fa7c3384490fccbf331cd223c347c809480d7f4ccd5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-08-14","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5118b5f61cb0fe2610fc121f68e3e4dff33e92af0fc50707794057d12bbd6283","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-05-22","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8a41e46ddf9bed90816b867573b1aac8fa2d6008adcad1a3de0ac8f8b1f32324","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-05-22","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7b9a1a69c3ede114d91d3b6283a6e8dad53e86cba72c4a1724d4dd6b2b53ed3f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-03-05","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"539a56aea20146b04ff78266f68a79b0944342b164b955b95f7413a7432eb127","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-09-24","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97af8462c69c4e9f7cab1fd289487cfbd71effb3eca0e21fffcf66299af863cc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-09-24","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0054a6800d61daa7940e52dbcc1c71203d5a5d4e472be63396a73c3180143b44","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-09-24","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"68022dfa56d6dc29dbdb326da522e1209e61ac619977b3e9f07f7b2f817d4cd6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-09-24","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e4747fd21cb5587bf5a962addf5ba4b174205de6653f0c8f49acfbfddcac4796","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-03-09","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cbcb32eb039e13fc9e99d09863d3dbf043795c0b357db21671f77e0965abaf78","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-09-18","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"176966ee94757abfadfe9f65a6bc615c653c1ae6a591abb90b3bbd87c7f0c874","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-12-31","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a23e48bdcdcf2725b60717e76bd83bb7399bc012f381e75cb3e7d4e68b61a30e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-12-23","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5118b51648c6a58f534fe426ee0d88e80fbcd5c433b0563d91450dbbb68ddcc6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-01-11","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"723a75de164aa96ea96eaa04d00c77410142d53f47239adb0b8632b0c39c5cb4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-06-10","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ffb4cf9d744eaa7466d243dde22ba3067a3b003db7edbfde864e5c375289859a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-10-20","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"36fbad9ae22fcae8c9cd8f56a6f564661d652b97e265505e232120ab28f91877","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-04-02","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"958be534149c568aa90e0260d6ced844a35970ce449d90656c518123a9da788a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-02-15","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"796b8cc024104dff3ad78b3a9940ae6713c7e88a562e1b08da02d2af5a3fb6ad","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-02-28","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"929558884bf2bef414cb9cdc854f3c30a9cb44fcc5e3aa2ba3e45819b8e49093","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-07-22","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bccb6449d0466200b98488d857f12c58a60b86de2049a573fe63289fcf13042e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-07-26","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1620307ce32aa875cd2d0ec7ba6c4632c60354d2921f4d6f2b830b8c741bbeb2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d526d3f96cd25b7690d695c319c02cb8b393e68bca330e3f4c3148e2ffcac778","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-12-21","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7e1b8ba7761ec8a58ba506c6c2c72bd042e9fe994e3e5038167981080d45d138","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d86cf05e2f0238e327f8de1ac138fa6583019e3dd28946238da4a03e09d6d4ce","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e3d50fbc1c980af2e40fe57a700e01fd6cc08548a07b2aeb524f46c08286c299","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-06-12","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4774adf4da612e3fccd6587a0b0815e8d4f77f17772d212f720b8d8f2febde81","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-02-27","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"249088fecd601d81c07cdfa8fea903727f6e404f7956f88cfc353e704b3a5154","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Proprietary Name Change","level1Code":"LABELING","level2Code":"PROP NAME","lookupId":29}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-02-28","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"607090b12e53e2cd58f12cfc633d780df17c515ab72a0e928c56d153d9396cca","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-02-28","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9f3c6e5865842602b91c25d3de3f63d222262f1be8de7a38b1c19e28f9461599","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022200","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-03-24","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a432c684906bdbab8f4656df8aa41c5155d7a166791b74ce4050f42e45b6d1aa","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-01-25","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f74efea775af5bd0c5eae39733bbd812d151170c465640fc176fcf12c8f8133b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2010-12-22","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"67c7486422c742d6f5d952fc78a7af752983b80aaa645421cdbb2fbb8d1d3c48","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-12-03","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1026f504a397c37c457279342814426d4393d6fbee3aa34c7ed6543e68dbbeb5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-04-06","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8b9c5b1bdd352ff50d493a9ffced865e7222fc917d246e6c956fcb916429d04a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-12-13","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"96de4921ee6e68ac0d603969b347fca4ba03ea27d9b07a3783978139146d8cca","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-04-16","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb70d8a378961e405cbaeff02de3b77c5c5075d30f225361f8b0a75f4e2385e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-06-13","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb9b79ebcb2281531397e7f3d463b6fa99c4ded8e2d6c8639a9a231f50dc68e0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-31","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7865bcb9c81b9ad96a23d36906e8db112cca32bb27bb8c48ca620535bf103d45","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-02-25","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"304133e494442661a63ee430e9ee433ee7653621723ccd9183d9af6aecf29a48","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-03-09","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e1e53db88f75beb06fc618b8a96d105f0aee6708bb67b40b6608912f06d6886b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-07-01","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b6d3ca19a81fba483fbbf27367bdd455e957ab8658681b902e2eecc37cdcbe16","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-04-22","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61343c0101f745f797791a5bd0c078136c67b6db5e5cdaae520fbfb1068fc976","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-09-20","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9baa5ed7c5f1cdeaf1f4039cbaec45e3e28beeb42dbd24e4f6dc9a3de4292cbf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-08-25","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35795583da3b96eed219b349674e31b5532e3032cf05ba7fa6ef4dd577267616","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-04-25","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"14ad4a355a345fc915d5950e2661da46ba3c9b3c2e81133f391df2448f9a285a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS - MODIFIED - D-N-A","level1Code":"REMS","level2Code":"MODIFIED","lookupId":55}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-07-26","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"592536451f149ce37c2bb414d8697275ffb0bd69202ee8cc5f6736c459e4a021","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-06-17","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"70cbfd7db94d2d796e205df103ea282352b37e2eb142606070dc7366eab29220","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-08-05","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"244e0cb7d05840063ba2c10574ca6b1f1c8b3915dcce891733e522ba49e7242f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-11-20","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33c9e35baae9daf9a9da15f344484f9d0b9751d1673a8ca55982b3706bb62ba1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37bcdafaa64e43bc894ef59f38f6fe2380cf8d82943893961fe6cf782254c10b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7dba280d9ff1a26baec7ff65ed1747a9c2b9fcc7fe8fdd39be307155a795ff00","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-05","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1430146ee5e0fba8b21890ce87e37585df4e2d9d8cd765ad3c48f16fd50413c7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2011-05-18","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c86966ce28910f2b3ef8eb229ebb5dd44a95599fdb03e01968443ed79f087f87","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":15},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-12","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1635c935d0c0a1015d00315a266d01d9ee64b1744859e3e68f4a76d8c42d3fc4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dc2152044f606f3f0b358d1a05ccd429d6ddc8b33b1603781d3ade10e8807c24","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e1aa02abd0b44e8298d0c81e486a31555569e3e4a7b66c6f8008347b0fe60985","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-14","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7651f0444bbf6de38d84bf9ca5a5144e61d428b08a9d844ecb9ff2cfd145264e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-04-06","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dbaeb1144b68c6fb249e09322c03678b3dad8b3272ac223fcb91ca4c50302982","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA022341","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-04-06","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f84fd247897138652905332d5221495e7ca9235dc661e86616e028e3918dff74","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-05-08","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c1e6c28248721dd158cb4fdc00fc2d1fd1912b1fe016fea7b23bdfe920bb2d1d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-11-03","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c01483836272e4289611750ee57c31beb8b39050a136971635f93686e5b783d7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-07-14","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61bfdb4b3517e02c212627b308b8b40fa751103928be8f165f85dc2c5e5ca486","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-12-01","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d30895b9f2cd72b98116ba4e7bffd3b6861fcaea5573955bc600e1d74445e667","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-07-30","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3167a28b0b0c8c99d4406496bb5ca3968438347b9281be03a2df4b2f8f521352","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-11-03","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7abc092f81d892e03deab50f3ec28973b393a2802d7cacbb96d992e4742fe1dd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-09-09","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea1c8c8ac76a2e8557f34adbd052fc1defac51ef01d5b7b3042572d310e348b8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA201849","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-07-29","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"65468226009aa0639a0bac37a7c97fd27e1bf634e5bb8ed66625148d88cb5ea3","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2012-08-30","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0bf54061062d62ea6cb2dd67848a269213dc5c55a1e9aa8c302f1256b8627693","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-12-11","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"230ddd1729a4df88977e230babd1e6a47e49f035c98fc2344703301d79d36a8e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-01-25","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"505a964f9a9ba73d7c3c9bb7cff7cc7d0713cfaf7ccbe99ecbed561a3ae88a35","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-08-31","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0f5d9ea8c3bdbadb4e0eea4af862b7c00291f94d2653e2891e61234ef1265d40","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-01-06","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5bf35e674f0c83d54530fbcae7dc40b6ee0912febe0894e99a1bb488e5e09a3b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-03-08","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bd637a316a1432c2385990a7e0d0e64475650bfbc97bd44bd1b410b629ae5499","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-09-22","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2455de4a522dc9c22ab5749527bef34f890c931086d283d609e5933ba741c9d0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-04-12","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fdc7a1e540dc2e5ed6d1414482102fba865beb57a5811d08a370b69579388400","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-08-24","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"01bd0def7fc35f03bd9c149166169c85162dbf02ac382ebbf50ac95f494b6edc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-11-08","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d0a13552beaae1efebd9144bfe0cba06b49c463e7f6366145bae7614ccf8b3b9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-06-12","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d68c391bf3112a93fd7d45e5c2fce85ce00d5e8ffbedc595cacc57ad2b024a00","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-11-04","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e67974a240988347ae28eb06a5c852e41f8cec7e9ceb46f644deff3645797806","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-21","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0f393762b8397c03962783204adc582ef8b86db63237309d9dcfbbbe8d9aea3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2013-08-08","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d0d2012640f24d61337afc2e84d4f92aa8e68aa08e74a2373ac6312c3799aad1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-09","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"09924b65b90bc7e63584a589edaf683a7035d330c05270ad592d7f15c4cd33e7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-07-01","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8e899bec49b87b426fc3c2367a933498ac69c6ec96eaca25665b5d82374f52e2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-01-05","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e75789f9a42e258b1389cb684ce6d23ed10dc9ac5c12abef6c75e17f4ad6de85","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-04-06","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ce8c8ef9878b5a6ae400f95fd51406397cd5459846dadd0ade010e53c9636e9a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)","level1Code":"MANUF (CMC)","level2Code":null,"lookupId":30}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-05-18","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a61cde27e0460331f500b1156d60fd27758fd02d08ed6c727b1a3a655dfc9bff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA202811","peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-11-23","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"db3e1b06712f2382c4cdda1d4cb35464204adb899096e2b083fc0460e6553a4a","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA205054","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-08-28","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5629e37c743c83488cdac4f19f6d2b35af367622b474ebc27177b88324d8fd32","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA205054","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-28","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"96a69be62b768bed85ca409ce341b05d01d25a13ef676c9b9beab819051e8c6b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA205054","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-11-30","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6e32f63da6372a8118eec922b9c4b23f1043b4b5560aa90e0b5647ccb325356","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA205054","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-08-08","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bc4e0d6296a14d34912b42f0de1092f5ee9f0729577f03bfc0cd5a8a8d8b494a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA205054","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-14","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a502769ea16f4dca1a59695b531bdffc8660a88587ab4850e5d40afd9b33d2d9","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2014-12-23","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dc80c37614e91c20cae35876cf81d48d45626098314bacd3f8efcf0aeedb1d9e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2015-03-27","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"048945cea167f3d07991adbc69d5675bd179dabfe0f453d0d8ad27935735de2b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-03-25","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"58f3902fd19f7c99e725ddb85584f2403d8bcd113156fc2e47769579cdbec431","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-12-04","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a266e5f06937e268c6ec34727ed2a85ace86025089bfc2bdba684dfe9431d02d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-12-04","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"704d2379ecba69a5c4f777be229bf5272c6fac08b44b69986c237a580f9133da","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-12-04","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"078c8328cc07dd171fccb48984fe5042c35fab9796570209e2a69de5417f64fe","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-15","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3223a81f8dad0711c7ab0008b7b77119bf71181ed4910a517591c915f47a01cf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-04-20","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c42e6245ce4d13a26daaf7e58bf36acc9204fc1000fa32adae082b22b851f0c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"635a418810cc499336c0708d8d4751eb1ebf1d70c1768c54d042c649a57709f9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS-Modified","level1Code":"REMS","level2Code":"MODIFIED","lookupId":51}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-02-01","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1003d6380e1bc37e7b89706eb696c3e6f403b8fbce4773b69b75dbf93427c147","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a6046fba91acb37b51b5eb99c902fc2767ea68dd10accc98ceae52206729af55","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-14","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"86a00667564eba4f992e8f7e908f7447e0b3b267fb11d33dbecea69df13df47c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-06-02","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e895cf6f23afad7368608feff87e62620fd9c49b37cf9faa913479866053ea61","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-02-25","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ee4df25cbcd0d8915a1d54a32f469f3aeaa841cc84f4f20d514465d56d63d3e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2016-09-22","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1b825b15e40dff5f370b9e2a78398289060d34c8f64b73d4854adc474e32f8ff","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-04-26","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"53b7818dcd80b40bb369829d019e89619aec2ae1fcbc287d4607111c528bef23","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS - MODIFIED - D-N-A","level1Code":"REMS","level2Code":"MODIFIED","lookupId":55}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-05-22","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd2876667bf9e263411aef3cca224515d51ac1a53aab0d7f6be84e11869e219f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-04-26","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"40bede966118df5bd4ad24f2e7d088429ebdf2e25ef2dcd651c3d08d55f02905","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy","level1Code":"EFFICACY","level2Code":"NOT APPLICABLE","lookupId":2}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-10-19","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6754548d73c0393a503e567f782eabacaa8aa5b308391e8cf620b23dafeffc43","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"REMS - MODIFIED - D-N-A","level1Code":"REMS","level2Code":"MODIFIED","lookupId":55}],"applicationNumber":"NDA206321","peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-12-04","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"51b0366ca12d743a84775c6b7aad3f0141134b73b5cb3a97703f3c2fdbc61527","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA208232","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-06-26","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6d2babbc6364533061383c9fbc89a48ffa44ab022313be4fb93f8ab834ea0c7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA208232","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-11","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97e9658d9b393c0d59ab35223108695ab918fd9ff74e2c68234668324b349f9b","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-04-28","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"53655b7eeb5e4aab80b6ec9504ac2b80589ee97fa6e16dd7bc9dead451a86e78","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-02-05","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df68fc678b573811040de3134273d7936202d860f8b352713a923f9ea746eec5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-12-22","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e113ae0b683c7395551045a9c25593b9758a706587d24ed8392a1ad29714ab2b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-12-19","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5805a3458d46ad8a17166e4392954cdd05eeb6ec8aee6a114b01e24be1cbeadc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-12-21","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"70edac73a6293d3ec9ac92b2817d0895681529bb735a388544cc3d652a05477b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-03-28","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9e6fb90606e6ac47503cfa87d8a72301b3b4043278a800716641751b0088edd1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-08-03","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"853bd892393de3161adc7bcda24b76e56c3a2b6722371cf56bd4f38863609cc2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-10-17","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97f8b3b5bc25cc6e54e303a303253a7a3f7618745dbf0612596fbaf1ff314499","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-06-20","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0fa2e4a5cc2d2126f1ec7771f8bdedebcf84fbad49130a773da7c86506fe6726","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-10-23","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d46c740d03e1ad3d2ac09d6c7e6667a940ec8a9ae0481725999629178b87c7fe","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA208743","peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-09-20","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"99fca8ad6e52310fe3515d82016976243f6e31aaf5efe236b52fdb6ef7e78aa8","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA208745","peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-01-19","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d3a01e08218fc68103c3bf2de486af1f43baf5623a27057d24f6d6d78f4b1e8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Manufacturing Change With Clinical Data","level1Code":"EFFICACY","level2Code":"MANU W CLIN","lookupId":6}],"applicationNumber":"NDA208745","peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-01-24","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"365b7f650b718637deeecd5e6d1c940f77f97d53bae71e8c36f13d7c8b319f35","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208745","peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-10-29","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30e86dedd7d502dbec5fbfa62b12bc27d295415ef1dcf19e0563cbd9a0f4050e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208745","peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-04-13","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4d032f5d8501f4a0cc286f0127e431ad2fd2876c0288659fe53ec17b35a65304","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208745","peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2018-07-25","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"29049fc2240530cfcc7ade963b3904ea2213b1b9f4ec0268a74de32a63101621","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA208745","peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-02-10","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"31711945f6c67512e41ce4ea0cd794b413c2e1299356cf5d2efcc9b7af811ed9","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-10-20","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c30d5a80972d75ecae6f153f078b5277aed630fe0815fc1a316c19d43407ade","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-02-15","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ead69cefb12b06b3950b5839e5943292d58cd0fd7a69fff05ce0c8836829ad22","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-02-28","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1dc373846353ae2a0b75e880976cf3e4a18b1b92d2cce5befabfd3a28d2e40f9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-12-02","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6aa3df35476837a751827e7da1f2bcca8587fef37abfacabf8b2fb1d9cacdac1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-07-22","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8816b195e5ec8699d53deafde51ba3f1d6be403f6a638bdd2b719a9d18f93644","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-07-26","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d0f084e10e01eb70b3bc30d97202199c46e0162a4807b8824cb61f5bc8600ebd","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-25","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0aad4a5423c9b8422af1992c4e49e0993bfc601a3c546ec2e6c87540599718c5","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"913970b54dd01ead72371b6160e4cd229d4410432c5b6b64d13323d79830cf0b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-12-21","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"565d37f4aff0fb83b3eaa353296e8f927b36ebe6dca91df4c9d9c3e8085c2520","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-03-06","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61371a4dc80238333b2480fde98ccfc1de6e8fd7aa1bc6d3969148b95cc49dc4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"143c4479da17865fb4adbebc695cbd7d577e494177701e7694f7df63ddfca5d3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"08c2c38be1e8a2cbba8b4b790c5cab168e2b08a9736a2518a5618cb320cbd22a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-25","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"280e1840dca9e670572345effef107f1c5e0b8f15508e6a24c2501056ac6ce4d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-25","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"53a2ee252c418027b1d9a37cc323e799fc6d4e4e03f399dd15b406ce0e1a10c4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-25","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b12698573a436331e62a31a09da2639fd6f7e9c00d59a4a91b9432a2ce9a5c59","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-25","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5eee47b97eef22408da48104376482948e7b9a6a85d1207701d603dc8afbaae8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-25","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a7366f31eed33e94d1c344689b89a6cf55b97ffa0663bca5789890ea522a70c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209210","peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-25","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"98b92c96b7530f5117dd26798cde3aa8c018a97eb03e2abe03893c9f6affdff9","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2017-12-05","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d958c2d07c8846fd9f2861473c0c6f2646885cbd7c83d8f7bcf4db01b7d7831f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-04-09","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6aace614b3b7173218db05a3eae9f14105a4fa01bd4878e559366a662c19434a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-10-06","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"be4150a714fc952bf7cdfa8fc973527a75081a2ff68b1de75972d5d95e00968b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-09-22","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f86c71713576892cb0e0e7fd1355b11c3a5441bc617760b021c992575d6a5d10","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-09-22","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bf585abc00ab9f38f30f92edb4fc8f0e907711a410126fa00b309e34cf15e9fb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-01-28","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"96a2f0cb355fc89e27c195a00add8cf15403804e207632197331a3a13d059d2b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-01-16","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"73c9126328ea7f76000239cab4f45c639a5b31e7f3a8bf0d0329ebb9d6565d0a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eb15a463bec512a7a9f21ca129e6f7d921bde4eb171a898c70b3c720cc84ee03","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-14","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"74679697fb5b569a1c8468530a469a7eecbf1e314cc496a78f47372f0550edd2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-14","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cba164cad342be5f3965f77c2e25347b67ee80e3991492cbe90bd848f6713a0a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-06-01","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c3ef460887e7d3856b029c1cdce4494608e21c0bf1ad16529a9bc1f67acf108b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-11-27","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8105b92b4856857723b5043d3a0ba7494b8f509ad04e3e6421720bf6626b5204","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-04-12","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8395306212eba2c82d2337e594d86fef98e1f8585cf8df889e176e303361b4f0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA209637","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-03-28","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5124ee3316950d632ca285d1d502991f077d3e62bcb55cfd877c7ef9ba4a8a97","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA210134","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-07-24","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed3e3f2bc0d0d22e9d8f168bf2390af7b06cb5c2744720404cf9e1c269d6d023","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA210134","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-10-27","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3813f536a0f3a537cfeb33566004ac1c61ab99268aee62c080e48e0c03fcd2b0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA210134","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-03-17","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c43f1bcb838a52bb9f268945381c6ec50577e8ad1763690ea46aa713cb6ecf45","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA210557","peptideSlugs":["bremelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-06-21","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d0128d66ba9140fe05c8f25216581816e0274dbf8ae9d593850322a656688db0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA210557","peptideSlugs":["bremelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-10-23","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1794eed4fa3889bd0a8741f86fe35655bc4e78a6b840f06a1e2613549c646eb5","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA210797","peptideSlugs":["afamelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-10-08","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2c5f04be8c330037cd17eb2fd8ce9675ab750d578af60162a34dfc6b2ea4f278","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA210797","peptideSlugs":["afamelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-08-12","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ab80a676a3823800ba87aa87dac20fa3aa31708ef0da692cb7d37b13e63a34a","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA211939","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-10-04","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42579d6fabe1552775c1d8a486537dbeab540a281d99151189e1d5fa2e1e2ce3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA211939","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-01-24","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b80180878b61c550886cf9bcc940d46d7d436d777dc1923bf518b727350c9a05","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA211939","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-08-03","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61cb285eb23cc3eb66c1c2f6cd5d922d6eb2c290070b358a59e116f317680f33","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA211939","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-11-16","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"87a45084ac196aab0f98c110d998acb404eb76ee81ff99f80e21a49acc979df8","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA212097","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-09-10","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49fbc3bd2de704d97c6d925f0a3b6bcd3a39b46cef8ed85cb9d13fba87c25940","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA212097","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-04-07","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d21e36da4d8a9cf87ab8509d757576738266402a04c534bd3fafba6ec55b829d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA212097","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-03-14","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f1bc701e7a58407e587cf2a84ec8e7145988a12747342ebd23d309ff22ff9c7a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA212097","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-12-22","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b903d899bbd015211b13f12c2d6b343b7f43a771e3e14dca1a491982665d88e3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA212097","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-08-20","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed599ecd27088c9c5c41115e9cbf8ede13331a4308030fbbf9fdbf09f729118f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA212097","peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-07-15","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9f0a294d8685808ff4bae0db0fc550388864fd3ef99dac6740fd016478f0f02c","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2019-09-20","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0202eb15baea53065bc33bc7513fcc4c618a9e625ce1c067c747b2b72b0fccdc","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-01-16","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d3ded611a967cac39fca9d786b0ba353432a17d5f7548927c27276d80cf5a3d8","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-10","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"abea5ebc23a8a5a4dfc27c58a7f5a3ffb60fa667133b2760f98d40007c5ebdaf","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-01-12","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e60a14bdf78a4987a1144e0628623f4fc0c1c2a1ff6f1ffd1733c6bdc1c81e3e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-01-24","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"56789b4897caa06a18a8ec601250ee69b5a4c6e3d886af6e146a0bdba463d79c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-12-09","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f73d13d5d1e1b85d43777a0a7a350b9e7ef8e58f282784a940c44f14ef0e06a1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-12-09","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed4cd82045194c6f22ff0bd99875c496c31dad03f3f377aee796a40f8ed25ee4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dc8ca2db8b83679b6eaa785d1ec401e7b8038b5568b3d6952efd46142c5496b3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-17","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ef3091aa3de364ca33c1c6ac70d31b190558a27df1e1387d33578e59e6ed30b","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-17","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"74451adc3bfe79a52024735304633e876c9c8b86b3f3dbaa0eda39624c064193","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-17","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2296fad3fc0c7e8a339c6a7a0349f69770c135b63161b3bc396f80a216b25552","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-30","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"149623be3c3dc79d42d210afa1bccc30a391089ad1bf36a259d29b73ea65fae7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213051","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-04-30","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84b9a0b145c4cf6486c7685e0455398c9046c2f5d789965e8be8d45af8bf122f","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA213150","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-05-01","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2a3126ab4f0ac7d4214bc6ad8c1a6ef492774f09dc6eea91065ed10cf99a4aa4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213150","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-23","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5d27a9c0f93784c7b710bfe90bee5b02949421888fa91ffc9225ec35602aa9d6","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213150","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-04-22","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5d040676531f26882c750eb37299d5bd1bfaebc3c964eaec46ac1a0d0a051e0b","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA213150","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-11-25","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9d871cd82b35c064d09777249f519047bb923e523af1c4a174b235d5a552b87a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA213150","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-17","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"949b55c0a7b06565e46a4d779c4f61f6d9f1c956c808adffa0fb52b8ff0c4808","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14}],"applicationNumber":"NDA213150","peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-05","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"64551b353eea95a763f32d6ec8a4a0f710beb52981675d1ba0d7e929bd8401ee","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA213182","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-01-16","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ad72c3138fa77c1f694ba3125540a774c4fb11c3659d7c9b1758d6a06cb2a30c","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA213224","peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-09-27","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7995a21681d84616dbaa4e6d500f590dee7b024068f966a9223055c29801319d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA213793","peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2020-11-25","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3276861acf399ec7586b52a8c961b79e184d0c1d2aa94203cd144ee0af75bfd0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA213793","peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-06-16","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"786e5efbf3094e519b975eb02d5bef61ea6aedee363982e7ae4536c83e33ecea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA213793","peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-11-15","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3508e3bea2b49fe6fa3539a84b552a661a19fa8070f02b88445f1f64b3b80d20","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA213793","peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-12-20","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"92d15798636d8db6dc4589d626af58fe2dc446440229901589c8287e53f46123","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19},{"description":"Labeling-Patient Package Insert","level1Code":"LABELING","level2Code":"PPI","lookupId":28}],"applicationNumber":"NDA213793","peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-08-21","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a04b57039f2562c60a951efcc47b7b00746b3ba14b1e4c9eb110a06ed172d98","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA213793","peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-03-19","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f6aa2558d94a8e7e0472303adb9536b870333a74a28bbb98fe709b6af8995476","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA214938","peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-11-19","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7f71c392e84284e671973178d3e5bc3b7615e696fac2f207ac39eb0d583ad2c4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA214938","peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-10-20","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"48a50fef4222c478ff4de00f7852acafb36263855b47271d0e88992bdc22e927","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA214938","peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-04","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2994bb0eb92c8455101bbce2d052b682d1923d933a632f00a24b7d8bc0f93b7c","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-06-04","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f34f13fe334a2908488516d9c1cd89501426be2ecc001634eb223e0e337869e2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-03-08","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91f763f80062fde6aa9741a94c07232c8dd459a39f8dc818e1446e71d2ef2e5d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-27","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"96b6c563799c389de5ddb9cb83343a4f626ffc33f204398abf87e6cb315cbdb9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"55395b83ef636bc63e28fc46345c5bf3cef73187333e20b571867c29a74fec70","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-11-21","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8752a6f1dcaf3d797f2a24390c5a73dc20e6c8b26143e75d23616db20e2dae8f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-08-15","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"52d3571a5c4b16888cbf8fcbe2d7e766132d78a0d949d2c7a98a6200f4aad114","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Manufacturing Process","level1Code":"MANUF (CMC)","level2Code":"MANU PROC","lookupId":38}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-06-18","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f82784dfa8028bf7a3b72cf23ad27a99870f2535a4851063dc5e77e51949b2ce","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-10-14","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d2dbdcdc861efc144ed848c26e1f383bdd4a992c5ad0501ef5854eac511b3764","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-03-19","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da2f8bb18607a9e8ad147fc3e9341a8cae1e0646b41c23ced06a6708da1adaa7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-08-24","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"89035603e1a889b4634f02274fdf2f14a26b6d8abd798a17bee84f720e62577c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-29","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"25b2203738dbb5202174209fa32f888a37d1c754506ecf98cc6385a0e5c1c92a","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-05","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ae2885695133e87d78b7f0b8df813bd4e4d3e13d29537adb9e128349017e1cb","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-02-25","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e65b082bae2ace3a10b6e02abe76e20cad0aa6b8ab731fc881285e025ebabc8f","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-12-23","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e88a4f6e47f06af57c119fb6cd1d69aced80d73843122cb44410433cd9ba1f93","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-02-14","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e9c5f12cfbc08c2245caed4153e5a5bb49dd78649809b28fad0872ce43412902","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Dosing Regimen","level1Code":"EFFICACY","level2Code":"DOSING","lookupId":7}],"applicationNumber":"NDA215256","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-21","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f7828e6af42e301cb2c633a056bf4078a08ad33e743a79b25769f940eba769cb","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA215395","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2021-12-17","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f0083f45a846cafc334af6258569fd2468bd425eda3b0cb38e19e0b4af5fc600","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA215395","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-09-16","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d2b89ae9d09ec07a9f43ab15c31d6bb49403b9f4a9e0891bc7993978a4d9676","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215395","peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-07-11","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"47e985be58ef86080a253a22ef4720c2565cd235f5d383887420cd12c737ad8d","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2022-05-13","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a46468f3c8d7a86a503ec342bc6e44929d48d6aa66d331868770b61f7c2c67fa","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"590488b73d1747fb32fe38158408b0f66672f357365cf4196a3466147cabac65","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4f71260d3b9258769a52c279c09c5504fb38abefba94f67fd88cfad543d6184","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-28","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20a17f116db0aab7e72fe4815284f510e1f6c55c906b6d3d87bf74205ba6efc9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-11-01","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8d89e2bee6060d48df140b22ec13f740d1361205fc3142c32fbe8da6b493a585","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-05-28","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f322eedf7aab51ea6f14f06243dc12dedf41f76d953107cd79a7213f8bdfb209","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-25","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aef4459a657db5c812f28dfc6369413a6d831480d8567656e9d5fdbbfbb0e6f4","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Patient Population","level1Code":"EFFICACY","level2Code":"PAT POPUL","lookupId":9}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-12-19","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eb1e0eaaf8bfdef86ba96ed6fa7321cd48630467287761d21a7d3ec7482af307","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Packaging","level1Code":"MANUF (CMC)","level2Code":"PACKAGING","lookupId":42}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-07","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4b3deb607491e8f13f9af777f9045242068d4075b9a5da6597b180838bfab160","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-07-28","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bdb703e9d7f66a4a120a96df6095355a13ce337e903e75e07ba3e31d7c7c1030","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA215866","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-20","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"56c7cd20a66a21e2df01d010c1370e8471c2b3f0266ab0117753942f0639c71b","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2023-11-08","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b5d2ec9188be4c795ad21764b22ac7970e3124343cc7feb1cba13c49af55bbad","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-18","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b6ad6c9268ede63518b212d9e05995c651561a3052037a1108d599efdb54e0a7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-New Indication","level1Code":"EFFICACY","level2Code":"INDICATION","lookupId":8}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-12-20","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49ca19d371fba3000aeb30d78791a4f1600695bdb330c72a9e9fb940af9a0399","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-18","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"62d2ee1c4efb401df59473d6a9ec89e5bca1d164733bae8dba6be717591bcc5c","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-18","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"415cd03d2c7639a64d7a5625f000729d60fdfed49ed9e09134abfe708665c9c9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-20","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f59dbb3e40c0b5bb520a174b7e264fc90ed3ab1ff3353967c3c62367d32d8ea","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-02-07","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91d71d68b44b8f7a84461bf99631ce70b6315f57653cd61e4f934deac7a576f9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-03-28","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0052e4522d12821e481bda3f3b036b3c03983090cf0d51c2f77bc9ec6ebcb7c3","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-09-25","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"724d716d4781ff70e170a201643c328159ae5e7f88902cf60d973c5b65c905fa","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Manufacturing (CMC)-Formulation","level1Code":"MANUF (CMC)","level2Code":"FORMULATION","lookupId":37}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-07","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f72628dc731168ab34b135b507c8e5fe2cecad12a649a1ce7e67ec39f6db5bb7","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-02-25","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8fcdf394b0ca461f4c8fe7b3eec71bba9b041f077d159efd05eaa71aca031dc9","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-18","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3334fba40712e52e4a5697804b2cfd62a4cfe2fb575fce642d42cb0659fd15e2","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Efficacy-Labeling Change With Clinical Data","level1Code":"EFFICACY","level2Code":"LABEL W CLIN","lookupId":5}],"applicationNumber":"NDA217806","peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-10-18","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"afe972b29b3099854356c12b0a67b8371557a85779fc6e2ab3f057664ca7a18f","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA218316","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-12-22","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f43fe7edb2362ccb932120c5ab08d5cb5e3601e0a63e4c5062cd745c1939099d","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA218316","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-01-29","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"303157d42345b5f706c15d137147cb622fc2adb323e4932ee018ded874b033d1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA218316","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-05-05","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9a24e60a7d05a560a65fea9da16f0ae2cbb57f7a4a9c10393833305ac488cae1","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA218316","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-02-25","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1dbc03e1cef0325c91a649af2b81ca0b4f58de7868086ff7059547d211441ca0","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA218316","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-03-19","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d15b65c194788500a9bc81c7960f26687cdf08042d408dcd909a5bf4fec0ef06","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA218316","peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-06-18","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e7eda934a34966c91813ac5e1254bf1616a3a9e7c353158426e694d962b699bc","publishedAt":"2026-08-24"},{"actionTypes":[],"applicationNumber":"NDA218771","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2024-06-04","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"960609e12493c0660a8fced51dbfc5cc21378db5503a05d365b19b61d5921d3e","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Container/Carton Labels","level1Code":"LABELING","level2Code":"CONT/CARTON","lookupId":14},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA218771","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2025-01-23","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"64ac37341aebb26cd1adb9a20afa37ea180139be45de4c618e932c5656cc5c84","publishedAt":"2026-08-24"},{"actionTypes":[{"description":"Labeling-Medication Guide","level1Code":"LABELING","level2Code":"MED GUIDE","lookupId":18},{"description":"Labeling-Package Insert","level1Code":"LABELING","level2Code":"PI","lookupId":19}],"applicationNumber":"NDA218771","peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-submission/v1","status":"AP","statusDate":"2026-08-03","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5d9faa36477c2ba87d1403a073b4c275e2379f2f738da104115eef779739b619","publishedAt":"2026-08-24"}],"documents":[{"applicationNumber":"NDA019010","documentDate":"2003-12-02","documentId":1194,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/19010slr027ltr.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"12b0735426ad6f99db43518ba26aec21d29b9ae5ce026dc785f9c1102d145989","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2004-10-22","documentId":1195,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19010s028ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3e5992eabe83097fd4ae11eb81c9dc74f7854559bc1dfea44825480c4153a009","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2005-10-20","documentId":1196,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6a8d0f518bb7b545612490808a95631322bea5442a65aa4c97dcd9ea4f42fff","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2007-09-25","documentId":1197,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/019010s032ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4578df2788e9ba797426ffd8da88514328d2567cb95dac34a4cab127c514e832","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2010-05-04","documentId":1198,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019010s033,019732s031,s035,s036,020517s024,s028,s029ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8ce92530950c5257ee6fa0ff2691c683fa88d2fe06190e26bceaa576222cbe6f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2011-03-24","documentId":1199,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/019010s035ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5d680d528e51d0ac570f08de5501db952b6cc72a8d2f18440aef699598e94c6a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2014-07-11","documentId":1200,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/019010Orig1s037ltr.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"477e21f12b7601d061804422ba6fe4bca43adca2276dff074d9f5638d23b918c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2002-07-24","documentId":1474,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/19667slr028,032ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"efb55d948399df8f1fcb4f9a1216ca6067cb28daae2ddeca8d4e8fa445135a05","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2003-01-17","documentId":1475,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/19667scm044ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a2ed8d234726ab008a997a4ba927fe4d5244714fc4066f2e36db37289348d83a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2005-09-08","documentId":1476,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/019667s050ltr.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da740dcc675849c73b292b09d96f3316535ac34308fae611244a32c04abe53c9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2008-08-28","documentId":1477,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/019653Orig1s058,19697Orig1s054ltr.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"357db694f9e0188be439213151eecce754f3f7060b0040738518195ed35b2fbd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2010-02-05","documentId":1478,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019667s058,021008s023ltr.pdf","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"48e8353af286a457e7a1dadcf3091e154862381ae7187096baa8a12984cb6b41","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2014-02-11","documentId":1479,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/019667Orig1s059ltr.pdf","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c4026c449a5a1b5ec447693abfc02a5c79f94f28753d53d5021a62384b0dae80","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2003-05-30","documentId":1549,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19732-S012_LUPRON%20DEPOT_APPROV.PDF","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fd275059dadba9c451f3767bdbe531db3926db17101c3a1b63ff45e9f97ef2f5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2005-10-20","documentId":1550,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"104c22062717fbde4a97dcdd2e9d37cbe22b2e1412c4af2fe0d145ae20354436","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2010-05-04","documentId":1551,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019010s033,019732s031,s035,s036,020517s024,s028,s029ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"086702f595249ed7f16368bde337e714192caa8c6bb276ec2ccfd86e17553929","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2011-01-20","documentId":1552,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/019010s036,019732s037,020517Orig1s031ltr_C.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a7c6872299a15f69f37a7905512ef0f9d3bd7dcfd68b55c0d8b87cc024c5cad9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2013-07-12","documentId":1553,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/019732Orig1s040,020517Orig1s035,019732Orig1s000ltr.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"120295573e2afe478bc4bb328d680670394e7abe8df4991da034da713a02c455","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2014-07-01","documentId":1554,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/019732Orig1s041,020517Orig1s036ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"45422f1233871ee8dba3f7c67c24f7e2958873d00a9d76ded79feae39ea57cf0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2016-06-08","documentId":1555,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/019732Orig1s042,020517Orig1s038ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d63920881e0a4b1d5285d1159c5a7dd8b733b5d6ca987b7956be47744b0a18a9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2005-10-20","documentId":1828,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3ebe1cc6edf7817a615b70bae444771221532c35337e4eea74cc29de117e9cad","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2005-10-20","documentId":1829,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"756580c39b43e7649488db7e374fbe10d2e5276d64063240dfc8e113bcafc73f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2007-11-08","documentId":1830,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/019943s026,%20020011s033,%20020708s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d6c5da126b3448d77b55ce6c3ae38c556ad1edae8d48297505f34965ecbd2d68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2012-04-02","documentId":1831,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/020708s031,019943s031,020011s038ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1d0e5f6676aa19bcd4b6471208d9b356d635dfa335a83bdaf1a9b34bee037cf5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2012-01-25","documentId":1832,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/019943s033,020011s040ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cfd78589ddb393a9130b1a4e8025aff5a314ee5399c4edfe8948ec431660760b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2013-10-31","documentId":1833,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020708Orig1s034,019943Orig1s034,020011Orig1s041,203696Orig1s001ltr.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"00ee2dcaf534fbc4ba715beb6e2f5afb000151581406e7bd38c3445d1b9e4c08","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2001-09-21","documentId":1904,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/20011s21ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"73e00d61cdc9d65d0a605cbd54fd289b55500ecb9d412dc444fa061d82fa8120","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2004-01-22","documentId":1905,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19943slr018,20011slr025,20708slr015ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d863fdc9963dcc756036ddf2c30b1bb7f13abfe9d95a665b05b2c2843b43064","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2005-10-20","documentId":1906,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"04cf77f6d28988d52ebf21b9488e3549f165af4804f85ace4b29682517695fdc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2005-10-20","documentId":1907,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3130d89739d17054b28373d6e02b3aedb0da8bb6e7f8b5e254fa8d4975235e52","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2009-06-08","documentId":1908,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/019943s029,020011s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0809992f9f002e80c4ce0795937ff54f07eb2e322896637a271a60a66f39fcdb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2011-06-16","documentId":1909,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/019943s032,020011s039ltr.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2d006b15a2425890128bbb9be24201e2405f5a2ec7c235743c8c35c41f3058bc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2002-09-24","documentId":2265,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20263scs020ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"569acc6624cc5d5f1afd5fd804baf75f22124db673667eb8c85a0c236806f7b8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2006-02-22","documentId":2266,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/020263s028ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b2605983671a0c04e200c56f878fcadca4e144d4835d273cee09b76d3bb2ee2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2008-08-05","documentId":2267,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/020263s030ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4a3a4f630ef1fd8e4bdc7776dce6db9bdbb8c5bbbd2f8899528b235b8d17d2d0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2013-05-16","documentId":2268,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020263Orig1s039ltr.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c8eebf91d37f3592d07bcf47da3b78f5dd499ab199dee5d96440b0b031e17129","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2004-01-14","documentId":2643,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19732s026,19943s021,20011s028,20517s016,20708s018ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"86e112a75245b171561bccfc10c20a01e175804af4d10cf653a6f8f7685083fa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2005-10-20","documentId":2644,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7cb2e32ed5cc3ec92e61ea31e0f349864a10be9b3f7af67491a1d447f2685028","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2010-05-04","documentId":2645,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019010s033,019732s031,s035,s036,020517s024,s028,s029ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20680345593a8acfff12773bdc145d250275842ea419e95efae4c1c3f85eb34f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-06-29","documentId":2646,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020517s025,s030,s032ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9dc81766a9ad4ca9db69b1c047c718383d19d6f7b7d4dab04ee29751cd5aa18f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-06-29","documentId":2647,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020517s025,s030,s032ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"173c53a2f83d57114b98e2d05f2b714c5e759136c3a1da10ea6984c7c97c004f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2012-07-20","documentId":2648,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/020517Origs033ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"29de9b2b0de4fc493852fed2ea77864f706c4dde4eb28ba1dd7aa1ce35162ac1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2013-07-12","documentId":2649,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/019732Orig1s040,020517Orig1s035,019732Orig1s000ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32f0faca741f4bcf24f7400a25d6e2743520f7da7309c4e08db217f654fa0faf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"1999-02-11","documentId":3145,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20708s5_appltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"36733c31adb0c383afaf94af649163f0deb59bf34a3e5f2143bd46965681a14b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2001-09-21","documentId":3146,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/20708s11ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea98de480724c4f2f80ecaac5b7e15a05600289fe83c357d077192709fd754c9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2004-01-22","documentId":3147,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19943slr018,20011slr025,20708slr015ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"974b5f3ac7116d6769c9df8c6336ba1ac027d7a10c8a0f692fce393498a37069","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2005-10-20","documentId":3148,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8433577d50989d8c28da41d44f663800e6abc5645fe18517da3cb9bacbfd6e43","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2007-11-08","documentId":3149,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/019943s026,%20020011s033,%20020708s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32b4326c356decd1503ff1e8ab96beeb0b71bea14f2bdefc9c620ab63768c8f1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2010-11-02","documentId":3150,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/020708s030ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df510696dcb89e33790f1c698fa36fec8f98e7a3cfa5be0e9bb1ba8778a33ed8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2012-04-02","documentId":3151,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/020708s031,019943s031,020011s038ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"03f69b8fb9f8be9507fb2cff5c56ec689f7899740fed8e4695140e91affa8a89","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2011-06-16","documentId":3152,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020708s032ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"82c4aba9cd6f3b2146ddee35b9798102f66006b991f159a32a18846face26ca5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2013-10-31","documentId":3153,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020708Orig1s034,019943Orig1s034,020011Orig1s041,203696Orig1s001ltr.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7c9fb04466cd96ca6e1eb3bb8a6bcbf22460fb3c5cc05af2dbc12b2794598ae4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2002-07-11","documentId":3741,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20918slr003ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"60777789fe2b3ba87179a87ed014e61dc8b14681bd41e36ae03bb5bafca93773","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2004-12-29","documentId":3742,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20918s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"06c43e5e9b162910c216afe301125fac312951c62d0abc90c3da027cdcca0204","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2010-12-21","documentId":3743,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/020918s030ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"62b132ff801be5608cecd3d00f0459dfdcf7c7423956f94c739f1afbb4bdfe16","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2013-04-30","documentId":3744,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020918Orig1s040ltr.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"873f5334ee86971e672fe09106bc81b432438460af04f8fdf2c46757ff7f65a0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2014-03-19","documentId":3745,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/020918Orig1s042ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7729ff3ec6a46f854b4163431c0390f9f30284fe5788cca7fa93e4d400c34510","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2015-12-15","documentId":3746,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/020918Orig1s043ltr.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fe2f62cdc34efc79953e2c4c17e8f3a9aeebc55e0c037c4f0e148b247cc41c68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2004-10-18","documentId":4027,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21008s015ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4a3e472442162e4c6e307de2d1799013887d9205a8ea7c9ba4af5e980694040e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2011-10-03","documentId":4028,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021008s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a0412d424b9c5d6f1f5d5982cd0a79f7e39d966c7c4d3b5541b23bd349fba3a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2004-12-29","documentId":4181,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/021060ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b8e70c13fb7bf188bae75ccfad4e0e02419845fc4f8d39741abb0f57a3e2c181","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2004-06-07","documentId":5012,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21318slr002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"82388404703e05b6f0878b32215b1d79fcfe36a8a9521e2d5da250ec7d6d4b8d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2009-07-23","documentId":5013,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021318s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"efd6999938a66feb02595c0e36317247bc1573452829d782db63a29095c46cec","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2008-03-04","documentId":5014,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021318s015ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9d45e3c8216a9b6cff43b8c5e71500bc5fa3002a9c7469224978205f091a6299","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2008-06-30","documentId":5015,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021318s016ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a5ea0c97762212a49363db7fcfc2b1a4f169bf7bfc69fefbdcf0de8cce471b2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2011-08-12","documentId":5016,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021318s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6f16c71bbcfbeb8e0c30a21760103cb746af45d5847d0da3894faa5efed6467f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2013-09-04","documentId":5017,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021318Orig1s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"302a4cd4a3cbf96ff2e72aacf7e311bf4a95f7e41dc2b6dc5e7eef87f7951726","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2005-03-18","documentId":5059,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021332ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"015b375b1228af30782c0d953722789287d647119aa469d7cb803e67bcb2c9c3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2014-06-30","documentId":5060,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021332Orig1s007,s016ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f53fc2d986673868f996ba1cb26707dcd30160ec7672953a760287fa617aabdb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2008-08-06","documentId":5061,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021332s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b233d631d346ba4d5262e8a9835cce4a05bccdfe4170a753498a01f26dc34c3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2015-02-27","documentId":5062,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021332Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a4b023ea9f181274b1362820459c0a4f94e2527fff5bf6dbb3a8e1a4947e283d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2002-04-01","documentId":5089,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21343s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"838e52fb2a380c81482376bd1175ab611f59455132f4b9431121bb8321839e45","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2003-07-08","documentId":5090,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21343slr002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9be2af3f93c8426f4712ee0b26149295bb72f62ef1f1efcc547e3fc3a108559a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2007-11-19","documentId":5091,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021343s015,%20021488s010,%20021379s010,%20021731s005ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"48688e912281205bdef3d5243a98ce209a1d2c3e1913f12938599ba2609b84fb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2011-04-11","documentId":5092,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s020,021379s016,021488s017,021731s013ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e934083d143cb9876ce0a1024ebdb60e0efa737d7c78ce5e4c31440bf3795a3a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2013-03-01","documentId":5093,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021343Orig1s027,021379Orig1s025,021488Orig1s025,021731Orig1s023ltr.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0e237229c8a3c090886dce4683932d28c6c55dbe8b3a45e0bdcb46571b716ec0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2014-10-14","documentId":5094,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021343Orig1s030,021379Orig1s030,021488Orig1s027,021731Orig1s027ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0db6deee3f5410d327c9734e5e34fd30556c1ab2279888a65c0a4e2dffe99d12","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2002-07-24","documentId":5227,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21379ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"738d63fcda8592901be15c4698e422efb5fbcd7ce75c0c2e0eb294d6f0d8d2d2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2004-06-03","documentId":5228,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21343slr004,21379slr002,21488slr002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"44a56619d53685de4c4263e3247d03636c9a38fad9bf2a6a33035cf6f37a77f8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2010-10-13","documentId":5229,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021343s018,021379s014,021488s015,021731s010ltr.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8b9a8354c5b8f212dc157e816351bd88284a336067d58dea90d753aef21bcea9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2011-01-20","documentId":5230,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s019,021379s015,021488s016,021731s012ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cf92293508ea228f2ec2dad8262fdc4a2c461a577330738e81b5e62492ea2de1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2014-10-14","documentId":5231,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021343Orig1s030,021379Orig1s030,021488Orig1s027,021731Orig1s027ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b100fb4af3c5b7aa20da90a5bbefbceaf122f626a61dc8da1c21a301c02b81e5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2004-01-14","documentId":5523,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21343slr004,21379slr002,21488slr002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f5dde877122587dded9c3a5105249aed9f56aa9b083b9468e77162480cc8ebf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2007-11-19","documentId":5524,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021343s015,%20021488s010,%20021379s010,%20021731s005ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"982004bd9229cff6e0399147a063270a9ddb87392470f96864ee5eba6dff2c9b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2014-10-14","documentId":5525,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021343Orig1s030,021379Orig1s030,021488Orig1s027,021731Orig1s027ltr.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a70db61f2fd05b44bed29475e46d4e6f80deec0fadf5c678b973e7e1c54a42aa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2016-03-02","documentId":5526,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/021343Orig1s033,021379Orig1s033,021488Orig1s030,021731Orig1s029ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ab2a720585c5e169e297d7af17443e1374ae17313ce40ab76d8668045406cac","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2007-11-19","documentId":6076,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021343s015,%20021488s010,%20021379s010,%20021731s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a7ba6f86a23a80b404ffa87e0d39f8234bbed99cc9e4df7aca4ef7c70879e7f1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2011-01-20","documentId":6077,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s019,021379s015,021488s016,021731s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"48215c8a89a181491014ef0f7dd7dedf35908ab1c4d869411c61eaa2dddf6d03","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2014-10-14","documentId":6078,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021343Orig1s030,021379Orig1s030,021488Orig1s027,021731Orig1s027ltr.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a8e04c86a6c7c4a32418707bb21f3620529a141f49047bb8e87aebb041bca2c7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2016-03-02","documentId":6079,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/021343Orig1s033,021379Orig1s033,021488Orig1s030,021731Orig1s029ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"19bb51402b61c884084c658566d19cf41a46b6cd0c0149e292cb7cfe0cdef744","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2007-01-08","documentId":6145,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021773s002,%20s006ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"16e9b15364d7917d2c464f8334ec4c13bb5a96afd06b94f8847641a1c925345f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2007-02-23","documentId":6146,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021773s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4142f88df37c9df0cc699b9ce3a7e8cfb4e6cce47ad90c9eb5a5252759a4f603","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-18","documentId":6147,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"17c7c14b32327e8df05c44c2c0be99d6af5924a015cc495f54a689978fe0ea89","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-18","documentId":6148,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3e69c1c03eef53c2ccc24d25612f0657585dc60b6eb6651bca430bc2b79aa75c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-18","documentId":6149,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"303ccdd7cc0a02330703db733a368c35226351276413d4d3dffb9aa2ac159993","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2011-10-24","documentId":6150,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021773s029,s030ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3237a0c874551c68c753699c277d0d94fa279c01714d448435d1f6f956c67e0e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2011-08-10","documentId":6151,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021773s031ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea3719e9f1c5895beba976a1a1e6d55b9914bcff423b597b37d0816efafccd8b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2014-11-26","documentId":6152,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021773Orig1s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"99a742846053cfd5d4f08b43eb14567fb3163a0688cbb4215fe472cd5c310fe6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2014-12-24","documentId":6829,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022074Orig1s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8691ff78bb7381f7c7c8b1956ed0f42bb30733ff3525b416af617252908787aa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2014-12-17","documentId":6830,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022074Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f48802194c6cf3c89882e6463157a7a958063fd51194554462190315893f43f5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2012-01-27","documentId":7029,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022200Orig1s000_corrected_ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"695e8bab7ae534c5843040ffbc080a753b545701ced2a593228335942cbee7b2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2014-03-05","documentId":7030,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022200Orig1s008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f97926301b651bda7cb2ba70a9e8dc2a73a0a1943495dd0efccaa579b39f9ef","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-05-05","documentId":7031,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"097e60e20644ee110fe9d3e1721e4ed1fd581cad864ab02cc7e148be88b4d625","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2014-05-27","documentId":7032,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022200Orig1s012,s013ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3af3f1ab9a63ae8ba0f16aea25b5f916f163d6f2595e2af0617477393ff9cb76","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-09-28","documentId":7033,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s015,s016,s017,s018ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b1b10141d6bd2112fda2b577758657c9ff195e3d92e77bb3be434ac8e7c83a95","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-09-28","documentId":7034,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s015,s016,s017,s018ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8de3c874475ee2b3a291d71dbe7a353c9652a31c9206a91f5a3eac55e0d50645","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-09-28","documentId":7035,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s015,s016,s017,s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6244f6801752da313660814d2b5db4eb8b9c06dd0b4347a45e3666f6e4db833e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-03-11","documentId":7036,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s019ltr.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a61815598c5c1abdfe9c293b2a145b438c7406b13fb5730da2cc1cde1559398e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-09-22","documentId":7037,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s020ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c364be95e7f5e2d76c673b1ee6228c53e511fa622d2c6891537efaca7056035e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-04-09","documentId":7265,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022341s007,s009,s013ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f18ceb94fe33fc7a5995bd7914e02035579403383cba4cad824691c875a83d9b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-04-09","documentId":7266,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022341s007,s009,s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e30e0e845047e11a5f8e0f0043ce41ee3a8b0d25bce93959a695dd55da98e1b8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2013-06-14","documentId":7267,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022341Orig1s020ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5710afb92776e5da68ac2fc42ba882b4e11d3c43c48a2d06f30f0b147f2f960f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2015-02-27","documentId":7268,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022341Orig1s022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ad1cc5d5e23999bde5656eb377e7ed47a9226772177b78dda172f22672c7416b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2015-03-11","documentId":7269,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022341Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"62de306e50337bfbf6ad555e50b29b8d2dad363e92b18f02fc538a6ff5213dc6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2016-04-26","documentId":7270,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022341Orig1s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"87eb8260124f339cb85be1500afd92d508928a5d93cf4bf1b8df2dbc7eefb101","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":7466,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022505Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"572478d96aeebaed0dd896e9ca3866d8004a115a9ebdd021a0642594a70ea75f","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA075721","documentDate":"2003-04-14","documentId":8774,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/75721ap.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"03b4feebda4b5a1c43f58c5742e560d1a7ca383f168c65fbd5acf754cc9fcc2f","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2014-09-19","documentId":9761,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125469Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c8de391bdeca6de712f3d93f09fd1f49d0794e32e169c6c7ececaa0fa67d5283","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2015-07-28","documentId":9762,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125469Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"16c286c427552dced86df472aae037832b948972ad510d0c521955ae1f22e963","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2015-12-02","documentId":9934,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/201849Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e7b6ed20d1edaf85a90eb643063e2b918955f3e082aefe031915113e81f85197","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2016-04-08","documentId":10114,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202811Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a55ccc546b4089377e75dfd565aecfd2f026f30b362cb6653db5115d15e80d1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2014-12-31","documentId":10560,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/206321Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2a560b5a6fae26354d41f429f50814323f5d42d0b09663ea563ef5fa60d79d8e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2010-05-07","documentId":11411,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"188aacb72b3135b974910e3a364fe99c127eec491d495c8f9977b7e78e091d92","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2011-03-21","documentId":11412,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019010s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"468db6d03c9833f321fd259b83b3188855bff78859694d11035b4ae5f6d3b3fa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2014-07-11","documentId":11413,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019010s037lbl.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"13d1b15656ea14dd0fc3cdd2123cfe66650b99bb99e7babc984a2a2035fdc8d9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2003-01-17","documentId":11612,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19667scm044_Sandostatin_lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2d5fb6b4bda352361fd0a97daeb25e5a8ac5b8a08f22944091dd5ee8e913aeb0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2008-08-29","documentId":11613,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019667s054lbl.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"95308ad4cb8b68978dd9559713ab482ade314f278505b02c6067bb484cf85636","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2015-03-12","documentId":11614,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019667Orig1s062lbl.pdf","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e3c01251569a37c6652607c63f7002d55917569f59be9b820a5768def26bd535","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2003-05-30","documentId":11658,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/19732-S012_LUPRON%20DEPOT_PRNTLBL.PDF","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"66d1b94f3fa46cc8efc84d7c597f77fc305b73bee00677d45cfe98abde599542","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2010-05-07","documentId":11659,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6cebfe069e15cc7e86cb5ed9fcdadaef93e23c3f1e1cbec87fb460d82af80594","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2010-05-07","documentId":11660,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b6a631dd7f69a306a25e1ee934aa666ff55d2b9e7e23d977a964ad71c4beb3f1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2011-01-20","documentId":11661,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019732s037lbl.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aac1470c9b51d0558bde1bb1a8d966d34a426ff22e8dc47fcb88831d1e667380","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2012-02-22","documentId":11662,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019732s038lbl.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"47a4da5095b5197ee7b5e84d8b2512c8acc7e5e7e696aca54c3aec82cf9527a3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2014-07-01","documentId":11663,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020517s036_019732s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bdaa5ed091175ca38b75215942cd961b5cac2f3c7b20a3435b2f85d36338e13d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2016-06-13","documentId":11664,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019732s042,020517s038lbl.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49f61290431d53ddb0a5c4a0ef98c2154012e52e4d909188aabd5c920173de5f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2010-10-29","documentId":12082,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019943s030,020011s037lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aae9c2ad09e8f4b737757886c37eec82989f19fa8e39a0ebd79941bed97ee921","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2001-09-21","documentId":12134,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20011s21lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7326d3bde7d611b663d8d3ed11171a69cb8e988395d5a7a9f89182372789170c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2009-06-04","documentId":12135,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019943s029,020011s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a602e1a5f74b40ee705d09869cd473f9762b2da0ea77027ed6cd2056e92463c0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2011-06-16","documentId":12136,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019943s032,020011s039lbl.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"067d269202dae8b200be5d28ba68a763693273f17ee7ce23a3bd12ec7ba913d9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2012-01-23","documentId":12137,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020011s040lbl.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d52b0c9f677d5858007d2e4e0e8caff9d95fec90486a07f2d7d95c6e85fd10e8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2013-11-05","documentId":12138,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020011s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e5e98734245019e5d46ed7588ad9cc96b8f8eb1ab4539aa00632a4036ff5beef","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2004-04-05","documentId":12392,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20263slr024_lupron_lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1f545c94cda9217ef498e91f1e37b532873d51446abd9c6106b91c616af0a410","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2005-11-17","documentId":12393,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020263s026lbl.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd5bd8035ccb8c3f42dfeee2126d2a07da6281dfaab22f421ae6ed0a0e08abeb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2009-06-29","documentId":12394,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020263s033lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"720a19fe33e0ef8e624283201f2b51dc2240a3c84ba8f13c421c606e87334168","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2010-05-07","documentId":12665,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed9ee6095bc4518e002fd8e72393d6c73b62d2fcf3aae8f84e1b2d85cab04190","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2010-05-07","documentId":12666,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f89c604b94109cff5d50e63ccfc04e41d6b61fac692492e2042e648ebcdb75fc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-01-20","documentId":12667,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020517s031lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1353df259c8a128716fe5f3a26999a5aca704d004c4496e7462d96da68643959","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-06-28","documentId":12668,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020517s025s030s032lbl.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e66ab8b41d8e06cec396f3dc8e67ca1cc1d004062f0f7564dfaba4a031adf354","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2012-07-19","documentId":12669,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020517s033lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2c005b24d890f560024d164ff648618c01ff3163d9c44478f945d9f63f726159","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2013-07-11","documentId":12670,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019732s040,020517s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"34d66c90b274fd980327712be422751335e957070fca3bfe6368fbbdc06085dd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2016-06-13","documentId":12671,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019732s042,020517s038lbl.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"759a314965a0a912385db18352b634210dff4f4e925cf117806f05f7e2c88fb6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2001-09-21","documentId":13256,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-708S011_Lupron_prntlbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"166811b85638916769744c1977dbc969a04e95fece7e2596bf36b0bbf65fb47d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2013-11-05","documentId":13257,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020708s034lbl.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"43910b52b379fd2d55a693b2ecc8cece69be977f77e201502e4f657eb6e381a4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"1998-06-22","documentId":13732,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20918lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e5a255e586b548064cbf103abfa9735d717a130af6dd4487144a6417ce7c56c1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2004-12-29","documentId":13733,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20918s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"34e341e612f4f53f84ee5655ccab9becae051c7b7ad7fdbd1d057d30e380526b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2012-01-06","documentId":13734,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020918s034lbl.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2d78be71bdecb4aa1a6a2a37acce3152a7301ca5d2646a67411cc82958b8bdf6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2015-12-15","documentId":13735,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020918s043lbl.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c3a51fd6482dd442e31b28e070ad8006ec88cb50da1c7e0f9b56209af37eec2a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"1998-09-11","documentId":13750,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20928lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b1b4d36f9271522adace05b6723e4d4fd35f1fee04fd7a72cd4c4f4530741e93","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"1998-11-25","documentId":14153,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/21008lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"24f27306a7387ff47d5e5d419219751da988cd6ceca3855d11b03771d6cc5f86","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2006-05-16","documentId":14154,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021008s018s019lbl.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"18e80d2a61b8bdc6216a512c1a8b426239d5065bdf00c979a5cf1d5ab667ac74","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2014-07-22","documentId":14155,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021008s030lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"392e16c1106fa28ef3f007b399e36f538201a71d3457182c77930da4ad534b8f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2007-04-20","documentId":14260,"documentType":"Label","documentTypeId":2,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021060s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"04a3f8f94a77d6b21ba069a69cde236034679694b15a15ebabc40987efd89a04","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2011-09-02","documentId":14261,"documentType":"Label","documentTypeId":2,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"90da2730737a2122edf3079a0ae884944c883fb80ed8350cce7aada2101dd2b9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2005-09-14","documentId":14374,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021088s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6bba239e88a9811f20fd38ed237b24fe13b7074b6cd2e6950993f1396ef5bae1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2011-01-20","documentId":14375,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021088s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c2de9452b6e84c861ec12c04f099ed2e9df02a480949773e9f2555efd760b5ca","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2001-11-26","documentId":15174,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21318_forteo_lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9e1ebd241599d8f921469ad9c3ad04465a4632954a52c7ddeca8b0bbaca5b164","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2004-06-07","documentId":15175,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21318slr002_forteo_lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6bedcdd587404b8a3d2845b09e07fb5a6fee00ad1b2bc491a6e7ae121a2ced5c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2007-05-29","documentId":15176,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021318s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccd333ebc4e46572d554fd0241c2c258a23b3be679a795b5e76393e0909a3097","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2008-03-05","documentId":15177,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021318s015lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8538d9c873af8ad5b439aa77c8fa03be029195b68b23e9a0281bfb2dd4f81547","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2013-09-09","documentId":15178,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021318s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c52121f87a9890febb74469c7763a7d96e74724827e367fca20d20b2473b235b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2014-07-01","documentId":15205,"documentType":"Label","documentTypeId":2,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021332s007_S016.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6eec66b53f222c2b8f0fda3c5cd6b6bb441216c7f4fd25a83c2c75b7b8e3698a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2015-03-03","documentId":15206,"documentType":"Label","documentTypeId":2,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021332s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"15e46ec64e692db213c0c629806754873f5964692e568f83d4fbebbb8e61cd73","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2011-01-20","documentId":15223,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s019,021379s015,021488s016,021731s012lbl.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c9c41b4246b41048f3210a57de6c43e92471d4da0e14887592ec29c2056e5f90","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2013-03-01","documentId":15224,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021343s027,021379s025,021488s025,021731s023lbl.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ab0e15f17e1df4a505eee8e1195a5c112728f22ca351ba8b10739a1b7b1caabc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2016-03-03","documentId":15225,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021343s033,021379s033,021488s030,021731s029lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3360e0b77f16c7ca8703377466a5d7678c191d79da066ce0a9961923bdf400b0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2002-07-24","documentId":15342,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21379lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"08ecfc435531cac7d34242b343f0c8f4b87a20721a284ec64dcba6320940d3cc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2007-11-13","documentId":15343,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021731s005,021488s010,021379s010,021343s015lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"442b506b6d1cd292d9533b52505a840fdf3c0dba15ecf64bd5f7ac29c50bc624","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2010-10-12","documentId":15344,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021343s018,021379s014,021488s015,021731s010lbl.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d4df0bd683303aaa77db7205c17f6126529b60868ffc47b7c00d721d1571d4a9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2011-01-20","documentId":15345,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s019,021379s015,021488s016,021731s012lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bd2be357b92f237c67df00f3bdae62a379ca7127c4cb99cbc0eb5f70d04705ad","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2014-10-15","documentId":15346,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021343s030,021379s030,021488s027,021731s027lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30654e07ef92604a2c14ca06cb0f6eacdd435c22666d73b229281465950daadc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2016-03-03","documentId":15347,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021343s033,021379s033,021488s030,021731s029lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"66e637d0c26d0f276fad14c27ac7eda37f20f8c728223e8ef6b59d9e3ec84438","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2010-10-12","documentId":15586,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021343s018,021379s014,021488s015,021731s010lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1cd298419e2f16bdc8e58f758030e3b616fc1fb0e0a6d7ba3136818c6c8c68a7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2011-01-20","documentId":15587,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s019,021379s015,021488s016,021731s012lbl.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c960fc60817071bc61e9b5d6dd71ff27518b3095c9fe0812db8d13c30ba8695d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2011-04-11","documentId":15588,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s020,021379s016,021488s017,021731s013lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e7dfefa05be9d2d2577a6de7f500fdeb21a70c5523f599e3b19949271f67fa4d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2013-03-01","documentId":15589,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021343s027,021379s025,021488s025,021731s023lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"700152f872c4a2431dc5cb21d9d73ea4f167f29256b2df30c18ae8fefd2a0b94","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2011-01-20","documentId":16168,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/019010s036,019732s037,020517Orig1s031ltr_C.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"40da0cdda03ee920d633676cd58637543d6e7c661e9045cfa4311ce0e535f4b2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2007-11-13","documentId":16275,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021731s005,021488s010,021379s010,021343s015lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"77d6c9093d6b4328098468f39bed36aa7e761cfb4f8dfa3fd0ebea3fe9f92251","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2011-01-20","documentId":16276,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s019,021379s015,021488s016,021731s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42de96a513492eec7acf58bac5f7bc206c2bafdaf7b7e6cd797f6057a74681da","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2006-12-28","documentId":16336,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021773s022s006lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9fa07b63fd544d13223c05fdbf7b7fd89f0d40b57af82467b1cff0ee72b6b06d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2006-10-13","documentId":16337,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021773s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4bb61d1fa974b0523575336fe5f1730eb402fa546afdad4f2fca1b6473f48cbc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2006-11-06","documentId":16338,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021773s005lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ad4056fda114a04224a01c9531f939c192a5e9a98bc27bd66eaeb176860f0b5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-04","documentId":16339,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c6065f4d0fb4f7126286e89f87c7012261cb0cb24367a5738637f38da2f80a4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2008-06-19","documentId":16340,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021773s010lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"66a0490a60d39f90c8ce437907b4d05ffab55b3a513dc1b34eb2b7079ff4938d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-04","documentId":16341,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6afc25d5c843dadb569f9ff2c4fa7bf728996a3a02a42eafd0c643402249cde6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-04","documentId":16342,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1bb4e2c77f8be2fa0496f9335ffd783887029f3034bbb8c1ffe7853bc7929020","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-04","documentId":16343,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"392b543b63f8ac6765c2817487afb26630a5268ea26bd6a4dc59658932e33d69","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2011-11-04","documentId":16344,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021773s029s030lbl.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4780ff8309911b584b1e744b53010575c5edd7a14a28d05d72a501e98231980b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2011-11-04","documentId":16345,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021773s029s030lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4e76b1ef96663a8bf4c4478ec29e3ba0d76cb67367388d165a2769327708a881","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2014-11-26","documentId":16346,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021773s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"600dd555922755bb36c6a10996438bcc8b03b94f8f7a7429af899ce420a42020","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2007-09-04","documentId":16896,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022074lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2b99ddd72836a42e7f958f3d0890fed5bbbbdcec68c9e90571ed06cf5c600a79","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2011-03-07","documentId":16897,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022074s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2d3d4d3e7abc416e5547a5365f74b59899dc1c267ec1d365756d00344fce97fb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2014-10-29","documentId":16898,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s004lbledt.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c83fed9c1640ae35abb291192a7c761a60adf195ef70a6fd74afdaab60e5775a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2013-12-03","documentId":16899,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022074s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6f89a7ef6633ed0f4bd5d4a51cd4af536a555797f4c1bd4b5681d99a3fef7fa7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2015-01-09","documentId":16900,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s010lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"965ce4ac40dd9b7b5d1e2dcc04100b40f679723a6a0d1f8d889959a1fff460cd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2014-12-16","documentId":16901,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6e69b924c4665667308e8ea03825a7982a74f265bce23a901150cb7547d2fbc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2012-01-27","documentId":17070,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200Orig1s000lbledt.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d3549ea7b982678abc17add3c4840277fe537aa853220503bfab078d9ab42923","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2014-03-04","documentId":17071,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022200s008lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0314887ac5293a434b1eda364da4b571569ea9ef95182fc6bdd70a7413b5b8f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2014-05-28","documentId":17072,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022200s012s013lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea0382a81a2f1dd5cd2fdb4b55f65f79be9ae438c94fa9d2baad4565916748fd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-03-09","documentId":17073,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s014lbl.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fc0244f9deb13fdd4213022007b1c685555357fdd1dd74789fddad1f42866dc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-10-07","documentId":17074,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s015s016s017s018lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea7c2ed552f43ba08e98f36feda94c61d623f2fd35dc6f0a70d5672d46671dac","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-03-27","documentId":17075,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s019lbl.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"21a6b18047cccf8a2c55c96ad7b3e6f824ba0dabc0c269e3c23b4bbce7236ba8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2010-01-26","documentId":17270,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f14f57eae236585a0ffa35cd36b1393af5b9e8b79e052da2f0cf631aeb120b9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-04-09","documentId":17271,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022341s007s009s013lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"850303c7cca45d31a9f3d71c94830f2b0ac68e25b1e1ddd953733ddbe078fb4f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-12-18","documentId":17272,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022341s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d22f4af29982d925e6b6bfa23dba679df278e308b9df23d9db0523a182bd2330","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2013-04-17","documentId":17273,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022341s018lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"082ba3e162b9b8fcf75362082e4c7916095f6a9502ac05b1b446cf347e86fde3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2015-03-26","documentId":17274,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022341s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"98dcf69464bf7b090177278859559fd5a2e0954896b0b62af9e6428fa1861e5d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2016-04-27","documentId":17275,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022341s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a5ea4131b3dd00e69968a6ed4804e1fb53e14e2e29d83c46438e345bd94020bf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2002-07-24","documentId":17534,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/19667slr028,032ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dfbdcd190d20e87a54dfe3116716a5a294ef7efc3da4de384d2985db7f79f937","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2003-02-10","documentId":17535,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/19667scm042ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33be374971cead42dea3b83f325e00fd743044e63d9a3169926e632947a90a3a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2012-03-27","documentId":17536,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/019667s061ltr.pdf","submissionNumber":61,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30ab835fb9b8f108ce8177040606c8d787c78f75fbd45c78da06799aee6bc1ae","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2015-02-24","documentId":17537,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/019667Orig1s062ltr.pdf","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f80b1ca07b4544a9f1e0f12209b419fbfd5a20a54349ee66795f8f287abb3cb","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":17654,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022505s001s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1672715a5aec20d81546d51808fc985ae0ab2217773d8449f6c0f52b41a8c16e","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2015-04-01","documentId":18917,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000Lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"946e19c2b449d147fdfc833d53cb83c9858a88592f1c50f1f83ccedd40732831","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2015-12-02","documentId":19036,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201849s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7f791c5d26920a52d586f871dbfbcf0c4067e5c8ac2ac1ffd93731a29ae7883d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2003-09-25","documentId":19126,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/20517slr013,19732slr023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4a35c56eaf3c351ecdefe51417d80136df9e62a80c70669aae82ea0f31436650","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2004-01-14","documentId":19127,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19732s026,19943s021,20011s028,20517s016,20708s018ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7e66e99df13f4d001ffc7efcd2d758aceaf104f7f5a0c65eca748d79dbec8560","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2005-10-20","documentId":19128,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a0c967b21b0e15bf2608ead02c12b3cff9128865657707fbe9b308819246c010","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2010-05-04","documentId":19129,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019010s033,019732s031,s035,s036,020517s024,s028,s029ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fa8c5f064cb3c69cfb6766cce946268b13f05cc480673fff2470d117ac1b26c7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2010-05-04","documentId":19130,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019010s033,019732s031,s035,s036,020517s024,s028,s029ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea70e315d8691e93cdd3e1ce7e0f06b1676f4dae39d99647b65854638baaec2e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2012-02-23","documentId":19131,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/019732s038ltr.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"23d4172f0cc31d63bd659ff275a4b7284d1cffa9f75bf96c963179db9e4e22ba","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2012-08-31","documentId":19383,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202811s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"93da2bd60db146a7921e4ab95dcb148907058ae035d054c1a0d78b2a0ad0dd7b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2015-11-25","documentId":19384,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202811s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"88aeed0c6a25fe69ce80b6e8e9a8fd90f80deaccd65144fff14fd23a1e1b55c8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2015-04-01","documentId":19715,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206321s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b81f403d409273f7f63079045d49529e91d3309a90a6e9ff8ffef057b556673","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2004-01-22","documentId":19859,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19943slr018,20011slr025,20708slr015ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3951f072de8c5f518833af467b561a643358d949898050c20a41e1085521fe86","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2004-01-14","documentId":19860,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19732s026,19943s021,20011s028,20517s016,20708s018ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bf8ab23d4464da543d41570d1eaf7cb0d81a0a81c1c06650d6a03a60bc937979","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2009-06-08","documentId":19861,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/019943s029,020011s036ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ae812b8d7399530245ab6f54880351f7bd4924114e1eb5278dc04f72b235982a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2010-11-02","documentId":19862,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019943s030,020011s037ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"baa3910eb249339156645c580facd91e10e736f3ff9154205cb198eb786d675d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2011-06-16","documentId":19863,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/019943s032,020011s039ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"76b8587dd2f77ee48229868ed7779786269b30880311ab2935a25fbc1f59ac3d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"1998-04-09","documentId":19933,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20011-S014_LUPRON_APPROV.PDF","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f0cf9370f20b6b2e398cb99826ac52e76bbfdbc778a569cdace47f897ad2c4ab","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2004-01-14","documentId":19934,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19732s026,19943s021,20011s028,20517s016,20708s018ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"73fd1481c856f010cf363e0538f7c98745dc925deecc90a2765e9ecf205d3f2d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2007-11-08","documentId":19935,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/019943s026,%20020011s033,%20020708s026ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0232d2388a93970fdc6a7562ac08e4eecdadfb5c2d7f5109f3d9ddaff75b5d73","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2010-11-02","documentId":19936,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019943s030,020011s037ltr.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"208e4394af66dc7a5605bb6fe4bf35b360e3f67d7be0135454a498b678319e69","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2012-04-02","documentId":19937,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/020708s031,019943s031,020011s038ltr.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f2d4d9b07f58d462e25eb7885783aca8c086757ab6ea6addaffa234e0cafc54d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2012-01-25","documentId":19938,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/019943s033,020011s040ltr.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"965d134f62c8dbc439086dc7930153ba7fe12c0f37954a7d8517da80e32c7b99","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2013-10-31","documentId":19939,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020708Orig1s034,019943Orig1s034,020011Orig1s041,203696Orig1s001ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e96de388b3af917160650045b30311c19b8d32f5bce50a2f3884a48576822acb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2007-07-09","documentId":20195,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019010_S006_Lupron%20Injection_APPROVAL%20PACKAGE.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"222fa7ef1d9fb383d80848a2382439ce5c59d932b498eae52fa10a22ac88fb40","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2007-07-09","documentId":20196,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019010_S031_Lupron%20Injection_APPROVAL_PACKAGE.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d1727c7c68d020d2b9778d993c37b9b0d8ada0ca1312d0ea850ace87049cfe57","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2006-10-26","documentId":20303,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019732_S007_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cdcafeda9505a772bfce30efe4c0a694591ffd4d3dee8bf080dea79958c9ec51","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2006-10-26","documentId":20304,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019732_S009_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ee7b9b2477c834617c7d7a4f693063f5b2e2ab57778bfcac02957904b892181","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2003-05-30","documentId":20305,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019732s012_lupron.html","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e8289f63c7f17b131f6d942d9cf2318cd7c7069ffba0e0b0a4aa17d54750300","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2006-10-26","documentId":20306,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/019732_S016_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d8a73d54c42507608763d7197c8fe6c09d7bd46d8ad68f935d68ebfc41fd1a77","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2007-07-09","documentId":20430,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019943_LupronTOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b35b678d924afea74d8e1a41dae5a76b3730c1f9a1f17149377e57705ba7a2e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2007-07-09","documentId":20431,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019943_S022_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"79465fac86e1a0d7f55878d0a74ded68aaae6e89ad57d426be5a8e40fdc0bae1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2001-08-06","documentId":20447,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20011-s014_Lupron.html","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b9b9428803d94cb35e51979c0783de4076b4d1d0ebae1fe63fb3a1cfa4abd94a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2007-07-09","documentId":20576,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020263_S012_Lupron%20Depot_APPROVAL_PACKAGE.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bebd59975eb05a336f96836163cc4685faa0ca1eb39526c4235841083b1ffa9c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2006-04-06","documentId":20692,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020517_S000_Lupron_Depot.PDF","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd81c362c2863907dffdc041842ee277c4d03b04b4326ed3f0a8d0b396dcbd98","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"1997-05-30","documentId":20693,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020517_s002ap.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c20e91ea31bc52d062fd957b1107a984f97514dc0be53cc1df76316a34401101","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2007-07-09","documentId":20694,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020517_S006_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"43bbaafe3dc44e81fa050a24b9cdbe80864d9ed9302f07646805d99fcefe1200","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2015-01-20","documentId":20695,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020517orig1s025s030s032Review.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"283b6fe4961d66a3bca0991c11a89fffaa7b8f7390a577af5f8940bb8dcfbf8f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2003-08-08","documentId":20864,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020708_lupron_toc.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5198057b94e7e8efcfddf304efc2dec81b670c334e9233b25de3bf410e8413de","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2001-08-06","documentId":20865,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20011-s014_Lupron.html","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2ddf7be6cb7f8afe2a0c53dd094de21fc870c32c664a69f9c7cf96db0de4682e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2001-11-14","documentId":20866,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-708S011_Lupron.html","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ca3b37a4291bb10434a65c929d08a4a38dd98d03e743368d9230b35ecc0629dc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"1998-11-25","documentId":21352,"documentType":"Review","documentTypeId":3,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/021008.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"733ba5678b85bffde9e0b1b55e29ff1d25ed739b7edff70f976bfa96e0cdd973","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2005-04-27","documentId":21400,"documentType":"Review","documentTypeId":3,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-060_Prialt.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b419fed745fb71ad10880b7ba6cf8adce812065f8fbc4e35250ec8a9a7b74362","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2000-03-03","documentId":21445,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/02-1088_Vidaur.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b569646c43e9f50e53b0e0419442f49911583f833821531fc02f6cb0bad85411","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2004-03-24","documentId":21595,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-318_Forteo.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"946e12557a5b682b0469e5e69a098bcb53bc82776a66b7773d33e67931b993cc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2002-01-23","documentId":21610,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-343_Eligard.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"670050276f290a7f46d65a92c4809424a8fbbc5ba1c43cf2581f2dfe4a5e6f8a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2003-05-08","documentId":21688,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021488_eligard.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ff31ce7d86780e12e7befe14b05ffda62e823f92e5f0b8d89ffaf57396555693","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2006-09-27","documentId":21796,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021731s000_EligardTOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3b18cf14bc284038742a72488f84d9a51e403052787a871ac5158910ac850b1e","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":22039,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022505s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1eb6db2d0324b7734063c2fdfc8ef4b8fad95bc6591495e4161548c8752a995c","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2014-10-27","documentId":22812,"documentType":"Review","documentTypeId":3,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97fe9928ad342ba583af4a290f481167f5a9e7876fe52d705c6f4c4ea47a8f0f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2016-05-25","documentId":22863,"documentType":"Review","documentTypeId":3,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/201849Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7397e4ed9f4acc46ce2bcd9b62a298a4e35457b7108c66e3a33656843ea524be","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2007-02-28","documentId":23256,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/downloads/Drugs/DrugSafety/ucm089141.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e0f0f56a15fdd2926e9c3e4b230c386a66c72b223c5f9beb140184216ef6db6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2011-12-20","documentId":23546,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"815afe6b7b0b1e5e9245aa646c9d1b2a60e64e557bd65ee5a9415503b12335c4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2011-12-20","documentId":23552,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a3ae6ffe7b3871f69f09fa7e288bdce95cea2f8cdc67db331b92a753acd3457d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-12-20","documentId":23581,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5e491e4ae4428eaa8935d0cfcbb651e8994d2c67eb8dac0c1209e880a6951adf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2011-12-20","documentId":23647,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"90fc3a615d7c890977a08bdd52e0b12386afd7dec1eaa888239f15e3bb77a84e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2011-12-20","documentId":23652,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"86537f20eb2b5aad81c7f54cd8954694680c96efcd18d15406208b86b889d97b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2011-12-20","documentId":23667,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d4c46d491ae32707c3884439a254165fd4115cfd18f66e233933a5efbfd7fec7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2011-12-20","documentId":23674,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"70062a415b6776d41c0bab8834d14a0f21174127e0d94a04515a92dc3ce68d70","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":24327,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ef0b769b71cc99dc6b4c33e246efda674863138e37298bc17e25457acf98e433","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2003-10-31","documentId":24686,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/20263slr022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"41b92e56c6748c677616cba8570b8927d06565d690abd170d796df0f1491cacd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2003-12-24","documentId":24687,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/20263slr023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"032dc469e3610f2a85084f2fa88ee6d452ed8cabd46d464ec637cf726f7cb157","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2004-03-10","documentId":24688,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20263slr024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0f8f05836b214101a20711c66ab840e8dac5c363f545f235f9daaf81ff107593","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2005-11-18","documentId":24689,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/020263s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6795e2ab35fd19d98f880d4510bc652cf70e9fbb0d46ccdd994cfef5d4b36abc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2009-06-30","documentId":24690,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/020263s033ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccfa99e842abbc99d0769404d4715bf791b046f49aa672d9e9c74ac19039e79f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2010-09-02","documentId":24691,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/020263s035ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f57e52987cc7441ffbd8bf5b61a28747f4e499252c621fb964f6161540230d4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2011-08-17","documentId":24692,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020263s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f060070f541794165def8c07d3dfa7777e334145dab54f9adde8ab1ef4823527","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2011-10-12","documentId":24693,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020263s037ltr.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75313eff3bf4e3fa4f995ddc9e9891e629deb1f23f35fc7f47fd04ec24f436a0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2003-09-25","documentId":25084,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/20517slr013,19732slr023ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"59605b81af9ff25073fd9d57509fd9e3a8abc47ad52cb106b3d46d264f52b81a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2005-10-20","documentId":25085,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33a2826768e39d727828552182717312382fb722194733fe4869d84c4688f027","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2010-05-04","documentId":25086,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019010s033,019732s031,s035,s036,020517s024,s028,s029ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1437cdab5f3b0e8c1d9f425c87212b0153c817e828bfaa3fc35ac1ade0a2b944","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-06-29","documentId":25087,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020517s025,s030,s032ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ddeaaf3eebac1b78beae6446ed6184b38d01b40972f9cdf3e283c2b6f7011c67","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2010-05-04","documentId":25088,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019010s033,019732s031,s035,s036,020517s024,s028,s029ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b39ce28c84a370e380e97f3f146b308bc6fa1df70ccc6901eeb0280febb128ec","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-01-20","documentId":25089,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/019010s036,019732s037,020517Orig1s031ltr_C.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a5f4b1fb27d3473f9905483d869bd732c75f74fd6e11b0e7824f28f1e2c5a1c7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2014-07-01","documentId":25090,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/019732Orig1s041,020517Orig1s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3dc07b0534ff0ba0155438233552fe4a7710a93ecb2dc7c7837d81eacc9def4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2016-06-08","documentId":25091,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/019732Orig1s042,020517Orig1s038ltr.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"14636119e8dfb619531174b31b30ae03fd4236f9a6f35e29a85376435c3e013e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"1998-04-09","documentId":25584,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20011-S014_LUPRON_APPROV.PDF","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1ed02c5df1ef2ac1f0e8a01c8fa9a728bd9b8b4889de3f4bf58647ee94d89a10","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2004-01-14","documentId":25585,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19732s026,19943s021,20011s028,20517s016,20708s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"13d6bdb9a62f1875950b749fa186bbd74f1d69fabd6ec2ea3f32dc89aedc79bd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2005-10-20","documentId":25586,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/0197322729190103119943222420517181920708202120011tr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"57df3f114d82a8f358aec942d523a5ec30e0e09da842ff5d342947f568f85546","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2009-06-08","documentId":25587,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/020708s029ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b731c9d3f92e7fe53e49c38b85ccc55a6fca80e63cc06f3f84112423f51ed615","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2012-01-25","documentId":25588,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/020708s033ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2b7650106787a3d5f4cd4fba038b9e43fbcd42e99238c48fb384200903a3002e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"1998-06-22","documentId":26187,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20918_ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4a0a37d1711f63e1de2dba2fb3bb52c88633b93438aa03db66ffe52bbc2b196","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2004-03-02","documentId":26188,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20918slr008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3479688d7e926e43445763bb4798a828ffa25e3ccc921c191749ec5e42ee4e3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2005-11-18","documentId":26189,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/020918s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f50d143bab18823d9d932bf8889539d53a3b3420b222ec95a4114619b0aa6721","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2012-01-17","documentId":26190,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020918s034ltr.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cd5afd984e5872622bae30e321f9a251086738c1d35b58c78f3449b98bfc39b9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"1998-09-11","documentId":26210,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20928ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b75c1d3c20df7611f2c46993336b42546566de0375e20f9c97caacda869bb54a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2004-02-25","documentId":26211,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20928slr010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0bf1ece5dfcfb52389bb0e2c28248d9d49830a0b31d393b089325799fed3dd1a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"1998-11-25","documentId":26468,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/21008ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d089c2c75bcea31c3d69ba0b0300430227fca7e00fac3e35e8c21328f35fcdfe","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2003-12-23","documentId":26469,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21008scs007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f2b7a4ef0806e0a59630e16ff4be0d8e1d25aef2c99041cda7b3780a0875a697","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2004-04-29","documentId":26470,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21008scs010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e8a0094cced98a05e2026d5a374bb6d4de0e0a2ec74bda1c49642b314e15d13b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2006-05-16","documentId":26471,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021008s018,s019ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f2c788f3005d151f8b8f6498e00ae41429ae2c2c1732d32c6646886db807d0ef","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2006-05-16","documentId":26472,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021008s018,s019ltr.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0561940811123fc02d9fe8c0f18ebdcb2459dd18ff25510fb3ff53b14e4ded91","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2008-03-05","documentId":26473,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021008s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d165fdd2186567da9992f9853d1d64d2059e60aa9e6013915c33dfe17ed79424","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2010-02-05","documentId":26474,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/019667s058,021008s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fc737b18786e2bded73554a8f2278fa0dfba64605f41f1acbe22e639300be1c9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2014-05-20","documentId":26475,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021008Orig1s028ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b71ebc55be442a77ed340f0083a084e1c7c475fd77bb778b2706b338623813af","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2005-05-27","documentId":26604,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021060s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d96239c242c1ae01c02c0abaff178f718c19962d1507dfdfccd20998a2988b0d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2007-04-25","documentId":26605,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021060s003_LTR.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"18497eeba7a617d313ed3374fc4cc581ae08c2495debd8f30433e3f3aba87f0e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2011-09-06","documentId":26606,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021060s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"225e2cf43854cdbc612933422448a056d2842c6e0a45c97833806d866fd7b6ba","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2000-03-03","documentId":26750,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/21088ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"64b2a444054a190f5118a557ef0a5c3cebde54d3b081408b8976fba5e5f7432c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2005-09-14","documentId":26751,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021088s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d958bdead0586c335c131543ddf0c5b0f1e8306c81aa001039f3290eee38a3dd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2003-08-15","documentId":26752,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21088slr015ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"309f6be5b790149e79611a5facc74dc19ab102996a85984c6fb9ae5a098f4eb1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2005-09-22","documentId":26753,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021088s022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84463075c1a11b5d9ec6867efc0e1385c71f9ccf6ea64907b783c26c61a1b4d8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2011-01-20","documentId":26754,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021088s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"55fd3324d97669119baac8a7e33915ffe4dca6ec15ccbeff7d78c646ef62a76c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2001-11-26","documentId":27463,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21318.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9e4530552e036a5cbbecb711c3fac69b8f8089cabe7b2c8055d43874a8d5353f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2004-09-07","documentId":27464,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21318s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"64719f344fd51a288aab421db0153a5b71a4fbf2a98a5c465d41f958f31fb26b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2007-05-29","documentId":27465,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021318s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"941de2645ecad609e37437ea71acd7ef45921ca6af69f498759256a41c85730a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2012-03-15","documentId":27466,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/021318s027ltr.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aebeba719fdb694d852c9c2eb5511de4d0bdca392ba939cd89f9d069bbd12c39","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2007-10-04","documentId":27498,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021332s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fce0455d31dddb95880000f12b2b6b2f0cca185d594bcbaee1666debb3861372","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2014-06-30","documentId":27499,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021332Orig1s007,s016ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"681beb8d4ff606b2d3f3b4fa62f6351fbc14877172e63d8f398c850238495a44","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2012-01-05","documentId":27500,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/021332s020ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"120d42398b6c4cf94a74f5b683c716046f9b2f1255910a1dce92b054c750aa58","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2015-08-11","documentId":27501,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021332Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7e8c9ed747c61569e4ebe655c3ea7930fb9e654c1d1014972ccdf4dbd99bc761","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2015-04-13","documentId":27502,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021332Orig1s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"026cef4e06a9c4fe633e0902faf8a98cfe535a44c11d1866954feccc26c0bab0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2002-01-23","documentId":27525,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21343ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f1be84d5180420733f6d284280121035fd1946df57b1f1fba4a1195538ed246","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2004-01-14","documentId":27526,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21343slr004,21379slr002,21488slr002ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f03062fa4ec77deec2e3da7d18a57e4dea3935f87105b5988755c89912a6f89b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2010-10-13","documentId":27527,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021343s018,021379s014,021488s015,021731s010ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c36b828244f1f9feedebe6a565b03cca78621eb82570944b3fadf5d5b0fcb9b6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2011-01-20","documentId":27528,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s019,021379s015,021488s016,021731s012ltr.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7fc97194fd868bd0222e118893964f19f33c404d097d9a4760393410e76393a9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2016-03-02","documentId":27529,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/021343Orig1s033,021379Orig1s033,021488Orig1s030,021731Orig1s029ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"effb74a75afb46b3a6f8a9e98b23ef3275bf4486e0b05299fc5a542af78537f7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2007-11-19","documentId":27641,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021343s015,%20021488s010,%20021379s010,%20021731s005ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"affee640277988a2935c12f91e416b54be02215980ed22e0403bb97a72600838","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2011-04-11","documentId":27642,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s020,021379s016,021488s017,021731s013ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d7a293883b811da033ce44bf34538bed788694ea594edb01eeaf7287a055c3ca","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2013-03-01","documentId":27643,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021343Orig1s027,021379Orig1s025,021488Orig1s025,021731Orig1s023ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c9f45b401dac39c9238b5a4d38806ae8b6f496a9934d1840949b544ec5bb5e0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2016-03-02","documentId":27644,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/021343Orig1s033,021379Orig1s033,021488Orig1s030,021731Orig1s029ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df4920c8e26b55f400d05216c217b52184d1d0c407f2570448d9a2853680c4e9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2004-06-03","documentId":27917,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-488_Eligard_Approv.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5af151fa8e955fe20ac6b26382399320a1195e4f001d095b2cb9db2c1e402b68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2010-10-13","documentId":27918,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021343s018,021379s014,021488s015,021731s010ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5b2db65dda97651949e8915e566568081e5177873650a1aec9e0fd1441cded32","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2011-01-20","documentId":27919,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s019,021379s015,021488s016,021731s012ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2109686e39f6df7de1507f206eaeb1c560427b2c6a0f0254414144bce8a422ba","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2011-04-11","documentId":27920,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s020,021379s016,021488s017,021731s013ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"27a46a7f618707f6b52f300f6003d49d77d31a971d97fab58b5fb0fb43793249","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2013-03-01","documentId":27921,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021343Orig1s027,021379Orig1s025,021488Orig1s025,021731Orig1s023ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"023987eeff19cdd4ba8162791d8b80b9fca48b2af0d35a835df0e0d2866fa2f3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2006-10-05","documentId":28487,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021731s004LTR.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aaa0be2be73099db8befd870a14dc163d737f27255ef9babd096a806f2a3a7c0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2010-10-13","documentId":28488,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021343s018,021379s014,021488s015,021731s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8272a2f27771c502cbcb3f95fc61305e49256e5fcb1d036917032cc51f4f157b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2011-04-11","documentId":28489,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021343s020,021379s016,021488s017,021731s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a0d6662734d4160ecae3ae165d16ede4e16528d5de6eec7bf937086a0232104d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2013-03-01","documentId":28490,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021343Orig1s027,021379Orig1s025,021488Orig1s025,021731Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a1887eb093c68e6e8e9161deb58f2fed33693574ee74fd9da689ee11f68464ff","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2005-05-03","documentId":28558,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021773ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f18148bbdf9c0d88edec3439f8d267361b8385c44bd3174ac35fb2f9bb6050d5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2006-10-18","documentId":28559,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021773s004LTR.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"206a5e688fdb49101a620f7f57d9c6afb3cc7a625362b144f4c8176430f20c52","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2006-11-06","documentId":28560,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021773s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0c1862498951b61a4542358b5c951799a1e26cd773d7a0284635ad99c29654fd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2007-01-08","documentId":28561,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021773s002,%20s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9ed688bee600aa7ef3ed9e47e206e1d780eb57c6a25f6c6dbaa59c4db2b9c08b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2008-06-20","documentId":28562,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021773s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d36eff8c8a1c7234e673a0579df48631ae1adb1eb04278a90341c0406ba0ae5d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2008-01-18","documentId":28563,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021773s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fbec30e387216e3935c64cb14950bb89c06fed760574c5afa3c3041777158848","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-18","documentId":28564,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"16aa09b2fe7dd47b5da2fb0273743da50ec4f8f00755c0ce706680e4edd9c36c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-18","documentId":28565,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8a23ed4c8cc557cfe0cbbe631efcf6e50c05d9a1b9b218b37fc16108de6ec8d5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-18","documentId":28566,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9dc6a1875fb0b14b7a855727b6d68568b1a9feae76ea57826edebf904c9e9823","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2010-08-20","documentId":28567,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021773s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"521dc99bcea9dadb8a93b2aad92f80c0bd0ce1cfb599655f7182cc76bd73b4fa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2010-11-18","documentId":28568,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021773s028ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a693564f0cef8dca96a11d8a71e226c182a73a64d383321facc9b4cceb726cb3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2011-10-24","documentId":28569,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021773s029,s030ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"354c7184d5f9a0da7fb9deaec7b2455bd92035469f9e2b2338897eda49b4b91c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2015-02-27","documentId":28570,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021773Orig1s040ltr.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9f8aecb4ac60cbc89560d6e255713cae97ae3504fc103f7f64a7fa8d98edb92e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021919","documentDate":"2009-11-18","documentId":28842,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f1a7d7232d6e77730d1fbb798619f48c065f2d5d6d9447533ccdfa4ac0feccb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2007-09-04","documentId":29205,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022074s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7af0fd58cb132c69b6fc8ac130dbd925e873d3c4313f64ce78a76c3618105a17","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2011-03-08","documentId":29206,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022074s003ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2c03efcf5ac45d1c255536ba5fc77718dd6c4b84df4c4b91bb7238a2ca16968a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2013-12-05","documentId":29207,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022074Orig1s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"925e50b99a70b4216f468758e64cf91645f81c520b4b9cbb6ec85a3cf30a5190","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2014-05-27","documentId":29393,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022200Orig1s012,s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8c9a1ddb98abb24cc61e0daba3c28de6f498169d400c5bbd1aaaddfbc1059e5b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-03-06","documentId":29394,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s014ltr.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ae1d1f57d6cabf9e64f1804a2afdcab4c234a019b616cfe1d1f4341ce898fb5a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-09-28","documentId":29395,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022200Orig1s015,s016,s017,s018ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"87045727a3ebd863e2b5a08e580be38eb821f35b137cb2efca5e9033ad8e5c27","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2010-01-26","documentId":29619,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022341s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ace40e404ae87677bad541be1c2a1bd251ed39518757c3ab153fc6761ce0f098","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2011-05-24","documentId":29620,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022341Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"15b8924aa689ebe7c31d17de66390a6310e412b90e2c8f7670c46e3b5982b82c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-04-09","documentId":29621,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022341s007,s009,s013ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75797b7509fe0484bad9ed227653f6c05ae2bdab7c9ef34bbcc687d0d66ccb25","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-12-19","documentId":29622,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022341Orig1s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84039b0b659523b82c616fd43686d4baab7f76c5328114272bdc7cfd43a2f96d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2013-04-18","documentId":29623,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022341Orig1s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fff4e4fe6440ec0dc977188d0368dfa99b62629e17d75d5532df4c281e6f1f2f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2014-08-01","documentId":29624,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022341Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"19aba251ab15996c2d8482c96e0c76145c11571d8b10f87df5fbf7ce486e7734","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2015-07-08","documentId":29625,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022341Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"11396ac122c0bdd8847d29d23c2b557783d458fbf94a9e120ab44d430f619e55","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":29793,"documentType":"Review","documentTypeId":3,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4d8714c72a5acb8d0a0448d03f6a88fdcb5604a221d01cb04e1514d355efd54b","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA074728","documentDate":"1998-08-04","documentId":30692,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/74728ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7f8b1d16bc064affe49d604d4976264636d37f1231339a1ae6df525907f54374","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA075471","documentDate":"2000-10-25","documentId":30899,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/75471ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f5dad1676495389488bb07e14f45ea864d83e543e74ab4d4162cafa42795b9e7","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA076313","documentDate":"2005-03-30","documentId":31109,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/076313ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"24882a8d63468b701dded3b079c4fea27815d8ab39e40e14b688b046f8faa4b2","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2015-03-11","documentId":31973,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125469Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0c606637ddf7a600528a28f783b1a28c537723cddcfc6717c0bd793650c38f6","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2014-12-24","documentId":31974,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125469Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"320eeadd0e2204e94347e5f5b329863d3af2ac9e522d9db46cb7dd2612b88a68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2015-05-13","documentId":32142,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/201849Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"897d04935beb4785c44ff74a0fd3963584adb65417953108a3ce140b11339841","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2012-08-31","documentId":32311,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202811Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a1c1e3aadec6dd2bc02bebab086333f37d1bdcc77423f6d5dff8574d76f4a33d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2013-08-12","documentId":32312,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/202811Orig1s003ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9c001613fcc9c4ea8f1bacb086e7a7d5a3b0e57cf18d47b1550fd53b837d5027","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2014-07-10","documentId":32313,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/202811Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"334212a5e705a837da5a02a127a57fe511ba3ea35abc464c5e0deb6ac157e357","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2015-11-24","documentId":32314,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/202811Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"113e7f7f5dd4bcf6ce0718b52776c7e0781c0f783c3278c6c42ddfea062cf99b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2015-03-31","documentId":32796,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206321Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c69a0bdae8e527905efbb5e5c958952f82f2045e6e2973eb054099a7b32521ff","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2016-02-02","documentId":32797,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/206321Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"163c3adde6250de5557a18ca7944c124764b9668e1f18ab2d4dfba648f78b496","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2020-03-23","documentId":32910,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208471Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b8438c73ffed070c38f8a99b6bc756a46bbb84a9261faf6c5360c8fde2ee03ea","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2011-01-20","documentId":33686,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019010s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8581257c2f55afd5cccd5ff7b7fa4fb811c91c85bfcba5689bf4513b86394734","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2005-09-08","documentId":33847,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/019667s050lbl.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"25fc0c48498a5ac8d2355e473d838300bba4ea9ee46751936b12bc0ef24db89c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2010-02-04","documentId":33848,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019667s058,021008s023lbl.pdf","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"57a49fdedb2e50f791bb151f0031d21df733b725614df13a4248ac676e32f630","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2012-03-27","documentId":33849,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019667s061lbl.pdf","submissionNumber":61,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6dc9c8ffb427d1f163a2d5fa75e07d2df74319845659027288c72eb190299381","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2010-05-07","documentId":33892,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3e7b6dda9a2426b526bc8a2d49909ff923a572fbe733c06766d97dc781e40963","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2013-07-11","documentId":33893,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019732s040,020517s035lbl.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1d63146de760c34c24f3b0c68ef4f8d2c8e6d0fc6940e6eca9d001f4e678231e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2009-06-04","documentId":34111,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019943s029,020011s036lbl.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"73efeea313b061cbf2b0f6bdedc4556df4d523280203ccf4f6f7158699d8cfa2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2012-03-28","documentId":34112,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019943s031,020011s038,020708s031lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"01eb78295320f4c39342ee5dbebbb06ff0efe0a779b273c46f7b1927d836c6b2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2011-06-16","documentId":34113,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019943s032,020011s039lbl.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8e3750fcb0cee2721fafdcc99c08e04d9dcd826e7b2785da7d8e917feea520d4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2012-01-23","documentId":34114,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019943s033lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"762e0b80f3d66e7563c690c16b03c85ef873fd17bfbc86454aa331fda94a4edb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2013-11-05","documentId":34115,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019943s034lbl.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2035c4d2cedf6d3f287f1f9a8eb5ab1c0071bda499c80ede0f71c3d4d80ce506","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2010-10-29","documentId":34181,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019943s030,020011s037lbl.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c91b64852ad4eb00930f9a3b2aa4f1d7a5b7099a9ca997460fec6e71560d59c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2012-03-28","documentId":34182,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019943s031,020011s038,020708s031lbl.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3b5542739246ce8a108a655018923473dec7c080a1835d94b5ddaf2361a09b08","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2006-02-22","documentId":34448,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020263s028lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4e22bd7f4e2233af06df543df13b3452ed1daed658a204fd5866e0d5fd3f26b1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2010-08-30","documentId":34449,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020263s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cb51ae5790ff0bb016ec6bff47c2ef63eb90eb21c976cb5b9fb4ba0206f05ec3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2011-08-15","documentId":34450,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020263s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97db4cae99437fcc17899f8865279b7f8338f6cd09931fce1d4c48e8e2c74135","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2011-10-12","documentId":34451,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020263s037lbl.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c683c7a43823fd7eb2db1ebcc6354a017ae8646f8803d33dc0326cf40a20f67e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2013-05-21","documentId":34452,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020263s039lbl.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b5bfda7ab204209ced86d39743806c2550cc4ad50e6bf191aac894ad9be61e1e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-06-28","documentId":34744,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020517s025s030s032lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"264a808a58c79af2a75a60bbc065abde854c760b815aee83adeb0a0067f605de","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2010-05-07","documentId":34745,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bc2f6d5aabd389a2ab775a1dc1e1610c39de3273d4942d6825d15fd1c3d122b0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2011-06-28","documentId":34746,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020517s025s030s032lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bccf6abb34426878f1f5ea13c1c0e5d79087deb862e0358ce735f3ccba1421de","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2014-07-01","documentId":34747,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020517s036_019732s041lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"15abb34bee7ef163150c1680364cd0d8d16502ecde8655b761c36204d4be7166","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2009-06-04","documentId":35182,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020708s029lbl.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b1e84154eaf79f887416d501728154d9aa7ed5fb5f7b1e8e19eed1a9ccd49807","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2010-10-29","documentId":35183,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020708s030lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aabb0d427df78d259c90baf1da9895c1aa5c805ed322820dd020eed5dbdd1703","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2012-03-28","documentId":35184,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019943s031,020011s038,020708s031lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2aca017c22e8c2a99cae330711a94409fca9e45c6561f9d236500bf6921429b4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2011-06-16","documentId":35185,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020708s032lbl.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd2b36f401430cf31d92ae1908f7a30199ec3cadd4e6e482ea4d99983ceca890","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2012-01-23","documentId":35186,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020708s033lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4517a6629973dc9300fcbdecbdb38ccbe8b6cf573c09b66ab2197a396fa939c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2004-04-05","documentId":35638,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20918slr008_glucagen_lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ce48d252710f6015b7519e5eb68a77cbfddcdce0523506e6fa9ec638ad0627d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2005-11-18","documentId":35639,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020918s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7a5bfdd178d4f75cfc9a140211bb6a1cd4bb6a681d011fb3ed2ad9b972a24a0d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2010-12-22","documentId":35640,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020918s030lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e64407861c062160172915cf3bb8702ca738c770003071be4f7e9274dd7612f0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2004-04-05","documentId":35654,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20928slr010_glucagon_lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"65ea2d4edd8fa629ff966b40997b60e3656c2607471ee430b00698a19b51cd0b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2004-05-03","documentId":35870,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21008scs010_sandostatin_lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"00d14a8e3390cd8bcfa7d42d97753539395cc33dfb7f6151d4a4bfee141f1e3f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2006-05-16","documentId":35871,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021008s018s019lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"46b0ee4c3551aa4db760c28ef30a556f9f3c6afd11a1538f5a456320e8bfd438","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2008-03-05","documentId":35872,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021008s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"662ee52ec12c093aa5f693ef32fca3333607a290f746c474519558b785b4b410","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2010-02-04","documentId":35873,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019667s058,021008s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ae822cdc5daed6b97d507d58f942106177afc25d01aacdf69033fdfc8efbbe1f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2011-09-30","documentId":35874,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021008s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"19a4c34ff6f9edef7d85d16d186d6f1df5d26cec74e074235e5fc900db53bb6e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2014-06-02","documentId":35875,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021008s028lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"48a5aeb23d46cd5f3b1aadc1d59db49bad6e68d58b3bcd6c8ffaa5d1152a43ec","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2016-07-25","documentId":35876,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021008s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e4dd6cd211c0fc1e8559dd3a66475d0d47e277b152c38d0d73e202d24aa45dfd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2004-12-29","documentId":35991,"documentType":"Label","documentTypeId":2,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021060lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ea4f268f3402bcc9b3325230f1fcae7159ef02171e68d62bf40160403393ea9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2000-03-03","documentId":36102,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21088lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"26e8c8ef25ca1481900f91a0c2ebb1dd602c4dd01db29703e3e4aa4693421be6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2005-09-22","documentId":36103,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021088s022lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5918e827f2bf556f71ab80fadcedcb654431435324ab057fd0ff846661655ab2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2004-09-07","documentId":36642,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21318s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dc45bb6af98169357b2e2661154354982c2d09cd02a87ccc42066ff57b474ab5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2009-07-23","documentId":36643,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021318s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0947a54d48046dd724c4a9c289da2558b71952bc623918e26ee997dd318514ba","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2005-03-18","documentId":36670,"documentType":"Label","documentTypeId":2,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021332lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2079b221025803ae8edd8f4fcd1bae6536fc291d7afefd18986186c167001279","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2007-09-26","documentId":36671,"documentType":"Label","documentTypeId":2,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021332s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a7682bff93fac075e8a72e973170b2466dc720408c3324d273cc515b1aede505","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2014-07-01","documentId":36672,"documentType":"Label","documentTypeId":2,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021332s007_S016.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1b7f81caf54bf0a18a16f91a7d753a9e75686c043cf6ae8113789eda082b961d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2015-03-24","documentId":36673,"documentType":"Label","documentTypeId":2,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021332s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"defea16ae8846c86463857467523786d0ea11b1e5b28e84dabdd47d3a7fe05be","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2002-01-23","documentId":36695,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21343lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"844ebc7f60afdbff70a88065b5c82378da8fb0478678fd413fc92c66e521d932","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2007-11-13","documentId":36696,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021731s005,021488s010,021379s010,021343s015lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"28e3d777b15a09bb61aae39f3b1f7ce132bf812365cf5a8d0db36369f92f8427","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2010-10-12","documentId":36697,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021343s018,021379s014,021488s015,021731s010lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97a1c5cf44ba31b2891005f76a9cbfd56943b21054a3aef1b6cb9f8af279321a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2011-04-11","documentId":36698,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s020,021379s016,021488s017,021731s013lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"03464a5ce1eba71de42c42afbbfb10a87b61a47d7fc4f9943c6ab7f206c976ee","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2014-10-15","documentId":36699,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021343s030,021379s030,021488s027,021731s027lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8498d9689ab7266be4182867d03238a6d53c83c954a19c328e4ad7063ddd6e68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2011-04-11","documentId":36800,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s020,021379s016,021488s017,021731s013lbl.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d7ee8ceb80de9a4a30bc5553467937f290c8917b75f7fdeae60bae99796a3faf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2013-03-01","documentId":36801,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021343s027,021379s025,021488s025,021731s023lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"80c179645e0099cb5d4b975390b67aba9d522c36a13f98d7fe7623523832a086","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2003-02-13","documentId":37055,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021488lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"66098b7847c05e11dad7cf6d1ee50b38f7e918fd6a952c69ffe8d963663c21a8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2007-11-13","documentId":37056,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021731s005,021488s010,021379s010,021343s015lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ca763b5fb108f17b3dc330d3a9a85af82e11abcd8cf87a79fffb6750ba718a14","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2014-10-15","documentId":37057,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021343s030,021379s030,021488s027,021731s027lbl.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bab0f9a81189649def5ae88eb14a9736d9e5ee9806eab568200187de7ca5d3b2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2016-03-03","documentId":37058,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021343s033,021379s033,021488s030,021731s029lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4983a7413220dbc1fac9cf0cc233737276aca037c20916400e30d786eec2d006","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2010-10-12","documentId":37548,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021343s018,021379s014,021488s015,021731s010lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9cb05990fc17c49e77eacaa94d86fea035a3f0078f29297a351b50bfa8da2cb1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2011-04-11","documentId":37549,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021343s020,021379s016,021488s017,021731s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8664b61b778041e372b7d6342385a25d894e13668d1a9b465da697e1bd0e0ff1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2013-03-01","documentId":37550,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021343s027,021379s025,021488s025,021731s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f22f79d7748307cf02228986e643a9bd291401974bde1cfd46c3434f4102b9b3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2014-10-15","documentId":37551,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021343s030,021379s030,021488s027,021731s027lbl.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c95d52d983622bdec521444480e2b3d2360379c9e985c8458dbec170db6dc3d6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2016-03-03","documentId":37552,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021343s033,021379s033,021488s030,021731s029lbl.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f2297c782d7f50f38b86a197db54f67eecf52a525baff68a69161c9cd814e538","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2005-05-03","documentId":37610,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021773lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5add2582b771dea0e8e7bdd28151f11030ce451433250592680c03459703d6aa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2006-12-28","documentId":37611,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021773s022s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da0bfaede0a1dbb63b2b4ed01cd6b419fd7bdce10ab678f28bc0169dea81cefd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2007-02-16","documentId":37612,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021773s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e1ba226d56ac7c1eca2b3b6924a7bb87bc7d0126ec97d688f59c93d5a29c21f0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-04","documentId":37613,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8be4646fc6b0442b11fd8c1cafff60fafbdf8d02a694228d194995985c8f073c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2008-01-15","documentId":37614,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021773s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ecc5ab188cfc3206e648e2b0abb2ee94df0dacec13cb2026e57a5baccf17bf0b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-04","documentId":37615,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6d54cde94e9750e4d39ed2ddbb0b073c53f2cc3ba292f8bda8cad9760a55a6bb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2010-11-17","documentId":37616,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021773s028lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6fe8feb58bbfd4e32821915047baeeda0c9c939ffe9a556f670faef6948a7ce","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2015-03-03","documentId":37617,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021773s040lbl.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"660a4e9528f4d0bbbf0a5dbddf75ba3b5948163be2018a121ce997e107b7dcd6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021919","documentDate":"2009-11-18","documentId":37874,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5db5a0c48e59faf6eef16c11e63bfc4778595badd469d17fe2c83c161b8fdefd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2014-05-28","documentId":38370,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022200s012s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"522ede8ac5e738061a11c087a0a79be6366e8e4a135a8607aa803df7ac5804dd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-10-06","documentId":38371,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s015s016s017s018lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d024be0120ef1f4038a8ab2867097d08e0d086b146d2dde3cf07f8fe3385beb2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-10-07","documentId":38372,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s015s016s017s018lbl.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d818c0520a8fa3f22d2cd951af774a746260057b87d8e564fa92e6ad7502493b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-10-07","documentId":38373,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s015s016s017s018lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"00217b476f2f307e98286986c83b83c5ab28ee44dca563d561442be685c6d2c8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2015-09-23","documentId":38374,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s020lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e725e5141fd2c2b3fdf66676a1f6c08682e5d48aafd8e7f97179f646a8e5f685","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2010-12-26","documentId":38598,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1d4bc8591e04654cde278c87e870027ffeeea400a6aaa49153a60463adb526a0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2011-05-23","documentId":38599,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022341s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"020a635b420c03520498cc32a047cfe24ddb1b73ee3335fae7b062b3771f6fd0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-04-09","documentId":38600,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022341s007s009s013lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3460c54766e0788548af5e381941c8b9f1b7dd8515ad1d5efa0a2c3d119471e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2012-04-09","documentId":38601,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022341s007s009s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35e9bfecf03b6a53cfe9124305d6eb8e7a5d64775ac93dc3bf20f852655dfb36","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2013-06-18","documentId":38602,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022341s020lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"053ea55e7abbd3614a11ebec61e16e0530f65ad1aa2e484430fb88414a435680","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2015-03-03","documentId":38603,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022341s022lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a427f87b1f3698c6eb35fed6be5f5372836da983ce0d58ac9ddf6c62500ca90c","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":38771,"documentType":"Summary Review","documentTypeId":21,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000SumR.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3aa0ee24aae8e132b7394f487eb6b9e144f0f3427462992ece7404ff7f15a480","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":38772,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022505s001s003lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b7fa3c41e0cb5a447b3e44c6fc45a5be250bd3029e04b02c34ba7b44ab431a28","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":38773,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022505s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da17963a10e02506330cc9a41b0b4124ff4e38133441a5ca2664b2f2074d19c6","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":38774,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022505s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2cb8056af11478dcea4a25e8809da417705416e85ce1172196613a0dd4d6162d","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA074728","documentDate":"2012-08-02","documentId":39437,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/074728s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"86ecc8760019ffa7e64ccfa4c3bf882cde85e1b2796a90040eb6842077e6125f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2013-08-12","documentId":40223,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202811s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ff75dfa72ba8587e8ba78f8adb485a37dc49489432989f66172f3df4e4a84d5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2014-07-11","documentId":40224,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202811s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c95477afb0756ced3ed017cdd92b612fce55caaaadad8c3bc90373da0d6504aa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2016-04-07","documentId":40225,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202811s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c9393468178c76869ffe64a80edc1846fcd78c4bce702c23d811d81c20087dc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2014-12-31","documentId":40537,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"27caf7f68830c93c25653e38d12dfba47bd3b920116c009780c012f8317b1c39","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2020-03-23","documentId":40635,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"552e027d9b3f2fc0b6eedf1be79779eb10af27b287cc0d16a824ca78371970fd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2007-07-09","documentId":40858,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019010_S023_Lupron%20Injection_APPROVAL_PACKAGE.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3924ca522faed94f114f1bbb52ab21ad69ea79133e0977e66ab6aa4857d5456d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2007-07-09","documentId":40859,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019010_S024_Lupron%20Injection_APPROVAL_PACKAGE.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"967dd5cc83676f878fe31d6dbf29ec05f2d4d8a93015bfffd171ba90b731c7bf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"1999-02-19","documentId":40962,"documentType":"Review","documentTypeId":3,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019667-s04.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"09cc16bd8055c957dfc191cab69e12d0212c8522f663f12a077376508d16e611","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2006-10-26","documentId":40986,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019732_S027_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3a5e8f3938833065606c2bbd8fc9f90c425522f21a056c51e51606ccaa6382b6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2006-10-26","documentId":40987,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019732_S029_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"07dc88bc4e811e0093961d908c45909ef2544b936ec16f2f3e2fdb1a4715001b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2007-07-09","documentId":41104,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019943_S003_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"78c85d60260ed1f871d7ce71be5db0e7bea069fbeb7e6c64288f349ec2916158","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2007-07-09","documentId":41105,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/1999/019943_S010_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30d3e3c83c63c6db9c1ef7fa89f9af4336e9a0decd8fa480dc4e580c0d0b37c5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2007-07-09","documentId":41106,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/019943_S024_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e5d142b2b4e10274c0deb384dde446d592006a1e72fe08879de6103caa93c8fe","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2001-11-14","documentId":41119,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-011S021_Lupron.html","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"68fede403998f4eed7e6b36099d18677794030e752b3999089d2cf1e91d1314c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2007-07-09","documentId":41251,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020263_S003_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3988cb21af4ff63d04f9e74f53b0ac7e3f3ef74bacf8cae5ab63de8b77ef5599","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2007-07-09","documentId":41252,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020263_S006_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6859668fc91ac385785b3fc5f2a980a3df7919b6ea534dedc48430af2558df5a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2007-07-09","documentId":41253,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020263_S028_Lupron%20Depot%20Ped_APPROVAL%20PACKAGE.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c3eafbedd038da8bd5bb25436dafea5987e8343e4ee39e2f617bc061bbe99d7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2006-03-30","documentId":41405,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/20517S001_Lupron.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"157b3bd4288059b8cbbeb97984a61c6de2ac50984112e0897de71cbffc70f382","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2007-07-09","documentId":41406,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020517_S018_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"201d74e3648b542a72d34ea0bd6815ce3915daf98b563275b2510655122f03b2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2007-07-09","documentId":41407,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020517_S019_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"887080736f18c9fef61141997e0750786cd32f663c4e8a4aa21d5dc83e10644e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2015-01-20","documentId":41408,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020517orig1s025s030s032Review.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3330062df4bc82c6c65a7f77aa8c28c198bd76b315778e2983e760b1b0c6e964","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2015-01-20","documentId":41409,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020517orig1s025s030s032Review.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"49cb0edfa73772037f5380120301758ea401b6440c07c7129a19341c48109cf2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"1999-06-22","documentId":41595,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20708s5.html","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"64faf682fd5eea8da119518a2db75b5e4f07ee3d6b454cc92987ec0bc00fe4d8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2007-07-09","documentId":41596,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020708_S006_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1e0cdfe97d9d52f3be1f79102b43b16fa4c7c9a081e1a0d9eebf678f794c95d8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2007-07-09","documentId":41597,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020708_S020_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a49131074d0a808a6b909cea95abc3c4a4a660fc60d60b1bf50441ae7e65d188","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2007-07-09","documentId":41598,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020708_S021_Lupron%20Depot_APPROVAL%20PACKAGE.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fa9919e9d3139ede1b98ef7e1c350a8b92dfe1fd1c1f3310a2cd81be8424ab7b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2005-06-23","documentId":41809,"documentType":"Review","documentTypeId":3,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020918s000_GlucagenTOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"182d5a01a07cafc731e6dc90534dc3b9701956e561a1ef3a25f12d423d7a54f7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2007-07-20","documentId":41810,"documentType":"Review","documentTypeId":3,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020918_S003_GLUCAGEN.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e945f8f5d546f4240c0c841981285a53dae55974365e75fbf2317783a9536de3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2007-07-20","documentId":41811,"documentType":"Review","documentTypeId":3,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020918_S008_GLUCAGEN.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"121b334a3f2069fd4f68190ad33711e0a85ef0904d53f9b00c2c02e3ff3f5bd4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"1998-09-11","documentId":41816,"documentType":"Review","documentTypeId":3,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20928.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c305e393b05be631aa306787b9ccc66c20d89d6de57e331e829d40ab4c4a4d20","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2015-09-23","documentId":41872,"documentType":"Review","documentTypeId":3,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/021008Orig1s028.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1b8eae65d741b7e75dd2debd8b40f5f350a0e50d3561ea11cb4d45eebafde6d2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2007-07-20","documentId":41916,"documentType":"Review","documentTypeId":3,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021060_S001_PRIALT.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c9a7b48f9b71b4d8fd2cb86a1765f3462eb22593a2656099ae2cb91c668496df","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2011-10-10","documentId":42097,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021318Orig1s016.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cc578b4b88a762d436baf87e8d2bc40b325ff0c7f284f8195b9f074425af6b7e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2005-06-14","documentId":42103,"documentType":"Review","documentTypeId":3,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2592f46126066dee9bc9308c0500166a3a262858eecd3eeaebae74c9accf90e7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2002-07-24","documentId":42130,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-379_Eligard.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3510ae793688d3269fbbbad0a1b0821f8f651dd20a65eb45a40173889c771d07","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2008-07-31","documentId":42131,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021379_s002_ELIGARD.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"34cdf946697ba1284992b03189b9648f4ad4dc42b9f530d35e4765192acb540b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2005-08-04","documentId":42305,"documentType":"Review","documentTypeId":3,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6e4f0631a1919231b3ede5cb97145072e8de1f8723e33d97025bb603547e081d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021919","documentDate":"2010-08-20","documentId":42349,"documentType":"Review","documentTypeId":3,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021919_byetta_toc.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f928154e50d3704dff0fe00dbf7a345e9ee7c816a6cf654f52e4b820342a4783","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2007-11-06","documentId":42409,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022074s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d57cdabc35722dc0387ec4c8c0d3463cf58810e123d043d8c71bf619d5e1213b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2012-06-12","documentId":42445,"documentType":"Review","documentTypeId":3,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8defc8d2ad26d75fd9dacab58c5550c2bd030aa9f0513e04b9f83268b190930e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2014-08-05","documentId":42446,"documentType":"Review","documentTypeId":3,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022200Orig1s008.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b7056b3c653d7bd50a80a4ed2271d533e29dd9d451651f6ef83cc0de09e69b0b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2010-04-06","documentId":42495,"documentType":"Review","documentTypeId":3,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9003a7d7f53ce7f49e8299695115276abf2625ab12facfde81d5801af33d1dac","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA074728","documentDate":"1999-03-15","documentId":42865,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/74728.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2607b57fdcc700559032cb9c53082e8ad52a9e7156a6f97bbbc4e26a06f55b52","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2012-10-04","documentId":43414,"documentType":"Review","documentTypeId":3,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202811Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"481923021fb355490cc06f0e1beb7bf3890c41f75b9e18c02a3b8e7be3f4d9af","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2015-10-01","documentId":43516,"documentType":"Review","documentTypeId":3,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fd7550e63d8cad978ea52357d09575fd957160e5724c17c646bba4903f3237e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021919","documentDate":"2009-11-18","documentId":43799,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d76a27fbe31bd5d2b5b52a9c2abbeb6ca951a7205df0ea352f152d58d585167","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2011-12-20","documentId":44040,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bd187056ca4f35043b4fdf915f6f3f150576cf1dfc1ddfda145017d4ab468dab","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2011-12-20","documentId":44041,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ebd179f0d96eec02a954f196fcf03546a04b8761fc101ef9f2ce58320436721a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2011-12-20","documentId":44052,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3699ffe28f00eafe587e513d6cc544fafcf0bc9f031917a68c307902153cf79f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2011-12-20","documentId":44066,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d8aa774add05589bd6c69416d14f91062d259c7f65d44609176136bb4bc91e73","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021088","documentDate":"2011-12-20","documentId":44095,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm209848.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a16d3fb98f690a1a9d214e1137ffde51425f5b6a268efa860460137f3d2c89e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2009-11-02","documentId":44151,"documentType":"Other Important Information from FDA","documentTypeId":10,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113705.htm","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"023b63b8a42823e1138fea83259f393acb83afb6898b7ee2065cb9369026c908","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2012-06-12","documentId":44698,"documentType":"Summary Review","documentTypeId":21,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000SumRedt.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0da07b5fa95876e754162ed0a20aeb94b81b6d8a1630e6758c83a02d5836367","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2014-10-27","documentId":44809,"documentType":"Summary Review","documentTypeId":21,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000SumR.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"591d6cbfa9316e641a958f4365f0e1263088e9f34f17af03028578a082741ea2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2012-10-04","documentId":44867,"documentType":"Summary Review","documentTypeId":21,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202811Orig1s000SumR.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ceaee007dce2746b7e93514b904b8f99d38b3aa2afec85e260d0298189955a00","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2016-02-29","documentId":44988,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021343Orig1s033.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a0a2c66165db051bba95bf4bb5135b54e5d5df384151df9f5af7d0ce7ef8a678","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2016-08-31","documentId":45191,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202811Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b695bc4d5b36c209ac3bb4ada64a244454f2e1b2052a1e717a0087e1caaa7d3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2016-08-31","documentId":45209,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202811s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a58a74cc2b5e73c53ec632e1594c181bd2baf23d651205c55797ad618917ffe6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2016-09-22","documentId":45358,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022341Orig1s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7ea632db86a74a0c4b551d9f7a29d14a4504b635dc8bb4ca8ec7ab923efa5407","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2016-09-29","documentId":45412,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206321s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da2d6d9dcc0b1eeb54cecee9da68d5656a74edd63ed0be8fd30f707634bba007","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2016-10-12","documentId":45520,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/206321Orig1s003ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"24d5d784e202508dc32f2c6c5e80a262c99d32f098a430d17f5986465cf1d04c","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2020-03-23","documentId":45985,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208471Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b6c4c7ce13e5c5d56127697a9ac7c99a9654987ea450afde1512fc9b20ff6c48","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2017-01-23","documentId":46926,"documentType":"Label","documentTypeId":2,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3189eb6c9b29070a5b66df83e5788e170fed0b42a4961c9a5ca1c04582a30447","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2017-01-23","documentId":46927,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208745Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84aa886263cc4327702fee4bf5de44b4590861cde2f8e2860dd2ce57c38d711d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2017-01-25","documentId":46977,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s010lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3b3e6db5e7efdd62811e0f673cd24d845f6b4f0f7babca5fc087f814549590c7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2017-01-27","documentId":47004,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/202811Orig1s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"99183506ea153e710f2ad6dd182876b2d13926a68bfe335d6b6bc4ee46a92f5d","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-01-27","documentId":47029,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37eff850536925880997eca1813d533aea2ea4f5f11d51a736d3369d17b9f875","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-01-27","documentId":47030,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0ae3a40c7228374c10c1c8aa95859b888e5acfa92dedba984397c985f1e78979","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-01-31","documentId":47051,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125469Orig1s007,s008ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2cb9cb588008451d24063a1afbc83782bc8ee1cb467727b9ee9707ef98d2ac3b","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-01-31","documentId":47052,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125469Orig1s007,s008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a0fb036e4e59e8b458bf3600e9a0934e2c4a7a382585d04f95c50173735a7303","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2017-03-03","documentId":47466,"documentType":"Review","documentTypeId":3,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208745Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a4fb6ee1055e2daf2af708b9e4fa01485f5dd6365128ee80cae1ad7b39bab03e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2017-03-09","documentId":47515,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"163b343352e32f2e0598b7c5bbdf2756273c0afefcaba384ecbe9d2145046d98","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2017-03-14","documentId":47543,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/202811Orig1s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"17625932639d60896025fbeb5bba456a9139c9e2d47402980ac43661c90e34dc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2017-03-14","documentId":47544,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021332Orig1s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dc5958e0395c8bec41ca1b3964f91fc7921b2583f30f2b0f94f43c481367a593","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2017-04-26","documentId":48119,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s028lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1cc7a87f530f313f0d91addc68f16a46dfd4f6ccdfd4649a9bfefa5c7d5faf93","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2017-04-27","documentId":48123,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206321s004s006lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37911d799c98026215d565663e0dfad7810fc91e432ce10b01a0d720bfb79777","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2017-04-27","documentId":48124,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206321s004s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f4fccaac28d18174a60461107e64396189c7bd37088e97b0a5f8e9ff5fbc79f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2017-04-27","documentId":48151,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022341Orig1s028ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"989593422b4a166136f4a75f8e3f3a2f69e0f22b359bc0bbb206ca9507216b6b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2017-04-28","documentId":48157,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5907180de90d729fb3cb12b5115d6366fa9684347cb0d3b36006701b6fc6e607","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2017-04-28","documentId":48158,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208743Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5e73896e3cbbe3bd53f8df3a5c21716d1547884889aa3cb449138bde80ffaf11","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2017-05-02","documentId":48200,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021318Orig1s051ltr.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bc7ab4f532cfdfffa9037a2755e0427f888b9411b80dfd8e0e9a18d3edc74e88","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2017-05-02","documentId":48207,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206321Orig1s004,s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2736d2060cc041274160a78ff5abadb0c01efd9775207146af58174088c9c5f9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2017-05-02","documentId":48208,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206321Orig1s004,s006ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b79972512d6da31a23e64d4d67631c7dac30f6aac4de29c50e868edce2eef30d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2017-05-19","documentId":48466,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019010s038lbl.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"661e79e63f507c616a298f1a50dd92b973f1e6a3d2a5d000301f7e4237d20ba5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2017-05-19","documentId":48467,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019010s038lbl.pdf#page=27","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d51ec53ae1270f162a430dcc689e2f92597968208e35e84f38817010131d1f7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2017-05-22","documentId":48475,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020263s042lbl.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1519c780969045ea62b70654ca692b26438d04cf59a3d2b50f03f745d1a45fae","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2017-05-23","documentId":48494,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/020263Orig1s042ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"07c1d63e254e2048eb81e0240e4799cfde89dc24df1f1b40ad9a6ecb05f4b11e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2017-05-23","documentId":48497,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/019010Orig1s038ltr.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d5883e488b2a6d9899eb833c316e5918b2f45dddac4acf16dff8b38c9e52c4f4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2017-06-01","documentId":48614,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206321Orig1s005ltredt.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e5bedebbf7a1ed5f3cb70114d89af25a57c0f2b0e876b6348eef3186873a73c1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2017-06-08","documentId":48680,"documentType":"Review","documentTypeId":3,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"775fe85a57ddc52cdffe44799832ba54704f9d1bcd3eca0c5133ab75111d2713","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2017-06-08","documentId":48681,"documentType":"Summary Review","documentTypeId":21,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000SumR.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37eef27b2d9f8f60db0f3ddceab35998535ea0f1c85d314ed80bbee356986142","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2017-07-12","documentId":48954,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019010s039lbl.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ab78f68c7ce6f9b55fbec43794815be3aaffa9f8663ac3090181b35f45b2ebe1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2017-07-14","documentId":48984,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/019010Orig1s039ltr.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aa7bd3bbabf70d173ece4258dada70d968559a9917d27af50845af157329f60c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2017-07-28","documentId":49108,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022341Orig1s029ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ba67973efb75d7389254671ce2f72733da8721cc4c2e832304235f0332a73ff7","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-08-02","documentId":49213,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125469Orig1s011,125469Orig1s013ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"501604b2e62bd51e67e9b4e258694f3307cf9497616a2863d7e1b886404dedbc","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-08-02","documentId":49214,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125469Orig1s011,125469Orig1s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"51feaa17f69e9954f77966bc4f6eba12da0d593c845b98a6b170e568ffcdc6b8","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-08-04","documentId":49231,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s011s013lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"23affdb95411d3880d4f358cadde8eaa4150dadd5b42867afeaa5b1a82403084","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-08-04","documentId":49232,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s011s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dc70a62284391d46eadf346cf76c2a9412a41a183ab571b15003e5af8d3f2d21","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2017-08-28","documentId":49547,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022341Orig1s027ltr.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"10e062b65deeeed9e679e03a48d20d7b1bb949cf3a45b3364dfe7dc35eb846f3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2017-08-28","documentId":49554,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"deced1faaf421fa7e9c730a70a3827eb0ef5354d7469f8b452b6a3c299670ba8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2017-09-19","documentId":49775,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022074s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"799e930ff59dd50df02deb0388800b19293d43641bfdd59a85d5bb12ea4c6f91","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2017-09-19","documentId":49779,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022074Orig1s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33ef186050be3ff00e47fa1f1e38800586008a48ea1a4a43c7d72e2042e5a6a0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2017-10-23","documentId":50143,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022200Orig1s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ff938d4e9c9558601c338558390185ac51f1d29d682ae85ac9859f8f508189f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2017-10-24","documentId":50154,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022200s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"81d97a6825d009662c7c04ad48856c649298b70663319599b1f7fb586a906ebc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2017-10-24","documentId":50156,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"12699cc91006ea8f6718de8fa93212d4cd937b9afb093580c17fba610033536f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2017-11-27","documentId":50488,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209210Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0efeca7a331f052e84079cd538bfa6dc98d8e08df432084badd4cbe2fda543b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2017-12-06","documentId":50622,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d202e6fd2d71aedbf3c2123d7a1d35537ba486d80eebfa48fcca442924a3ec9f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2017-12-07","documentId":50623,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209637s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5b0d75eceb49446b261c7dd4d35e1dc5290785df7b61c183bf1a5a45af449959","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2017-12-18","documentId":50749,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125469Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f2873363aa1be1097c32d11a8cff2c95f495317ea59abe5b4ad6c4762d7092f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2018-01-16","documentId":51050,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"59204080cb9a0ce00b6f68724747fea9d67d1b44ab4f1b388c43c28fd36c4955","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2018-01-24","documentId":51918,"documentType":"Label","documentTypeId":2,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208745s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c6eae83968ce94a517bd3acb9051cca88e87e065f6cf762ce988785885991d3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2018-01-30","documentId":52106,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208745Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2176b79de3d034596450700cfbcb15c03b7ff60b476db3bc8cb73facdb86792f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2018-02-05","documentId":52396,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9c15eec06bc5a19d649c8bb108c490bb57e6d48ea18ec6f16ae759c53e15dd27","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2018-02-09","documentId":52539,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"02c75fb7eb44f9c6c0172e53bbcb4346d5329849d341ac790a4e0fec731ca744","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2018-02-23","documentId":52695,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022074s018lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1b2a177f0eab7c16dc4d73dbb7c0f93de1b86213afe1b6994a17b0cf29702351","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2018-02-26","documentId":52723,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/022074Orig1s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3798bc6c278f5dcdbca9cd73515f06becaa9a2c4681587ed32269648dc33b122","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2018-04-03","documentId":53591,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"97383f9e85be02b2861c761f7e75b9d0994e451edfbc0289a6ff425cb0295f3e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2018-04-03","documentId":53592,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/022200s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"95c855eb18637742badef3e7f31b56e6ac024f321399bcbf9b0dd254bc2fd312","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2018-04-18","documentId":53719,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022074Orig1s004.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a3bb2a8efb13d4a461862993b0f2c84d4f730d8b06239fbf57d967706f956533","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2018-04-18","documentId":53721,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/019010Orig1s038.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"51bffa32a00f5c5c2d83855ded6c112852a4c1dcea61b889d83959cd06a49f7c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2018-04-18","documentId":53722,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/020263Orig1s042.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7b4df3859c7002400f6913fce1318f3a483995b7db83a0eb0008116a58ecb93d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2018-04-18","documentId":53728,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/22074Orig1s009.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"019b326c243f9dff3184244e7a5acfca87af3011e02ba76fa5a1e28b16658b34","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2018-04-19","documentId":53737,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020918s049lbl.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d2bbabb9571b9c8ce1dcb6a8f10d89a9686b1feb1119aa5ebdef645289be83b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2018-04-19","documentId":53738,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020928s055lbl.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1d010298c7b153b2a15a26e1d862482390f3f46f0e28dbfd7b7332af8c1e7eec","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2018-04-19","documentId":53743,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020708s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"053d1db411a8c4abe65250c1cbd2098eb668342edb44e187923008939f252f9e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2018-04-20","documentId":53763,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/020918Orig1s049ltr.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8069b71a777cde45505fe4387d75b4dbec9220e8f8060a896e3bd3f45bf1d515","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2018-04-20","documentId":53764,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/020928Orig1s055ltr.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cd1fea8ea11b8ae25df49580072dbd3bea915bc4fd293e01f1fa4b09219bd22b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2018-04-23","documentId":53771,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/020708Orig1s035ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"76c841d4c09258d3f16da725ce330d98daaee05ea1140b1fdeb056fbbfdbde6c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2018-06-27","documentId":54704,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"271f530d74fba7d7d6ffd98c97c006fb1a24965ad234fffbc10f9353b661d971","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2018-07-04","documentId":54745,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f440f92c1fc8aac5b5dc2bd61caf336a9cfaaead9c00ae21ce82ccdc54bcfcce","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2018-07-06","documentId":54824,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125469Orig1s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8c77c9f2fa5b1c0b87a21e9f9f36bac3083cb5195201d38dfc74c50bb9545759","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2018-07-09","documentId":54858,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/020928Orig1s056ltr.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6d993c05c622272d7d291ae90278ac4766178c709d44abedbe74878db55cb1b1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2018-07-06","documentId":54865,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020928s056lbl.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2b38784c7ac7f51ec95ffcf5bb3273c08e48ab41ef47ba65ffbae7bdea6eb407","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2018-07-09","documentId":54866,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020918s052lbl.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"78e40b8586a734205d27a60961167f67822715b0cbc1bde798023f09b3464db3","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2018-07-13","documentId":54880,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125469s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d9736602b61ea613d794164bb74a274419a26b016c1bca40ece4d43833587c31","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2018-07-26","documentId":55016,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208745Orig1s002Ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d9d2adba96eba020e65f66b01ee7b92b5a5502fa84b557d00690943038b5a763","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2018-09-18","documentId":55508,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/205054Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"06997a485bfc5cf1fd59fbf08251b984c9055223518f1b8bf0df47271cbaa4c1","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2018-10-01","documentId":55738,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125469Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a8d55e0fb3287e068715307ed62fa0fc919c011d84f8dbf2688f0abd4edb359","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2018-10-10","documentId":55864,"documentType":"Review","documentTypeId":3,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209210Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"047ea6255d3e996a1328f83f1f1d36383126ced01a71199dd340030025b68a98","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2018-10-15","documentId":55923,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125469s024lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bac6c2b6b97c3a22f9ee34bdbc0911f4f6207453112c4979c1934850f1855b3c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2018-10-18","documentId":56014,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"81df87982b4f601a1973386313247b17e654e9e0db9c6e376f2fe30a02dc2d63","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2018-10-22","documentId":56050,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206321s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3be85fba9e62e7c025ff9baab78ff6f570832d21a5de1ef6ae3f8c004f9aad8b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2018-10-22","documentId":56051,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205054s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e4635391b7b7ae8f1935929bf225b4ab7e5d5695467705bf8c465d419e75e96d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2018-10-23","documentId":56059,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s003ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f6b5a910bd2ecba475f7faf9e4047b612e0dca9344c2f21e6f6866a5be028230","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2018-10-23","documentId":56080,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/206321Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"23e1288145478cf062c7e120b6c96a071889943d7770eea14268638a6cc81b16","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2018-12-07","documentId":56665,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/206321s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccdf9296c9818786cdb7dbd995f1403744e95cf353129bd01e01c053c476dd6d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2018-12-20","documentId":56830,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/019010Orig1s041ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8378482807db107f871275e895b82c18675d631f9134cd47f59adec38544fb68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2018-12-20","documentId":56831,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/019732Orig1s043,%20020517Orig1s041ltr.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e23c1128c5f1a728e7613ace2b343c3cfa8fb0e9e640d37b1da245ececefd3eb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2018-12-20","documentId":56833,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/019732Orig1s043,%20020517Orig1s041ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"277d17e1487102d145943ce60ff8565e3c5a4f4586deb4f0810e38ae70fa8cf5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2018-12-20","documentId":56860,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/022074Orig1s022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"839901d6618b2365a3ae323d8bda0b658e17c58455ed1896eff0a55659ad5490","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2018-12-21","documentId":56965,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/020928Orig1s057Ltr.pdf","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e917cf35a52c5ef055aabaeb52c13f6c7e27f250c270a51f3dbb83463d33127e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2018-12-21","documentId":56970,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021773s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b502f5a458bf080d9483408deacc954350e9f4e504d46f189c0e2630028da9f9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2019-03-27","documentId":57012,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021008Orig1s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c479e0aca395f6726b808eaffc41dc6abf55e116637f09dc3660e7eed781d0fd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2018-12-31","documentId":57084,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/021008Orig1s036Ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"85bd86eb8cb66bbbaec82ecc2c117de7c2e90f5c07e35f9f27e5bd9f71303388","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2019-01-09","documentId":57141,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019010s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eaba2596c6aa2fcaa1730dc0a063d2709b607f9210459ea6d2ff32ccead3fe68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2019-01-09","documentId":57142,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019732s043lbl.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e9ac36e642cc3f46fbb4563cd0a6563791324afaa8b3890cdb5ec62978d034d1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2019-01-09","documentId":57143,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020517s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"145a2b299d2058f83fe83dfd4852b1045f322b9b072ec622207240241a241bda","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2019-01-09","documentId":57151,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022074s022lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"08a07b48d515b17723834da6162bf3de69546b1942cba82bb9c2f13417e092ae","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2019-01-16","documentId":57230,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125469s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e8727327a313023328bf16efdd5c41a6d2bfe92da5d0d7e4c285e395cd7e8846","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2019-01-18","documentId":57250,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/125469Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"54c369ddb03b4f4afc4b66ab89d356c939d1615619e8e1838d73bd4ba6c3a711","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":57285,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022505Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"95c94cc458fc5fc5eec44406e87f7e73194bf7cc589ac7646318445b07026f49","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2019-02-15","documentId":57626,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019010Orig1s000rev.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b9608c766ff4f722ed108ba6d0214d6accb10bf5fa84b762121b31bb6a37bcfb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2019-02-19","documentId":57696,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021343s039,021379s041,021488s036,021731s037lbl.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"54e48bfb60dc72840782a0d785e7b198c795e033da6c9e7da56e3c1a8eeb3fab","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2019-02-19","documentId":57697,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021343s039,021379s041,021488s036,021731s037lbl.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9220a7e09cbdd7b505cebe99f169231b4c2b1411075bc33c5cc30cdb154bfa7c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2019-02-19","documentId":57698,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021343s039,021379s041,021488s036,021731s037lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b8ad94377e8d4a26d46c687b9865dde0954e02f1cff4c4e4c807552e34abc3d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2019-02-19","documentId":57699,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021343s039,021379s041,021488s036,021731s037lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5b3a0150d19278afc241f62a1c63694e3f5f63600f6b553534a9a490e2a3b7e8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-02-20","documentId":57708,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f6d9f12c355a06f707f48d09dfb93a5c2a3d76add07e7913d55e809aa8443c8c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2019-02-20","documentId":57712,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022200s028lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b2ee77cf396cd9638b3e525d94e4f3d16d61b5b774a78c3b119f7e21040d4e23","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-02-21","documentId":57724,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"29a4f20f4b33d384f8b0e427d72229659503db6c8a7ae00949cefd150e2f8e5f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2019-02-21","documentId":57725,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022200Orig1s028ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f4939898c94cca7b0cc4d199dd128785778b1f23251a02d417316cdac6903d89","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2019-02-21","documentId":57733,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021343Orig1s039,021731Orig1s037,021488Orig1s036,021379Orig1s041ltr.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9f34a24138212e26bad90a19e9a885d8711a6701e7399ca9d07bfaca2debedd2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2019-02-21","documentId":57734,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021343Orig1s039,021731Orig1s037,021488Orig1s036,021379Orig1s041ltr.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b7812675f33892e6fbfd635144bb5eb6e3f6671580d439b97739b0d1b59b89db","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2019-02-21","documentId":57735,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021343Orig1s039,021731Orig1s037,021488Orig1s036,021379Orig1s041ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"242bdfe7f933324f3acbf9c06f318eea04357fd36de3d8871ee80f92bdba8082","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2019-02-21","documentId":57736,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021343Orig1s039,021731Orig1s037,021488Orig1s036,021379Orig1s041ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61b4ca5c499e7aaf6f0e92481505f3775e1bb7f0d540af6af9bd79a26c553006","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2019-03-05","documentId":57891,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020517s042,019732s044lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c42d3e283355eade92777bd0840eab271fff9888af2d35025864b34986d1403","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2019-03-05","documentId":57892,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020517s042,019732s044lbl.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f4190c85fba2cc079905cdca6d0876f3e96f52f9cb2f5fa2f88fd76c3220d526","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2019-03-07","documentId":57914,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/020517Orig1s042,019732Orig1s044ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1b6d6cf4d822a735429be9e5e9cf1e8b857e89caf407a2f258c8a9524ea25592","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2019-03-07","documentId":57915,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/020517Orig1s042,019732Orig1s044ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"62e0f51bfa672386db9234a5a3bb06b5f57d869eb75c39574e3be2228cf5e6d0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2019-03-11","documentId":57946,"documentType":"Review","documentTypeId":3,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/202811Orig1s010.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d14b930d43a4ed14b3e8059da300db4c9e851517c225c98c0513e9ae697e192f","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":58019,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c1aaeca35dd11da825095fbbfbba066dcf46106658e11c8d4cb244e02d71bb77","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2019-04-04","documentId":58219,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/205054Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed3bf7f15e045ed00ac7d83d336d352cafb638e5b925e8fe8995e0266590cfbc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2019-04-10","documentId":58271,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209637s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"daa019d1be81acecdc2f42e4caafb0b3869a3628b973bc445167a563af9fbb6f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2019-04-11","documentId":58289,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209637Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"447aa848a636939c03d043bd04a706fbd2e485ea77fad7282e4ee2e2fdd196eb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2019-04-12","documentId":58307,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022074s024lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"db7465c3f5b24b7289992d96cea33ec938d5bcdef75267095d7582b716e22a0a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2019-04-12","documentId":58313,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021008s043lbl.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fdaa48d0bc45aa1a39224d5ff77f2adb7f8f04ce13f9bbc8cf29c0ddb5b4611","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2019-04-12","documentId":58314,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019667s067lbl.pdf","submissionNumber":67,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d8284c0f3ab4350a1280de3d3366a3316ae1af7874b13c04861c2eb2cc28dc80","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2019-04-12","documentId":58317,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/019667Orig1s067ltr.pdf","submissionNumber":67,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e44f0b323b950cf785066881fd6da4dac65d7e8a7f315bf7f1aff9a1df4ccd17","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2019-04-12","documentId":58319,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021008Orig1s043ltr.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ef8c05a6fa67b677953a881d35ab63a57674f1a3e32e9d78edecf1a7b7f79282","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2019-04-12","documentId":58320,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022074Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"636afe661d441acc5751bdd520c6125b07bc12922f1a1a789fced432d3e6cdd8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2019-06-03","documentId":58926,"documentType":"Review","documentTypeId":3,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/206321Orig1s004.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c17c6ddbfe42dea4674dbfff9409315eedf0105d0514faae18dd99025c8b5716","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2019-06-18","documentId":59110,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022341Orig1s031ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"566e27b820fbbb309fbe714227126d3083888d9c604e82e98ecb87f07d384199","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2019-06-21","documentId":59151,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c9acb2067f2ef69b4d9993b79b77ae2881d8f60e6f443072d26a9e913a479cc7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210557","documentDate":"2019-06-21","documentId":59159,"documentType":"Label","documentTypeId":2,"peptideSlugs":["bremelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"43c6ffdda05ee9c64bafd05cbbbb2a3b0cf5b2c72590b2221d8593ec2874d174","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210557","documentDate":"2019-08-02","documentId":59164,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["bremelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"295b014ea09b794f967459abaa3b3ef5a4db617ba9e681947542964866addb1e","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":59266,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022505Orig1s012,%20s013ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd523dbf95d8f3bba10d41bea265164f7de640c22793a1583d59948b3683c381","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":59267,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0f1c267803898da4155677326d6be9cdb7721b265a8bf3199f92144829879d9e","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":59304,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022505Orig1s012,%20s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aa4176b3187eba7cf7bc19db2440118074a068515b6343a79f7ac418b3b1ca66","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2020-03-23","documentId":59305,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5afec84f56d0cdca48c6912b9cc776e7df848443accbeda0d0396df5062adf48","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210134","documentDate":"2019-07-24","documentId":59441,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c67359586ee6b1ce66732056a17e2485d6d8dfca83be1e734c46013714f17567","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210134","documentDate":"2019-07-25","documentId":59443,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210134Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4eef686ff90404b52b09a79e9d70d2a28ffa7325a5f96786690bfdf185bfa13","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-26","documentId":59455,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s002,s003,s004,s005,s006,s007,s008ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed2d9d339ddbb2b63b08ba6264487f06365e224974203729abb79eeed08312d1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-26","documentId":59456,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s002,s003,s004,s005,s006,s007,s008ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cf8aab89627570c716bb69473b9b8510c2e59110a28534251416a0d541f3ec91","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-26","documentId":59457,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s002,s003,s004,s005,s006,s007,s008ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33f095c47be57388b172741c55f16cf7e3c41fa1398c51d7322f3a7ae3614e97","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-26","documentId":59458,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s002,s003,s004,s005,s006,s007,s008ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"614a8ce9da3e3a22e96af2a749560a85ce1780b4c4561d16799da0ba5ab0891f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-26","documentId":59459,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s002,s003,s004,s005,s006,s007,s008ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d87e8a424acceaaadabbace19d64920e6ba13d63b63e9f8636f1e78ed3fbef04","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-26","documentId":59460,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s002,s003,s004,s005,s006,s007,s008ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f8c4937cdcce953156404b00ca789aaf0d2eda4f9f4e637b054a4fdf097c62a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-26","documentId":59461,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209210Orig1s002,s003,s004,s005,s006,s007,s008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"71973809ac90c5f5fe768d623bbcbc9c553a3eae8b26a1db05affd0911ac65bc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-30","documentId":59505,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s002s003s004s005s006s007s008lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"464a639af8c242f9da7fabde443bac53d74fd4b9b43917f74590644f4f137ff5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-30","documentId":59507,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s002s003s004s005s006s007s008lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"197c6d7169d4dfec83025bdf5efbc0ea5bca2289a2f59285844296eb725cf3b4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-30","documentId":59508,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s002s003s004s005s006s007s008lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4dbb57660bfd1b5a8f89e03bb3abca1db6984646f6de0627ffb59038521c2ba4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-30","documentId":59509,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s002s003s004s005s006s007s008lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e4e7c9dbee12ca49097d10e8238f637be2f6f2cbd671ad44ff632de10f674f68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-30","documentId":59510,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s002s003s004s005s006s007s008lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"817b31fe9849f5f165cd3bc614ff1e3e80a8c6e0c8168d9fbc1deff07d045586","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-30","documentId":59511,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s002s003s004s005s006s007s008lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2dbe93fadec15f66c81149def80b44811d009330d6a7e7c0ff2f0cfb59426366","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2019-07-30","documentId":59512,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209210s002s003s004s005s006s007s008lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7053d2f2ea2374169e03382b2f003802bc54860d165ad49f61cf069f8a04e09a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210557","documentDate":"2019-08-06","documentId":59579,"documentType":"Review","documentTypeId":3,"peptideSlugs":["bremelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"975631a4108944f25659c8b3eff12003846cebae48f1e01b53fd88684c922116","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2019-12-18","documentId":59952,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212097Orig1s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"41e0f57b94253b437b22d4fbc9a1ace873fe555d9dd17f947cef7d76c73d12f2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2019-09-11","documentId":59966,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/201849Orig1s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"79b38f512fbaeb72f320a4c556f2cd068f321ead51f0cdc1e7c7066a0e350d7c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2019-09-11","documentId":59970,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/212097Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"427bf5e5c7159836478ebdfc1021f54fe2a1aa221aeb9b11aee386895698f633","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2019-09-11","documentId":59975,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201849s005lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6864bc78f5893ad42f5c91b2b3a97e6605df9ce114431e6f6c16eadf91fb179e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2019-09-20","documentId":60077,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b1c19642a5d65e1a26a6b39102b48ecd08e59667e4a8006c0aa7437c919f69db","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2019-09-24","documentId":60094,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/213051Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fac65d0b0ae1545c61e8bdec83dc7d1e3ced3f0b20b3d2012774e70d088c7c85","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2019-10-04","documentId":60223,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021318s052lbl.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b1ebb4791682da2ae89da885c017dd1266cd7cb76fe195cdbc62aefe746c10e4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2019-10-04","documentId":60231,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021318Orig1s052ltr.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ec9a0b04c2d385cb69460b8314b777ea0bbd8747a7d000643569cb95a0ea219c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2019-10-07","documentId":60249,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211939s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4d0b11f95bdfcbfb02f129b1cd7621c8692e1e685f1652b062124c772dd0c0f6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2019-10-07","documentId":60263,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211939Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"27aeb2a4169b24ce6b4e3ba14b9a182e4d34bd245a26ecef716adee94a63ceaa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210797","documentDate":"2019-10-10","documentId":60508,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["afamelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210797Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2cf3ab3b79f62a3993250f031c5cb5c328e26de65a374276567ee354f496153f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210797","documentDate":"2019-10-10","documentId":60510,"documentType":"Label","documentTypeId":2,"peptideSlugs":["afamelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1aa245daa37d6d85b9ec025a34621d65df63f1eb1a0d935ef66888242368037d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210134","documentDate":"2019-11-25","documentId":61041,"documentType":"Review","documentTypeId":3,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210134Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6aaecc4ccf1f7edbc860dbbb8da3144967d6b228fd1c0d2fd95d1401450f6a8a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2019-11-29","documentId":61094,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209637Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"164390c506ca2f6c07b3d2aedc2804d91e82e95f8179ce60177932c6788a0ffa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2019-12-02","documentId":61112,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209637s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aa41340a4f43639f5d9127181855997e594e081b75ab3f6f7f88dcd2f4d807ce","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2019-12-19","documentId":61358,"documentType":"Label","documentTypeId":2,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021332s028lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ac0426747e826ec46a9613f5e937d697cf6aaf1c9fe37c68380a6d24094bdf3a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021332","documentDate":"2019-12-23","documentId":61383,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["pramlintide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/021332Orig1s028ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"06d7e1349480f59221b1147dd49e5e430cec7a884dc485a5e6be40f07dcb2a89","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213182","documentDate":"2020-01-17","documentId":61589,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"517bfdf806198457296c8840616ae38170621550f132ce22713dbfca5096e444","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213182","documentDate":"2020-01-17","documentId":61590,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf#page=23","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"130bc557728292972464747760e2bbbba2cb2c8e04b5a5a82290d3409e1d7ea9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2020-01-17","documentId":61591,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a825da4663c09e17b2f6faa4ce6bcc5b56fb0ccce29c051852ea98f0ae1d90fd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2020-01-17","documentId":61593,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9e2efb03fd8032216ccc8b7c8151bda4aef68ed7c1de8889061c333574b5ac76","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2020-01-17","documentId":61599,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209637Orig1s003ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91e4fab082f225d9d78887e376ebcb1ec6c0ee5b2d3663a283a9af46acb4eeb0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213182","documentDate":"2020-01-17","documentId":61602,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213182Orig1s000,%20213051Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c36c1827bd811c93ecdcf2291029d84e8f3b317af0014819146b139032260f4a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2020-01-17","documentId":61603,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213182Orig1s000,%20213051Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7da884684fa710b95525deb394a787c43f583f8af470152b1feea984ba265df1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2020-02-21","documentId":61943,"documentType":"Review","documentTypeId":3,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212097Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"06c76e6a2af27e2e3f4510bedd2c4eef55f187038149265d81dc0e94476043b4","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2020-02-24","documentId":61945,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"376aec11bbf69bec2c2d370943a79b1e724ded4edab79ed44af222f27f105428","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2020-02-25","documentId":61954,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125469Orig1s033ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d8ccbb5dfdca26d3456d2a712f6dc62a0b5490553c52a918d58e75fbf903f0a8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2020-02-26","documentId":61966,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211939Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b528086559b5f0cfa25190fc17cce32724e1e74174dae7191f0cfb13823a8500","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2020-03-02","documentId":62001,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021773s043lbl.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f4555a6728ca980126c56ff6e1bb4e27b5515be1f4b348f54061f754e4c4b39","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2020-03-02","documentId":62003,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022200s030lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aa9f8ff617dbeff139238cc3f332c5ffde3506d1313995b5ff6b5d7c05e0e5a5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2020-03-02","documentId":62006,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209210s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5814e49760f5f4059182e5569ddb4154a57d32b747d436458a0d3f4925f6067f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2020-03-03","documentId":62012,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021773Orig1s043ltr.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1679cbabcfe9e20f4f76543499e20277f886a894ed3aee2e65cc9094c2e4d309","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2020-03-03","documentId":62013,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/022200Orig1s030ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7b84ee1faec18fe22a754ccf531d06a456033d9f39e99703042ba0eb84b35f40","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2020-03-03","documentId":62016,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209210Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ba53e6dbe765875e08227709d64ff6f9e14f4ae46b07e67d0f6049021d57a2e5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-03-26","documentId":62341,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e56de3f4c40cb868e8577ae4239a480e15127f66b9f9d04a8ab77c9b2d6f5125","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-03-26","documentId":62344,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/206321Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7678cf5f468b1f7ee37d1bb8f605d0206555b2fae28c2eecff14f6dedc3362d9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2020-04-02","documentId":62416,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020708s038lblrpl.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"50e8b251d0fe2a74b4733fc175404b0972450696a781a7f5df3c83f11d97cbd0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2020-04-03","documentId":62431,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/020708Orig1s038ltr.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0f1ac3dd7e18957ec0c422157e979c4304fea86648b99545fe9696a11480267b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2020-04-07","documentId":62468,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021318Orig1s053ltr.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1edf477816454a4c5c2d271cb389864727bfa152c600cd9988479fe3c0b61970","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2020-04-08","documentId":62470,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/212097Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ce22b2fc87207efca310dc3b6b978d5c9367ad1c6f5dd0f54939391b94e7cb22","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2020-04-08","documentId":62479,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/020263Orig1s046ltr.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6caad3e7ac2b4b95c70e3b63e6117d262b4e647b509f087121b89dbe6b5b609b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2020-04-09","documentId":62521,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318s053lbl.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3673115d7db35058706f5ad3fd488e53dfdb7dbe3b9f74924541f74019ae4f4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2020-04-21","documentId":62614,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020263s046lbl.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6243aacdd93e9f96e334c99d3525b7f16f53b1a94b140db0031e786881b14b6e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2020-05-04","documentId":62815,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213150s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cb9b184edc6833b07d3948a817d6315b8371fc360ff855aab806022c6204f7da","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2020-05-05","documentId":62822,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213150Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"43820c9f8ae086ddadfff1db16c3dd62a9077db9f4e42945ba5fc3fd4490335b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2020-06-10","documentId":63478,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6b57784a4096ddf0fb439bfc1e20178246cca2c30f1f9e03dc8f402b21c757f8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213182","documentDate":"2020-06-29","documentId":63744,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213182Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c21e3c590ed93522eccea88ce8136088479e43a68e2cc477fcb6f23de9e6e53","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208232","documentDate":"2020-06-30","documentId":63753,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208232Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0d043ec66fc3db94a4f85b8ba4350c9323f6c4cdba7216e70cf7d111ec1ed21c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208232","documentDate":"2020-07-09","documentId":63836,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208232s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e91560faa96f4ba21a048d54dc1c98e42da49b07a400751e98ebf21c934da16e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210797","documentDate":"2020-07-15","documentId":63911,"documentType":"Review","documentTypeId":3,"peptideSlugs":["afamelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2cc019298c9853860974b6b014380885868f863398211c0b53793602b0430443","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2020-07-22","documentId":64010,"documentType":"Review","documentTypeId":3,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/022341Orig1s027.pdf","submissionNumber":27,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5ddd3725370f3df4917243c93307201a1b1fcf33e78da98f30dd7d5497efa641","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2020-08-06","documentId":64211,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"167f621148f99686ea3179d96bbcf5a8162fcc8402df0d7542a7f393f270474a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2020-08-06","documentId":64220,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/022341Orig1s035ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c7b0b274076c976243cad97529826fddb2eeca75ad3b2e18d4f5f1126f6f7657","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2020-09-04","documentId":64490,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125469Orig1s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e44272a2fb4f8ea0f0c5602d224960f93409f2168698553e0e90096c6c8a566d","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2020-09-08","documentId":64530,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ce0cb506f66d0421066e35b3e5170080f45877a339bb24be061d4c5984208492","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2020-09-17","documentId":64589,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/020918Orig1s053ltr.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fbb987e318836bcdffcd80625af8f31910d5bb0b7586f66f3acb30326c65fa0d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2020-09-23","documentId":64658,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/202811Orig1s016ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6f78a638e298e323f9174b7b5e4beebb3906ba9caf69cea4d6887208acbeea71","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2020-09-29","documentId":64712,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202811s016lbl.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c73eb71b05ab62f33db0372f0f8420a962381826f9aa3af32ae227659045e78","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210557","documentDate":"2020-10-27","documentId":65030,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["bremelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/210557Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c5278d38add95b0e632550ca3e8b24bde3cee7791772213641ffe4742e75b40","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2020-10-27","documentId":65033,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208743Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2623e8f34ba652181e0a50f9def6d9c59dec298c3fe78240694d6751b91e8d9f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2020-10-27","documentId":65037,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208743s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5bcbff5b79ce170d1ec523d7ab7b36f8699a8f09c36db08af41c4b120943ffd1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210557","documentDate":"2020-10-27","documentId":65041,"documentType":"Label","documentTypeId":2,"peptideSlugs":["bremelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b26d37e85bd2ca9b3a4b61c06e8a838bb96fe25b058b434de87ae0ddfee99c1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210134","documentDate":"2020-10-29","documentId":65066,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210134s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5d7782834bff2342d9e3350cfa0cabef2fa77a33238fd46192af04561f207c88","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2020-10-29","documentId":65073,"documentType":"Label","documentTypeId":2,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208745s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7dbd65afde2f8198d33f86ae20803faf1de6917099e53369f9f5ddb305cbb82c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2020-12-08","documentId":65119,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208745Orig1s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ef97eb5c4765e75474d5ea2e63da7b61fed193fbde8d2ed03e33f8d4854f9011","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210134","documentDate":"2020-11-02","documentId":65120,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/210134Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cd411a8b77377b5b955746d3868bf09078d343a51fdd087c68d154c20598d802","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2020-12-01","documentId":65261,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021318Orig1s054ltr.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bbf9862792ed4ae18e5c858e75ed6a426a6f127ab1ee9ada19172046aefb6eb0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2020-12-01","documentId":65268,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318Orig1s054lbl.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5c7ab96e25b776fd7f0c2a04abdd7476c774d6a09aa849bc2a95b8174c87a9b8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2020-11-25","documentId":65307,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/022341Orig1s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"929a01292d281f65c8a64616c3679e7035226f26523a69b2b8b55a81ffca5c4e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2020-11-25","documentId":65317,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a1eab856e71d2dbc7296ff3c7729c19f7bdc6eceb52c2ad208353298507d53a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2020-12-07","documentId":65358,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213793Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6781b7758d31fee342a7fd7a7c3e5cc0cff87bf08d866dfe95f2ed0a8dc3b8e1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2020-12-23","documentId":65422,"documentType":"Label","documentTypeId":2,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"28985d521926af1617d2702c0768061d486aa248b3ab76c110358a6d4e472fe2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2020-12-02","documentId":65476,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209210s014lbl.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2b59c1ff423f81cd8044462c486ff729c4c582529e0044fe9f9f17aa87279a63","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2020-12-03","documentId":65493,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209210Orig1s014ltr.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6bc890f27a119ecd53f65d75731d52dc7e084786ba3a76db7dd8bd08e023e8af","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-12-08","documentId":65525,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/206321Orig1s012,%20s013,%20s014ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e8d84c169f718cbcb003480c334a556bc83c17d8994e992109b10c6cc75763cd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-12-08","documentId":65526,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/206321Orig1s012,%20s013,%20s014ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dcc6c5b01d027c835c14f72f9f5204cab830e687ae4e1a5e5d12ba729acba2a4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-12-08","documentId":65527,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/206321Orig1s012,%20s013,%20s014ltr.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8b7f9e5ebe38eb0654e36aa4591de763550daccb840ddde4eae55646165f3cff","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-12-09","documentId":65551,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s012s013s014lbl.pdf","submissionNumber":14,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bcdcc00201b6e93c55ba71cfae88dd7d60f184dac3e04fb26796a824c06d3734","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-12-09","documentId":65552,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s012s013s014lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ef11a96551fa70792ad599b2b77366a8aaa2de09c3b7fac640c1172bc85cdaa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2020-12-09","documentId":65553,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s012s013s014lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"10f85cce31ee2d16060642cd75093bc2d9d2e243cf690dd01b3f821f34a87b6d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2020-12-10","documentId":65556,"documentType":"Label","documentTypeId":2,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208745s010lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8cb71117ff8de654fa532f5fd809cb0f7c6128ce6bd766feb4da86ffba9465ae","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2020-12-23","documentId":65729,"documentType":"Review","documentTypeId":3,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2cb521d82acb1bb9b8cff21e8e5bae963c6979d887199228cb889d096ffd8d71","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA208086","documentDate":"2021-01-12","documentId":65890,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208086Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6dd8757171ab508944e884df4e08b825cb7df958f4a732ad02cc969779b2c5d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2021-01-21","documentId":65951,"documentType":"Review","documentTypeId":3,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213150Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b7a309e09a29df2985488ae7a8f5bed5190d798a0767ef8f3281bb417b90fefc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2021-01-27","documentId":66006,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020928Orig1s060ltr.pdf","submissionNumber":60,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a01941e25591a70978cb94bf667888f39a53bf3653211d935672ae770e722846","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020928","documentDate":"2021-02-03","documentId":66086,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020928s060lbl.pdf","submissionNumber":60,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"57c583716b70683e4296f50894738adda714f75956ce105f5bd742f1a70ab38d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2021-02-05","documentId":66106,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318Orig1s054lbl.pdf#page=16","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a8abaf0cf5af74770b7555a3962bc89137659101a96b6df151dbe495d4ed02a3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2021-02-11","documentId":66196,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208745Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8e6f70991ea0abd9a296fc74e517f338ed5b816981b7ea777d71e131d8d99173","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2021-02-16","documentId":66216,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/019943Orig1s035;%20020011Orig1s042ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0e33ecca48385a0495a77bb5ec95a56afaca0e5a27005cc62e037b9d6f201eb1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2021-02-16","documentId":66220,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/019943Orig1s035;%20020011Orig1s042ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"84db8365052bccd91a3fb066c85b57e36fea598e0b39ced1dc963b8fa17655f1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2021-02-17","documentId":66246,"documentType":"Label","documentTypeId":2,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208745s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aae10162319e014febb464f50436f153d697b1e4ac4f7394f78e104bf267f6b1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2021-02-17","documentId":66247,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208745s007lbl.pdf#page=15","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"65e2e5edf0003b94e03359a5389051314a6b7d05f61781cc191918c1abc368a8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2021-02-18","documentId":66296,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020011s042,019943s035lbl.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3c7fdf20462fb2b12fe23b201497155084a505d8f2076054510836b4437a3d3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2021-02-18","documentId":66297,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020011s042,019943s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e4b4cfb1fd32865e9b4abe9778e04b77cbba27829f05c23922dca75ca797a2f4","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA209564","documentDate":"2021-03-10","documentId":66714,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209564Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9986117fbd1d4b6cbbe6cb66bed323c002e83f31cabc643c954ea7a6381a4efb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2021-03-12","documentId":66761,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020918Orig1s054ltr.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5e80d2f768bc232d1da55604c817d7d38d0656cfd167f0f936aeb8be4711d26b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2021-03-12","documentId":66762,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020263Orig1s044,s047ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8443247c159b238cc99b6414acd92feddb0d28794f888fce64d7affa68f3237d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2021-03-12","documentId":66763,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020263Orig1s044,s047ltr.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"40abe5a157aa3239232a916b9f14945a22016742bae30d8b01c696315d6cb618","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2021-03-12","documentId":66764,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020918Orig1s054lbl.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7bcd957e3aaef2c3764a25dc3e2f600ea3a7724ce5205618bd218f52bb0b3650","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2021-03-12","documentId":66765,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020263s044s047lbl.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0f6f74aebc06361c404f052b132424cedec3835b17d17503ce2232481d9b1c69","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2021-03-12","documentId":66766,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020263s044s047lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8f1ec24f310d13661ed5cd06144456f1e0702392f20ad29f5c829efd97567285","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2021-03-31","documentId":66927,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021008Orig1s041ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d274a0e82e061f7266ddcc738ed422803e5dcaee3dae1a90f881d72d692b392d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2021-04-01","documentId":66959,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021008s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"442c60ab5032b4b245f9f6640089713776baf33e3faee4837a1c92bede599713","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2021-04-13","documentId":67048,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209637Orig1s008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4e762a7edb27f78812aef3c16cdeef30761d94fe640dff4c83c7eba22cff96cd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2021-04-13","documentId":67049,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/202811Orig1s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"396285004901baed35fe2631979f7fdcb1a4465d2d04d077597cd01084474469","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2021-04-14","documentId":67054,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208745Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4e5f2ded0ab251278107e5d4cf68265da1bb30faa824183f83f92b73d1bd6ff6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2021-04-14","documentId":67060,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s008lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"05ab95b9cf71ca559f224138534a1538d26063222322757d0c328b2ea1bc0e55","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2021-04-15","documentId":67063,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202811s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7eb741f65eccfd5614be21560d3a3fb1cf8e59f31c797180cb84bfa2b946192f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2021-04-16","documentId":67082,"documentType":"Label","documentTypeId":2,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208745s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ab58760b618b9944202ea5cf3da884e12654bcd8f9b45331a37ff8ac8a87a31c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208745","documentDate":"2021-04-16","documentId":67083,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["plecanatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208745s011lbl.pdf#page=15","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ff9bb19177ebaeffaabbf96a7f912c2756c18184e42604bbd1c1e6445ad85a0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2021-05-05","documentId":67412,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213051s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eb6a2f8e2ee0cef1b2e75591e73ea98256f6e7fdca5ab574c2ecd7e780dfffd5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2021-05-26","documentId":67597,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/019667Orig1s070ltr.pdf","submissionNumber":70,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0db12384c36da79721c707cf4bfb3eb0efb829b2a35e184aff8ff56b654f5725","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2021-06-02","documentId":67657,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019667s070lbl.pdf","submissionNumber":70,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"aa6a59ee74d0853b38ebccf086b323199932929b20539961c4e88669ab6ae6e6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2021-06-07","documentId":67724,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bcc6bcf6538bda9755b6b0aa132b7198ce501ff54be3d58067d05a587ea2f8f4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2021-06-07","documentId":67729,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215256Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d9fdc6b05505c8d45e37930f5960d26811c9ace37e491a4465f72686bf61db70","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2021-06-22","documentId":67850,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021773Orig1s044ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8975fd6d527b439c5c5bd1380b1ba50671239dc55ee318be85e77afae81245fc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2021-06-22","documentId":67856,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021773s044lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"79f903974020e9309da9bf4c5f95ed20fd92fa460676738af06e9fe34dafaccf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2021-07-19","documentId":68112,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/212097Orig1s008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"21777568587cdea3f7608ffc46409b7dffd82d0bf2fe8eac318fcced700af545","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2021-07-20","documentId":68138,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212097s008lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eab41abbae776d5e7786a6467e772747b2562c46c31327a3461145a97694157c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2021-07-22","documentId":68144,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020918Orig1s056ltr.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e83280b5beacd0165ff8039ab1b21de52fc4fad49a8fd3d3be98e2fc4c89d322","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2021-07-23","documentId":68165,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209210s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91c4bbe3f956d0517c69e889f239c3df214f1496fa53c5b7c44a2098b787acd3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2021-07-22","documentId":68166,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022200s031lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a9166d43abe38104bdeb546658977d4c8386570905646207a37e6c6ec9be1e4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020918","documentDate":"2021-07-23","documentId":68169,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020918s056lbl.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bca0712acb5b94b9ee3832ac95cfc30ad581b5146d7f317ab112d63fe9d918e7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2021-07-26","documentId":68178,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022200Orig1s031ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e176631d589b0d7270524ba4038cb522851f0df886ab321e87b0b78d1ee3293b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2021-07-26","documentId":68179,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209210Orig1s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33e611d51009d6e6cc5c13952074a84b9cf0e6751b6d3b66ff71c35623b4774e","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2021-08-02","documentId":68246,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208471Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"09faaabadcb20533ccdbe502357c9db1329f77f9a72b6285dc27731874aff095","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2021-08-02","documentId":68257,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/201849Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"39b1994a3f534adfeee79c42a24dbe97505307e91815df79310c99de5fc38166","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2021-08-02","documentId":68263,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/201849s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9cc17716ec2a8bc5ac5283e1c588572cbcfa0d553afa2f228f5e90c51fdebc09","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2021-08-03","documentId":68270,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208471s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d18724d57db0050176326927d9016636b944249e161a262758e3bdf59e350e1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2021-08-22","documentId":68440,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212097Orig1s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"af26b8f9bb164ef35aa0990794878496d9ad7e33093293d84a0debe0af17e910","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2021-08-24","documentId":68449,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/212097Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4186f2c8e4910e6e7a39dcb406b90f801f4f3b3afda51b6a418d3fb89b98d1b2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2021-08-26","documentId":68467,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/202811Orig1s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7c55ff26288076ec5fb6f64b85dc2797cdb9348a9696de0796faa135f482f662","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2021-08-26","documentId":68469,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202811s018lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f125ef9043822c3b2e050ac4e8ea46e892470516a0601f487fcea4c1318de49b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2021-09-09","documentId":68563,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021318Orig1s056ltr.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7fe565282be7468d7ad00bca02caf7dec6f9eb5a2c4d646cf093a1405b6f3fb3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2021-09-20","documentId":68658,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021318Orig1s056lbl.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"efdb83d7ef4dbc52384531572fb28a9eeda06389f48b46bf25c37a0116cee4ed","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2021-09-21","documentId":68681,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208743s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"094c2ce7365d0c7c4e19ec531525f2a466054439172f7eefb73e031cc33afd07","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2021-09-21","documentId":68695,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208743Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3cb7f9a8ee967fa116e9fd2383a43fa8285e3ea4eded4a7b7cb74d14130024e2","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2021-10-01","documentId":68849,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125469s044lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4eb72dde005216914e57598bafdceb04edf3f162c4abedc405f804c8178e9966","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2021-10-04","documentId":68867,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125469Orig1s044ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6b959d72bf999328d159db70025b4568b0a82a4140d61d166bed641a2ab9f5fe","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2021-10-22","documentId":69069,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/019667Orig1s071ltr.pdf","submissionNumber":71,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e813e4a4a051a7a5be091a1959ae01d856ffb23869c531e3ed0aa21060a74c07","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2021-11-05","documentId":69258,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021773s045lbl.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1598ffcad3ef0ff9d0d0664acba6d4933fafc2456384d9216ea1eb48ad6cc5ee","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2021-11-05","documentId":69264,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021773Orig1s045ltr.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1199b0f53f0aaa270ba38cb79a5b8a9c00b1185158d83f1e010f67ee927fe72d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2021-11-15","documentId":69307,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020263Orig1s048ltr.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"01aa0c19b4c1009bfc1da682de59edc5b364571d5eb16c4f30dd227b315a1ef4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2021-11-22","documentId":69366,"documentType":"Label","documentTypeId":2,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938Orig1s000Corrected_lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4fa7a7793a86899ec05f3bd498142a96b656bbb652cdfc06414360505f34d200","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2021-11-23","documentId":69385,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214938Orig1s000Corrected_ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d9f247e193c3c5eb029e019a2fef1e6cc87399d925e270016b5f610a40443076","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2021-12-13","documentId":69537,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019667Orig1s071lbl.pdf","submissionNumber":71,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"928b0b10ffbb8eb830a326facec50ba57d4b5158ad81b5bedad77d1f80f9330d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215395","documentDate":"2021-12-19","documentId":69635,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215395s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b21b42e06fd8f3ee1392c5449da2a4cb955e2cb0bcf15a81afce39c9f3937b14","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2021-12-20","documentId":69646,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021318Orig1s056.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea65d54a3dd0c9ed26b3e7122ac5b7ec8d47238039c7f317567f40107c46b67c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2021-12-20","documentId":69647,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/021318Orig1s053.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9b4ac181737f6a19b129696cf24f684734a1c02b48946ab05e595783ed536167","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215395","documentDate":"2021-12-21","documentId":69727,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215395Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d816f52be8228545e39c74fdb0353857702b43c5a64337dbd92518f428bea942","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2021-12-22","documentId":69747,"documentType":"Review","documentTypeId":3,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e1f525712e0c6fc3bb81cf00e47c07066feb16945b8e179c0e1c83cc21a20c10","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2021-12-23","documentId":69754,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208743s010lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35eeb849488c291cf7d85093df01d6e07e4599a3c87177255940f5a458fe43ea","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2021-12-27","documentId":69772,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"534c054e8ff11d509467aebb3da5706447454e197bbd2e377656c2e4e3eb146c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2022-03-29","documentId":70639,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209637Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2a29a2e5e3b0d0ff6a896e35f68dc80c0be0f73b979b68b08df588ea1bc52993","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2022-03-29","documentId":70644,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637Orig1s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f27e422fa09070e0b8204e4bbc0888f161bbfdadbc1bad2e6874560e2d3eb007","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215395","documentDate":"2022-04-05","documentId":70686,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215395Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0abf63c04332caa107d62d43ba8d5da354868100bdb9ea3d9ecf5ac790010478","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2022-04-20","documentId":70790,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/019732Orig1s045;%20020517Orig1s043Corrected_ltr.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2ff31b6772f1a55f678390634e37d8f1bad4fc4d66bf22f41a9bfac6070c06e6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2022-04-19","documentId":70791,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/019732Orig1s045;%20020517Orig1s043Corrected_ltr.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0b312283533a0d21e90932293f72f0d052c60ddcd0c3fdf6760b0218f41dbd8a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2022-04-20","documentId":70793,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019732s045,020517s043lbl.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"44d707f309c1f18180be63cb356e5744692352fba7a33dc2e504bdbc6a116e7a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2022-04-20","documentId":70794,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019732s045,020517s043lbl.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb71b6a85d87cd4a23426d3c3a7af9dbc61760f8ff1be8a7ce9ad5eaec1197cf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2022-04-26","documentId":70808,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/020263Orig1s050ltr.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"38e19e53fbc996a267e8fc3334f8e00675db1665831cde3522eabac00879010c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2022-04-26","documentId":70812,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/213150Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ee5b5d73b385ccd7141da364f194dbe2fb3032b58023f53e80668ce998819a2a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2022-04-27","documentId":70822,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213150s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32580776aef9c3107c50439ad2b7e0c63f11d89d06a189dfd388ba965399a265","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2022-04-27","documentId":70826,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020263s050lbl.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0539580e3daf7147f8d6af8fab463a9390bb0c5b26d9de4f116c9876693b6d57","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2022-05-13","documentId":71068,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8eda9acd8b6fb04e81d133632e42ce0114221809d83e4b24bc9d3c24672d46c9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2022-05-16","documentId":71073,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215866Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75574c5c3c39daf56319c56f4439ceadb5a50bc6f99eb30e9d492b3b7061ab4c","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2022-06-13","documentId":71275,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/208471Orig1s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"13a5df1e565a5f6387b7e314a467da474f87266a1356b68be0c9157a2ab87445","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2022-06-13","documentId":71277,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125469Orig1s046,%20s052ltr.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d98bfbac875c6eaad9cd86d57c38f652526fc8528642de53ad82b177f265aa4","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2022-06-13","documentId":71278,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125469Orig1s046,%20s052ltr.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"82240f581d4c391fc7b48a3f8ac9a8251bb5932a03164b49189daff6c21820d6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2022-06-13","documentId":71279,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/022341Orig1s037,%20s038ltr.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"474eb72e71610b0adc5bec63491046de7371f92fbb20629da647c56295096e54","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2022-06-13","documentId":71280,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/022341Orig1s037,%20s038ltr.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"efe8ff1cd7ee4fe25253b4e7b8d86d0470bb36c1d5e63fb3681bb1f3b877734b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2022-06-13","documentId":71281,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/022200Orig1s033ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e65e1e1b0e527550e9f94e156581be620123a09bafb5b7dbde6c053d3393be01","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2022-06-13","documentId":71282,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/021773Orig1s046,%20s047ltr.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f1fa6f0a1998c40d753326606420bbf487278738b1559cca39b6507fd4bd4fab","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2022-06-13","documentId":71283,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/021773Orig1s046,%20s047ltr.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1e19db4369eb2ea3fba9d9533fe7cc3e6c58e87c09c0ca435bed8b222be9b799","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2022-06-14","documentId":71294,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021773Orig1s046s047lbl.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35db3345d2a0b6cc2fab9c8d716af9611294d1f378db904caa85c47d1534d761","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2022-06-14","documentId":71295,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021773Orig1s046s047lbl.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4c16ccbfde835925620dccade6bccf116008db7a121f4ae1375efe79909cb605","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2022-06-14","documentId":71296,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213051s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"574558bc003363a845e479b5e55d9343dc3ddcd280553c5cffcaa272c9c326c0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2022-06-14","documentId":71303,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209210Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3ddb820220e4dcd3eb738846d1e23483687aa67770a222de4e6547a692b503f1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2022-06-14","documentId":71305,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/213051Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ee0fd5ffae94a7a89c4347886a23dd8b6e9b43fc8cf27b21049be91201e1df21","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2022-06-15","documentId":71307,"documentType":"Review","documentTypeId":3,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c307857ccb93183dcbf92445a7cc1576b37598e089eeabef72c16d848800fd97","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2022-06-15","documentId":71308,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208471s005lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb1ba6e498e1196d2d79cdadcaff05008f13a84adfc2a66434be27208d310e3d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2022-06-15","documentId":71320,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209210s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c8b1c661b8232db29e056958165ed591ac0c11519d36877da459a7b9b48de821","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2022-06-15","documentId":71322,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022200s033lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f7cd87c407240e1955c50e463cecfd9fd1692fdcc56e62646374ef0924b049e0","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2022-06-15","documentId":71324,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"12f7752270ddaae63d5c241740aa05881b8466049c4aa75039d9e1afd4d78c2b","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2022-06-15","documentId":71325,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1e91243902a365b2b93f4f0b55e68b11aca10a5d6762bac4461822f60313d804","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2022-06-15","documentId":71327,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022341s037s038lbl.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"75caf7a68d07edb3dd44b41f0620816d58cc1dca58928bbef1480d3d8674d55c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2022-06-16","documentId":71336,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/206321Orig1s015ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"06a760ed4bbdb35bd874c9b35d571caeccfae260d3a8314a000b97d6ae4cb6db","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2022-06-16","documentId":71340,"documentType":"Label","documentTypeId":2,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6b6c162a5aa2a2c1bed212fe88a270993d37fb4ef2febd7bf0268402e8d706a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2022-06-16","documentId":71344,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206321s015lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8b3d176401eeed5040eedf147f96c0c191d3ac6e3ebe5da211681682e513dfe4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2022-06-17","documentId":71347,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/213793Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"be17f9ec422efda9a03beba711a2794a5642673aa566bb8a97bec618424806e4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2022-06-28","documentId":71471,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021318Orig1s054.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5e6711a4a23633fb99e9397d86d2f78e63d9dd3f678154b4f2f535550cf70017","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2022-07-15","documentId":71557,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/201849Orig1s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"07ece796043d6e1cd2907f23873383c64285f09efb277734b156e8b1c8c6d1c2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2022-07-15","documentId":71574,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201849s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5302c7aa590b46b3903c8fa0fa16e1d9df81e2901fbba37741d36890247c66ed","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2022-07-27","documentId":71637,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/022200Orig1s032ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0e8f2b01f5eb2b913f43a7ebd01572f7407e2351da8169765427ae1efbf08292","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2022-07-27","documentId":71640,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209210Orig1s019ltr.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9383eb7e7864201ac1b4925487a047de479af36fa8cf4c9c8d508e7ab3c8b320","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2022-07-27","documentId":71641,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022200s032lbl.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8bf30764c5ecd2c5980f4343863f4bf0188ab6a59dd0c6e6a4838eb4d536bfb6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2022-07-27","documentId":71645,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209210s019lbl.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6501f63eac1fc3e1d74392cbb68ab64641aba869b2279edf541975132888037e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2022-08-29","documentId":71941,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0c0cff9ff8c5acd6397109ac80372f4694d9a1e202941e0365561ff36390f181","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2022-10-05","documentId":72246,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/019667Orig1s073ltr.pdf","submissionNumber":73,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1aa731693ab490d917e21c29fb6d7656757145a787e4e34e8558c9de323a6bbf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2022-10-07","documentId":72272,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019667s073lbl.pdf","submissionNumber":73,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e1dc2710e860ec43cb00e8a55c6366f40615b7d3a4eb16032f4c9d184abffb43","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2022-10-07","documentId":72275,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209637Orig1s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"27342526027be6ee2fcd9eea287c05148f0a7db2a9a70399002e8eed5a6e719d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2022-10-11","documentId":72295,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c6c5820a4fba3b7c4f44279c17cacd4882c97d7337180c931ae35486bd15b940","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2022-10-19","documentId":72414,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022074Orig1s007.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ef1389f240ec559db22c17576640c21cdbacca81a9340024ee888cbe93ee26a9","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2022-11-18","documentId":72650,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125469Orig1s051ltr.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"942a9d06872136306f8db396563d5c01c62c81c3560790bdb22877cb9dd7e639","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2022-11-21","documentId":72660,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s051lbl.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bec2ffe8c4a407b74b7f3571a6db133c92acce05458f92891bfedfa9bbc03ca7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2022-11-28","documentId":72729,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213150s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9d18948c6fdba6b8079a797adb1af0648ccd9b1879412e01591f97117c476a6b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2022-11-28","documentId":72730,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/213150Orig1s003ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35a42037430459d445a366d50ff821ce885ac4bd4b330df52f42e228b6a3bd84","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2022-12-09","documentId":72839,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022074Orig1s017.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37935d1370be4581b32764a3dbdfee416e75adfce6db3dfc59f5918363db06c6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2022-12-09","documentId":72844,"documentType":"Review","documentTypeId":3,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022074Orig1s011.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"acf08cccd110d1e4c6d915fface814c5c23aec6ec9d4b44b1b8b8a2d1aa97213","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2022-12-21","documentId":72967,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208743s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ae35e818bbea1ded9381480e3d32be63493353f07cb3f13900fbdffd8a10819c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2022-12-22","documentId":72992,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/021773Orig1s048ltr.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea62efdc0db24e48eb4d072bcadd89647e0aaa051f7e573e443faa543303d67a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2022-12-22","documentId":72993,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/022200Orig1s034ltr.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ef78cbcf4175190d0519332df585226ef0a2effa847ba44f61ecccadca0a5fcf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2022-12-22","documentId":72998,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209210Orig1s022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"77f05c85cae2b454ad5c8f1e499827caa45d77759e6b1eafc023dde4f7d37b16","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2022-12-23","documentId":73011,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209210s022lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e1b476bebe7fc99e1726c7869940c1d734077ce8819b618de0a85f6138f364d4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2022-12-23","documentId":73013,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022200s034lbl.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0f7dfacb65b7ae67e1631f8d8e9a1fb50a05f55edec3b639e2e3268f25e0ec5d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2022-12-23","documentId":73015,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021773s048lbl.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e03533de09a521ad1e5f91dd586b7eb60dce6caa19d61d0cfcaa09c9e72abbf2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2022-12-27","documentId":73036,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s005lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4297ce4682c6ad26ec45c21cc53daa14918db9599caa2ab8781c7f6681493a23","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2022-12-27","documentId":73054,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215256Orig1s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2722242daac27830d36e623a4c132080568c50af610cfa717dcc13290071588d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2023-01-11","documentId":73139,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/022074Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a26ce65363cd3447d37aabda480750e88342414b854ccbb2e46cb2748e2b030d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2023-01-11","documentId":73142,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022074Orig1s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6b8847c48304f143bf08ab0db8c1425751f8f688a54d40d13445989b95017d41","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2023-01-13","documentId":73152,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213051Orig1s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6fc29ecf94f2ffff39446afe70488234016bdd201b45845146f90300ac946ff9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2023-01-13","documentId":73157,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213051s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ca51065929dc55d2ed2afc6b250aad64b04ba3d1d069e7e60014eb546916236b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2023-01-30","documentId":73338,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/020011Orig1s046;019943Orig1s039ltr.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ca189c8d6d111f0ec612b4670dbc4340fa33d43ffc1f30aab872ec2cdfb60243","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2023-01-30","documentId":73339,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/020011Orig1s046;019943Orig1s039ltr.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb08e675b5cf77e416111dc4cb9eccc3cf2faeb52a0b530f25fc47e9f0e1e997","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2023-01-31","documentId":73346,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020011Orig1s046;019943Orig1s039lbl.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"17732dcdffe1d4b316d4ebce4a332daaf7936a166d788fd62e28e4e40e7ed9e1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2023-01-31","documentId":73347,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020011Orig1s046;019943Orig1s039lbl.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df44fc6a26af402f12a29207f2451ccdcef24f7b64ffc7c00b9a321cc0f774d5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2023-02-15","documentId":73507,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256Orig1s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7603e0ecd092a85d7ef2778a4478c0ef3f56f5bd585f5477ed54bdd9adb5989a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2023-02-16","documentId":73508,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215256Orig1s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"242f5cea3082ff8e730b4f8be58d65e763929103b11421d7e90ad6e3e31a57c6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2023-02-27","documentId":73608,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022074s026lbl.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0fce253ba08b408254005cdb49fe8141f24dab0e17b607bb22dbb5ac77b91284","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2023-02-27","documentId":73609,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/022074Orig1s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6922a8590d61b0ca8776570c5a021267f2e7fc01e53184743709ae0f28ad5f4b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2023-03-01","documentId":73642,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/205054Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"00df8a257b0ce523c0005c6b642f6b1d386dc47a96ff194888a31435f2d31031","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2023-03-01","documentId":73650,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205054s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fa4b1e11edbdbb4330838bcfc5c8ee295c6ab378501aa3083b694669b33808e3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2023-04-14","documentId":73995,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021008Orig1s046lbl.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"381057f8bc53b68339ee8e919cd6d2736b4dc11ff6ef02e5a1de4dd4509730d5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2023-04-14","documentId":73996,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021008Orig1s046ltr.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"59daffc31acd6f2c8b99d28bcee602ffe709a58dce965b9edfdecda96e7e67f0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2023-04-17","documentId":74001,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020263s053lbl.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5be3df0c0aeb1f5c72a8d88ddc2899be7321afee3ee14fc8f68de4780cd2322e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2023-04-17","documentId":74008,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/020263Orig1s053ltr.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"586bddb787d01cf03aaf3f53c1342a99acd2c2386af6e276e455d1b5e8de5d4e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2023-04-21","documentId":74037,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/206321Orig1s016ltr.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f17fbf732d751edb8c65c664895c4ced322dd15fe794bec7e93074a6b902980f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2023-04-24","documentId":74045,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf","submissionNumber":16,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a773f9b1d1a47d2ec34dc5c2c4ae153c83b844a331db90b729cde6d1e88e0d7d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021060","documentDate":"2023-05-04","documentId":74178,"documentType":"Label","documentTypeId":2,"peptideSlugs":["ziconotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021060s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df1809ce7e73ee1fb07aa91a8997b0915f67209b6507b17d049c5c36042f38ce","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2023-06-13","documentId":74482,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/202811Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f454530d82a8b28147d0f5817b170cac1bd8fbdc666db9136c4ac6927af7879c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2023-06-13","documentId":74484,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202811s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4a489ea20e8646d9118c56d34da8f64222a94bcaf18e0755f5c923c1cc1ac0b7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2023-06-13","documentId":74485,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202811s021lbl.pdf#page=23","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b28eecab571f38fad63021d87ac3c1ae44397ba8a22b813eb18fb7f97551526d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2023-07-06","documentId":74703,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022341s039lbl.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"404ad20056ba1605dbf01672440e599e3abc745b1ed44068bf9d31f42fd563af","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2023-07-07","documentId":74710,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/022341Orig1s039ltr.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a1237d37c0d03ed66008813beb9b849d784915b59f04cd1cf7ec4439b5e35e68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2023-07-21","documentId":74846,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"37e3773999231933f69b6d8a5efd51c2e076a1e2811e25cedc8896e919eec880","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2023-07-21","documentId":74847,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3e24ab2213986d09b34bd7d3a568c67703f67896e74023a390499dbd6793d1b9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2023-07-21","documentId":74848,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"39737231bd92442714da63cd928a23124bcce61500ed84ed45f4ba3eb8ddd61f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2023-07-20","documentId":74849,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6d80947040ce995d07d5b1ddc226a09c5be289930bb9b41067d504976a4ae1e7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2023-07-21","documentId":74851,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35d696b364e4a48d71eb964111c1a89f576b444b7d24cfc401b9e04a4b515af7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2023-07-21","documentId":74852,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4935238b82830814b7957c0c30f31b1cbeef3281592950ccad0ee73f83725da1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2023-07-21","documentId":74855,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20a686a245f253cc84bbc243048fade8392b2dfd7bdfed33cb2292c7937a226a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2023-07-21","documentId":74856,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"845b365e9b0cdc5a1d135737aa2adfb454395023d1ed15ef6d8599f7087416b7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2023-07-21","documentId":74857,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021343Orig1s047,s048;021379Orig1s049,s050;021488Orig1s044,s045;021731Orig1s044,s047ltr.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a3473dbe18c8e5168ab77fea422bb28fea71f090f02773a713bd9ddad2be22f4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2023-07-21","documentId":74858,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9090377f48cb4d0c0f8274ba12c22985533b1fc691a53ddd04c20e96e6c4f2f9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2023-07-21","documentId":74859,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a88f8b3d02a648dde4d9d45db637c1b85001f0e7c362d1e3b4ba33162e66f9a2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2023-07-21","documentId":74860,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"565154340c227a80cc59f9ae5c87a4da06ef3c30a7501adf52e54ef3eed244f8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2023-07-21","documentId":74861,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b011c72ccca067c26017e5d1ed17af9f2fa6c8afcec333097584caa29e54c73f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2023-07-21","documentId":74862,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"827c056cd7c67191f6a5cd65b95157206e32e3aa5bf279200b3832cae66534d8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2023-07-21","documentId":74863,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a82eb8616f7e1507fcec682c6d2858c979386651c3b816be3a7b9c5ddf6c258","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2023-07-21","documentId":74864,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021343s047s048,021379s049s050,021488s044s045,021731s044s047lbl.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea2c867ac1b17c06f4c4d9f460cab0207ed4889ed01d1ff0f91d010176b3bd4f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2023-07-24","documentId":74868,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215256Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"984779bad1ac322a62d23b90b1bc9170582ee6b9f610ce6a4b9a4cc20344fa78","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2023-07-24","documentId":74874,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8c7294f2fcfac17e17e885e12411bf6fcc22d18e77072d4354d167eb1216dfb5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2023-07-31","documentId":74956,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215866Orig1s002,s006ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b97d7f338570e49fa4365aed3c753a8b933a535061665f13525c5d09c285279d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2023-07-31","documentId":74957,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215866Orig1s002,s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4a51a25968b0618da173be509ae6249a93a7c66f40de5fb7d6f0f75cd2368508","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2023-07-31","documentId":74959,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866Orig1s002s006lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"28f556709263417219865550cb00f8df94f9846319c27dd9349ccf61b8a4c151","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2023-07-31","documentId":74960,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866Orig1s002s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42c8cd8dbc78b345a4f95a180abd7f5f4195dddf571f17500b279977f2418163","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2023-09-25","documentId":75550,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/209637Orig1s020,s021ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"edd3a04ae0f61c4e7a719896b26fcb6f428c494f941917d14298de5d53395c84","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2023-09-25","documentId":75551,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/209637Orig1s020,s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"722400825b6fc63919a7cdbde21b0871cd90e2cb3cbf9975037419e905cfea7f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2023-09-25","documentId":75555,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8cd183de608b86297e9d3558e8e87a4e4356486f6fd8dc95cb3232a7e309229a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2023-09-25","documentId":75556,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"23a87fe10ecc71edfdc1f3c55fde2820f84b518852c4aeaced19e37275753594","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2023-09-29","documentId":75612,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"acfe203eb0aa0cfd5bcf26981021305294320dfc22c76de0a3518a8ecd802e83","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2023-09-29","documentId":75623,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208471Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d6ea88be79dc10adc53ee5ab9082900f65e108959e9dc9b887b40181b05525d0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2023-10-23","documentId":75887,"documentType":"Label","documentTypeId":2,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214938s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea3a30c921df3a6f78a2ebaae40e26001411770d1d27322db9df254443029103","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2023-10-24","documentId":75892,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/214938Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"11f1ccdec780996e4172ad4466fbe181391afa9cd29fe6e9b544f8753d2403a8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2023-11-06","documentId":76376,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/019667Orig1s076ltr.pdf","submissionNumber":76,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"48aafcb28a6fe46e0ffe8b8c0d8ba35cb8b89a093797c09fb4d32a57b606a046","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2023-11-06","documentId":76389,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019667s076lbl.pdf","submissionNumber":76,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f489d7b4808af2dba076e39a127bc3a61c64165db6d741399e6d8e63f583624d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2023-11-08","documentId":76538,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"abb92922df17173cdf7286cce4a2a8e28ca578daed42444b695b1300059ffd2a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2023-11-13","documentId":76547,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217806Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1caebef17b602617abfa632d0dba959c0633c0a9cace926a241d956839e7ad5a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2023-11-16","documentId":76581,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213793Orig1s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ba7f23d0f9724b304cd563b34c6568212a42192fbc9b6a9ab93a345eba1c579a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2023-11-16","documentId":76591,"documentType":"Label","documentTypeId":2,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213793s005lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f2525e30db07175021c019abd1d83623869fe77262ea17834cf5544069b11d2a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2023-11-17","documentId":76603,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211939s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"445ab3f657e5d41c60ced12c020e6b4ff6bd2127c9e23aa8e9027d476dce15e2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2023-11-17","documentId":76618,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211939Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea0a54dc839b243d1d68e953537045324cda59af8923294537170fa6d5c887f2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2023-12-01","documentId":76709,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205054s005lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9f9259f53f173ac6dc38213c50f7a28d48ac88c15740651a27bd58480a4e6405","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2023-12-01","documentId":76713,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/205054Orig1s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1e9d77ff2d355653f676b8e223feb26923c8cad15d539d96c381f360af2fab51","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2023-12-05","documentId":76730,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020517s045lbl.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9adbb781a03fe242bd5ece8c1dc56998cde4b00ece86c7ab44ddf1cf7490cae8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2023-12-05","documentId":76732,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/020263Orig1s054ltr.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"808b16fb62fe36a285be5ea88d4be56f1ad9e86a87b810bbc1410a81c906f19b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2023-12-05","documentId":76733,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/019732Orig1s048;%20020517Orig1s045ltr.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"76743ce784ed7505c75c0d469a0ae14bb25113711f23476d883851527ea24155","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2023-12-05","documentId":76734,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/019732Orig1s048;%20020517Orig1s045ltr.pdf","submissionNumber":45,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"83c337d513b824dfd67a438d4a35430920e940a76a17372c299d9a4b3ef53266","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2023-12-15","documentId":76735,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020263Orig1s054lbl.pdf","submissionNumber":54,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b83cd1276d51f4a213e745064ac18cdb20bd4e2497fd92877430e9b5b9dfc30c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2023-12-06","documentId":76743,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020517s045,019732s048lbl.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e3931204feba90513f7887e9c8e958cec63e08441cddd6a21a6fbbfc7eae6265","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA208569","documentDate":"2023-12-14","documentId":76798,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208569Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1718b5aaa622fdbc7a95402461f407ea1cc5a66b0ec1bc2baf7ee73568817131","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA211097","documentDate":"2023-12-14","documentId":76801,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211097Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fc178065bed230a93fcacd4ae2367f7efe4eeeb78f0772ece94ca1b8469b656","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2023-12-27","documentId":77113,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208743Orig1s015ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e2cea448faa2442d73e0a65e26e5955b592a5c08e8381809684361ee751d90ab","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2023-12-27","documentId":77140,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/212097Orig1s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f804c9b487bc88b2eb345bd2feb2f5448071bb851366b627625d7117f1f3029d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2023-12-27","documentId":77142,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208743Orig1s015lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c48a07d5f2baa84776d6dfb2dc7b04d925e5e4533ffeed1e3f1132a625ee46d1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2024-01-02","documentId":77174,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212097Orig1s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3c5150b285b3dea59195647160056231f830c76ddc571928f8705496dd9a18b5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2024-01-25","documentId":77196,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021008Orig1s047Corrected_ltr.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d45c33b67d95b323dc460f6746dcdd06bdfa1ac936a9980857724875ed6c5d6d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2024-01-09","documentId":77198,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008Orig1s047Corrected_lbl.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0ef2d825a133e4c50f8e9e17c0c8dc92afdd03e3887a1709adad32044084e772","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2024-01-24","documentId":77285,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s051,%20021379Orig1s053,%20021488Orig1s048,%20021731Orig1s051ltr.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7b45cdeab3ef5287cd504d50d7b236618ad3af9791c47c122cb84b37836cc679","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2024-01-24","documentId":77286,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s051,%20021379Orig1s053,%20021488Orig1s048,%20021731Orig1s051ltr.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eff3c38ab1f5cc3b16629a774587348a608fe86eb00e207d0e900366bd7c3bd4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2024-01-24","documentId":77287,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s051,%20021379Orig1s053,%20021488Orig1s048,%20021731Orig1s051ltr.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6f1f50b04961e16ac1d8e0d7391f16fd5793ccd0e726ea74879b3e8d2a176c1d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2024-01-24","documentId":77288,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s051,%20021379Orig1s053,%20021488Orig1s048,%20021731Orig1s051ltr.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32983dee03beff92a11297e2c5390aadfb92b901b3aaa9040657680b2cdfa078","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2024-01-25","documentId":77291,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213051Orig1s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"502e42da03b779adb80ceb0ca66826c95c1c5c04926386582714b1c44c434967","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2024-01-25","documentId":77293,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343s051,021379s053,021488s048,021731s051lbl.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fd3a8dac5226955f32428b64a2591954590746fd9bf3101eacdace2e849d4958","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2024-01-25","documentId":77294,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343s051,021379s053,021488s048,021731s051lbl.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0cff4005939a33517e68d3d53f7936d9b70d62d1cc5226849753c1b96457e9fb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2024-01-25","documentId":77295,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343s051,021379s053,021488s048,021731s051lbl.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3c627ba29631f0c336116ef94a92877d396478dc1112f61c6419a3949cc2b3d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2024-01-25","documentId":77296,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343s051,021379s053,021488s048,021731s051lbl.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d4204b69d188e9cef08e5ac94352d261b37ce7814e346ffbc60869c6fc60bb2c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2024-01-25","documentId":77299,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a48112b0d84a86749dccae34d89cbae751dffde2cb7014d8c63028c8f0c913e8","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA211097","documentDate":"2024-01-31","documentId":77372,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/211097Orig1s000.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7a03a7920b13ede25b81248eaff9e0248d06f7f65e9db0bb1118e1029bf31aca","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2024-02-28","documentId":77641,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"143c4fa5d4507e14e3b99b29cdf56be68b14a39d39da2df5283bb61e667abfd8","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2024-02-28","documentId":77642,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022505Orig1s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"622ce4576d9d8580e04c738e7df20128b5d5d2150fba08cb80965d4106e09aa9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2024-03-07","documentId":77748,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209210s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d5879af47857992dfb2a46b0c8d339eb83cb2c71c5251204027c44059fe48df4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2024-03-08","documentId":77770,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a6476489a777aeaa2547dc32d54c857bd589bb892ba6131a7a8ce170120e663","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2024-03-11","documentId":77775,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215256Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d0960c1ebe70a41f21b921390bae5bca2ab9a3d957f2a2754cc8b15c5e85a1c5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2024-03-12","documentId":77781,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/209210Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a92596736013dfd55f00455d8c17a07cb2d186562de2e666bfb8ec834a2f1c07","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2024-03-22","documentId":77916,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/019732Orig1s049ltr,%20020517Orig1s046ltr.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9ee3d40b26de31e49d15a30818f7506ba5c42f995d8deae3affd761bdaaeb640","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2024-03-22","documentId":77917,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/019732Orig1s049ltr,%20020517Orig1s046ltr.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5fc7b1fbcfa8d28a0b19d0f137a90fec6434fb7e3383155635fb3ac7420dffec","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2024-03-25","documentId":77926,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019732s049,020517s046lbl.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"72e8ffc911418d6e7a9bbbd254b0138b9ba5ab4b45b2d6334821376fab6716b5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2024-03-25","documentId":77927,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019732s049,020517s046lbl.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6ed40ef39974d8d0241668d19ea58d2159932b9f080e1005e478120d4fde2d9d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-04-01","documentId":78015,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"482586fc1bb20c9ecfe893fc6e733e57c265c02a0eb79286aece1c3bacfd0f37","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-04-03","documentId":78043,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s003Corrected_ltr.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e50ea6523f0e9cc94588c21110a44787323a6cce48094895c5611d94aa6e6e84","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-04-16","documentId":78149,"documentType":"Review","documentTypeId":3,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217806Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"364f90ee84a8fcf5e9e15359f7e8681eb46ec271545e600fe79bf6f3b0421fd6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2024-05-22","documentId":78526,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052ltr.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8033abf7a1afdf620f8937d265b0cd19ff564a50168e7ebd8dec5ba778114c29","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2024-05-22","documentId":78527,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052lbl.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d8a1bfc69036c6a22f337f1431b33ec40b0b08e5af4aeab4f8e603817a083a6d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2024-05-22","documentId":78528,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052lbl.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0adc0984ca00b50a772915bc94088f57ab5dd1913603e3b4f5ba5b1c9200106d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2024-05-22","documentId":78529,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052ltr.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"51c09c8bbf4c54ebc0d603668d1513bbcfbcf4ac80de3d8da91fcfffaad47488","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2024-05-22","documentId":78530,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052lbl.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"39e458f2f01b1e2d9e12e4b90f9aaeb36a39c1fd039883cb1186305ca8090d67","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2024-05-22","documentId":78531,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052ltr.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61b82d114fcd9f4b88c6d5092d6c5978098a27fa4e82d2a497b879245b636c27","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2024-05-22","documentId":78532,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052ltr.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fe3d3eed09bc93c2f7d29d037e300fc91475e9271b05c7331880c958e8dd5324","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2024-05-22","documentId":78533,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021343Orig1s052;021379Orig1s055;%20021488Orig1s050;%20021731Orig1s052lbl.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"be3e514bed1d1c61c6902b4d62c59e05063b864ddfda6e02b8b396dd24608d4e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2024-07-02","documentId":78639,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218771Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e966baf033d000c819182891fdc9e2ba5df581fbe4d0e8d69362c182702d42cd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2024-06-05","documentId":78650,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218771s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a7adf211746716857b14e4f81213e50a3dbf4ab012506a665fd8c5ae99ab273","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA217193","documentDate":"2024-06-20","documentId":78843,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217193Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ac03bacc3f9ee5c34826afc1a647c9d79987c1758ca7ae03f9b8acdc8a24f64f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2024-07-15","documentId":79060,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/019667Orig1s078ltr.pdf","submissionNumber":78,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d29166e18c6b9c15ad9aeede556e4477726a95cec39cf4776a0917fcb98aa6ea","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2024-07-15","documentId":79062,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021008Orig1s049ltr.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e156c877c3a279dc5e9d67dfaf21c67e338d324da9e93a00d115200790dffd0b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2024-07-15","documentId":79066,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022074Orig1s032ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"80a50f340e0bf1b5667a3654e75ff1ddcfb7aa2d1898a25ac940059b5b52f2e0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208232","documentDate":"2024-07-15","documentId":79068,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/208232Orig1s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4ca2a7f61bfdefe1aafc3bc4c914ca407f369ae5e98a1f9765743d4661a14a5a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215395","documentDate":"2024-07-15","documentId":79070,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215395Orig1s008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccf9898b937ad0ebf5f55d60189aa884569dae2792e9fe8f50a791ba8da2e6b1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019667","documentDate":"2024-07-15","documentId":79085,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019667s078lbl.pdf","submissionNumber":78,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2836e5956808502e3e3e7f16a3f9adcec6e5c78eaf85183b99bee7a97952582c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021008","documentDate":"2024-07-15","documentId":79086,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008s049lbl.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d6e6042b51e1e6d801bc6a4f27aa3103d6bd48ebef6e9764f8ef23884f8385cd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022074","documentDate":"2024-07-15","documentId":79087,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022074s032lbl.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0ebeef9e30b93b3a21217051554cb5037c8f5d30b2310ee55b3c5422b838198","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208232","documentDate":"2024-07-15","documentId":79091,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208232s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"124235820af9bdf51361aad288919099c20178e92493dfddee590e6e8dc83b1f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215395","documentDate":"2024-07-15","documentId":79092,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215395s008lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a4c6d28f085d850e685350370eea4719d2c9c4c2cb80ec8a6b0d551251d135e7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2024-07-26","documentId":79221,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f1448309fe7b314c190cfbdb301939bbdf53a6442baad319a948c56e217a547f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2024-08-09","documentId":79357,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/205054Orig1s006ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"db45230a4748368807ce7dd26e47d8bb55ac2664a13c6fb686d026a47c78595b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2024-08-12","documentId":79363,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205054s006lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"281903038a1ab43f03662063eff99b1e8f3d2ab40abaf49531ac4d2159d4f9e6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210797","documentDate":"2024-08-13","documentId":79378,"documentType":"Label","documentTypeId":2,"peptideSlugs":["afamelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2c5e0b91fd9147f11a5a277dc69e11da427707824a8b920e283db117243724b0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210797","documentDate":"2024-08-13","documentId":79384,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["afamelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/210797Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"53037aef152aa1e88bdd94ca6b8bd055c9897885740abcb54dfbb5ec353058a5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215395","documentDate":"2024-09-17","documentId":79639,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215395Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a94c3b1f11126bc1db7ad10fece28531db2411b597473f33b716b28c4a23c665","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215395","documentDate":"2024-09-18","documentId":79645,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lanreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215395s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7a299a3ec8dfec06bd955972339e6e44bc5983812c3e5e4a01edb66b15cd3d85","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213224","documentDate":"2024-09-30","documentId":79780,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213224Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1de44293256b7cde61b641ac0b465e6012fdf4b3bf37cac080e4aa69c7c4e77c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213224","documentDate":"2024-10-01","documentId":79785,"documentType":"Label","documentTypeId":2,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213224s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"afd67bf27d0dd3f7bb472344c939aa271339626bf89b582b51230b32b49fb348","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2024-10-18","documentId":79914,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213150Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"66c423698aa5032d8e1c88badf8fe375b30ea574de547ff98e788b13496c95d6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79925,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s005,%20006,%20011,%20015,%20019ltr.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a6724e59a569d22f2b3fb1da0098a6007b81a54f91a0f31ececee25579f90863","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79926,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s005,%20006,%20011,%20015,%20019ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d7442b383d063c7a519031f1485bd2739110e365b94b9d400ab797cb2a4bd5a9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79927,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s005,%20006,%20011,%20015,%20019ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c073a714b6a3a56168097beba3ce4ff7e8edc1f3dce4c72fd9b18baaf2e91ca","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79928,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s005,%20006,%20011,%20015,%20019ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"763ad667f141f3777d4a6792b2842d819c6c1a4688bd1c4dc05796703997acf5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79929,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s005,%20006,%20011,%20015,%20019ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"59af42067c7e320e9406080de46cf5e56c135984f11dc2419894694a1e1643c5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79930,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s005,%20006,%20011,%20015,%20019ltr.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"648584234e3e62c09aecec5eafb7fc64c9f5e77e34d99524c677b0a3c9a6ea1f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79935,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7f79996610a9c673b0d41fec8b4bcd72ff029184c55237f36214d0c1424232ac","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79936,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf","submissionNumber":6,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9868385f624ac481f1a5aa94d0ea9b2fac5c13cc8ea01396c818351a7ee3a51e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79937,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f6e78a352080dc866f5fc3e5fc7733e0fb951021103fa7429a5a05d2b68be36","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79938,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"98f76bb8152c1f2f5685a7ec5e709fb9dd5c07edd6a8aec482d4f4343ee9be77","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2024-10-21","documentId":79945,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213150s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d6fe324eb10e787a30c694e3f597123288ba7becfde43959f1f150c0d6b76a21","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-10-21","documentId":79952,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"88df76c55c50fad97ae895e52dd1ccd2cf3ab364dda7761f68a1463104474f8e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2024-11-01","documentId":80064,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022341Orig1s043lbl.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"14bfc94f50e2609fe9b50c1ba67381a62139e5b6443bd6532751edde9f02fbf4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2024-11-01","documentId":80065,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022341Orig1s043ltr.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1c37f488e880505b2780d3de825747739ae1ddd911f76758f224d7514f001cf0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2024-11-04","documentId":80103,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206321s019lbl.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"329803c4a03d2a77b7617a79d960375e112facd9f3aad6365959c63a75adedc5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2024-11-04","documentId":80105,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022200s035lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"76fde82246257a0a1dff9a2180902c1389505e334ad066cfe49ae8c80ee20167","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2024-11-04","documentId":80107,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"034b062645b12d84a9da112d52325f888df50d65a3ebff5ddd3ac1dc5958ef4a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2024-11-04","documentId":80108,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf#page=37","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b15fedd05f42569825592d925751db8aa1c4bd7103039493e70aa91fe52a85bb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2024-11-04","documentId":80109,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021773s049lbl.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4f8bde8894fe2adb7e79f782b6764fc818987466885b01cf5820543dd6949744","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2024-11-04","documentId":80113,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208471s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"65949f657dbae1a256802c850b7d4a20742164b609569a05a83deeb6b87c0b82","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2024-11-04","documentId":80115,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125469s061s062lbl.pdf","submissionNumber":61,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0506a6bb26e684afc04bc8d7a5a5cf2585c675e2505b1f94eb2872bc0cc2ef36","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2024-11-04","documentId":80116,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125469s061s062lbl.pdf","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"de7c9048aa7e06d033f151ee476aa73ef22199322981c81b807910273ea01617","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2024-11-05","documentId":80118,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/021773Orig1s049ltr.pdf","submissionNumber":49,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f5bfbf8f48d5e12d9e4a00094ee57a9f602cfcdd093ed108219c24aec939e26","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2024-11-05","documentId":80119,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022200Orig1s035ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"50d72a01e278e51bf7d8cff373337d53d95c7308cf666d6f0a5e1ab3c4bb6b95","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2024-11-05","documentId":80121,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/125469Orig1s061,%20s062ltr.pdf","submissionNumber":61,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"725cf03d690335482cf804ef2597d2610a33c77756456af2f4a71fa5a3ee8da3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2024-11-05","documentId":80122,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/206321Orig1s019ltr.pdf","submissionNumber":19,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e0283513fb15712e2fdd5e7883f2188a73199f4245e46312a94d79a808089841","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2024-11-05","documentId":80123,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/208471Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e58cb4eb727c1cc88ec6e700093739d6ce6725d8bfdab692365069c56f3c7a51","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2024-11-05","documentId":80126,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/209210Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ba37e64fa107b7283613ea04a8beaada8a9ab0e2c8e2d2c5fdb8d682e5a909f2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2024-11-05","documentId":80127,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/209637Orig1s032ltr.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"67292f95c44a226ef50b5f717431c99eca3ada82497bb057ff8ec7f2a3eeeb4c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2024-11-05","documentId":80128,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213051Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c8128cd1fb1c220cbfc096bfb83c43820a3d090b79a3c8ff3a751f2d933b2c3a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2024-11-05","documentId":80129,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215256Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"02d2163cde7f274df9469d2147cfdff7331c9611a6319cfa2b77d0210fb807aa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2024-11-05","documentId":80130,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215866Orig1s010,%20s015,%20s022ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"72b633eeaa72090597391145493c8e0ea494bed2ad70ca299a6f4a9d95d79e3b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2024-11-05","documentId":80131,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215866Orig1s010,%20s015,%20s022ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df3c701af148f026d8a1de5c98f4d2350922b48847093e0551e92de0d68c47cf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2024-11-05","documentId":80132,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215866Orig1s010,%20s015,%20s022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0447ffa09166e188b5d671be3e68f05f0ec8e861b691f4655c5a73be8359ea4d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2024-11-05","documentId":80134,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b753ae41c6613b584bc251f77f2799cbbfb9af0d1aac355fa3e526443a061b82","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2024-11-05","documentId":80136,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s010s015s022lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1240f4fc8ed4c2a8fb88af2140b80425a89cb1b875b31b62970411ad93f010a0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2024-11-05","documentId":80137,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s010s015s022lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a7c3daca1b5865c76703cfddc49fae5328610f306a792051c26dcf4cf48dacb3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2024-11-05","documentId":80138,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s010s015s022lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"905bc2a66250c6c33d25a6dad15b7ffa7950d11baf19fba73af0989288e89bbb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2024-11-05","documentId":80140,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ec9ee099a1c334e3fad6a2e6103702e34226284d997a5728623d44a8768fdd0f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2024-11-05","documentId":80142,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209637s032lbl.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3215ada53f8444465de4c8782190c8e16e4c11e717969d8b2f5910c24d673b68","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2024-11-05","documentId":80147,"documentType":"Label","documentTypeId":2,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ab7994d62a1e78ab0dfe5e31ce0afe5b83bc3c4f9e1130c94dfa44524a9eeb39","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2024-11-05","documentId":80167,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215256Orig1s011.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1e6c9720ecd9cdb0a6fb601d569b48f749aa89de5a37d64352bf3e4c37abb643","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2024-11-05","documentId":80175,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/214938Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"63b077bf785882d7d52de586b66c5cc0032d56ce62c3e7468f24a031e670df6a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2024-11-15","documentId":80220,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205054s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7f339d22229582e0d3d5f2179eadd6f189d08855e6ea4dec9407a5d30035e5d5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA205054","documentDate":"2024-11-15","documentId":80221,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/205054Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"df6bff18ae0e0e08b6c5911b522e242a66b175a07b2e2fd9881f3e43a8ee84f5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2024-11-29","documentId":80452,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/215256Orig1s015ltr.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f3b158642ccde87bad9f76ea753013f6e9583f3b632ecb09656ba75e19158139","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2024-12-03","documentId":80472,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s015lbl.pdf","submissionNumber":15,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cee976939a13ce17ad1bef72f1466961a170c3495e28589a8c182eae17a31a72","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2024-12-04","documentId":80489,"documentType":"Review","documentTypeId":3,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215866Orig1s002.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dcf098a8f1a40039d40af0017df32469abc50df9ba371f81656312176988625f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-02-11","documentId":80545,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051Orig1s020,213051Orig1s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"45c7e5107e16b7f102bf9c85ece7566bcca70fb497bcfb4d88db969229e23bf8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-02-11","documentId":80546,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051Orig1s020,213051Orig1s021lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4a4807ef5ac02b923ebeee58b4eb15b5c624fa773b907a4adb098b7226981d03","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2024-12-10","documentId":80550,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213051Orig1s020,213051Orig1s021ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f1ae7fbd3e9a67e2d0e23d767a1057a04eb3620c63bdbdec6133024f33e191d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2024-12-10","documentId":80551,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213051Orig1s020,213051Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bc0be070f49cd8cae075ec76fe9fac94c7756770fe72b6d59da07b6c8bfe877c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-12-20","documentId":80674,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b105d8b780e19ebdbeaf9d84118cf7b52a8e5b0331edf2e2d0822931075b93a5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-12-20","documentId":80675,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf#page=32","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ceddee6b9700473d5489d3b16d3995ca2320da4e5f40cf967ad85c31b9f41e8e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2024-12-23","documentId":80697,"documentType":"Label","documentTypeId":2,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbledt.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0c8a0f66434fe41eea0a2b2a59cc3753fb051ffd16c93e87332b1e3b23e21893","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2025-01-15","documentId":80711,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213793Orig1s007Correctedltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0dec787c85fb6551d8aa80409a49dd7ef3eda73dbdf30006796f1f61398cea34","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2024-12-26","documentId":80713,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217806Orig1s013ltr.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"76e422855bcbdfbc35abaf663b0483391e7027323b08131142fd47ffa7527190","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2025-02-04","documentId":80909,"documentType":"Review","documentTypeId":3,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/218771Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"27763d2c6976ae21a764c71637212ed25a159e2a954d297aa626c6f29c688045","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2025-02-06","documentId":80963,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055ltr.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fe4b8f360c5d90cf892ce2a0eb089da9700b6958868b7243571bf2225171a51b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2025-02-06","documentId":80964,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055ltr.pdf","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4d473a5d18bb5e732eec8070a6d2cc1944f14cd59deaa53783bb54f81d291ea3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2025-02-06","documentId":80965,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055ltr.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5bc36906ab422fbfbcc872bc77642ea458349aa3e84e45d588e387e08bc910c6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2025-02-06","documentId":80966,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055ltr.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"26ed22ce4fd8e496f3e14d68615181ea26a3af318e5b816e34efa9100acfe464","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2025-02-05","documentId":80998,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"20f3fb389eee7fb690bc599b5de64d9efdcaf3ed3e8a165c9815e13978fa962b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2025-02-06","documentId":81013,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055lbl.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb6f01ceefd718a093b97f35ce50108b3eea1c4b21b033a145bc42a3a8a82e0f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2025-02-06","documentId":81014,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055lbl.pdf","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"640958fbbe18c23bf8e36de21174523b5e7300801beaeaefd51b76394fac61e7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2025-02-06","documentId":81015,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055lbl.pdf","submissionNumber":52,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d4547670cb97983983ba9eb5556a582335af3afce40d635151546453b42d178b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2025-02-06","documentId":81016,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343Orig1s055,%20021379Orig1s058,%20021488Orig1s052,%20021731Orig1s055lbl.pdf","submissionNumber":55,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c9798a49a5c15ae7d70d8d184c4ffaae8f357383669a738002ade91aadf1bb9f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2025-02-06","documentId":81034,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218771Orig1s001lbl.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5929e8b85fb8aad6b5b795cb7461548955fdedcb54f25ad1d8fdbf6f3d4c700d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2025-02-06","documentId":81035,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211939Orig1s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"febbfb923e01a1c398dde3c48ec287156f45e996c27afcb91838110550f801fd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2025-02-06","documentId":81092,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/211939Orig1s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"24fd8ebfd97f926bbff223bdd98f2d5d4fd2c0c07e8e9aeadbf20cdb24b6ba2d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2025-02-06","documentId":81103,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218771Orig1s001ltr.pdf","submissionNumber":1,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ebd8bdd3ebb6c0fc016e2f7c625b7b5c3186b927782b8705c69e9cb6c70d4092","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2025-02-07","documentId":81169,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209637Orig1s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4e400fc57aaebec62eb4ad6bbd6866f0415c970661eb668d0800666f118f1e42","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2025-02-10","documentId":81181,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217806Orig1s020ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8f015a0eb853096ba6bee81e3190c344b32d0dffa8ef48cf77bd3a15c67e663a","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA215503","documentDate":"2025-02-10","documentId":81190,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215503Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c9f9c4fe9ade55a982d40c7b725c2e927c15800287cbb31f5c61e3c708de760b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2025-02-10","documentId":81191,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"317f4499a1974a8e466e9f226270b3583ff5317a2e1b41c49d1a348c9fe93914","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2025-02-13","documentId":81237,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022341Orig1s042ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"08a3fcb1fe91ba34cc9816e8d15899db942fb7137d5670cbb4592fcc64503461","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2025-02-21","documentId":81252,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341Orig1s042lbl.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"276155fe16eeab99ea6337489e24b91115bbdaf6979dd3d84bc8e95e27e68260","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2025-02-25","documentId":81344,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343s056,021379s059,021488s053,021731s056lbl.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5084643f4eddcaef9872799a81ff77f87c908b3beed638cd8f5f533a3d108c5d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2025-02-25","documentId":81345,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343s056,021379s059,021488s053,021731s056lbl.pdf","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"100485d097c4d272857bd2833e4a67a30bab380a2567f260f828a75209937985","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2025-02-25","documentId":81346,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343s056,021379s059,021488s053,021731s056lbl.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"36f559e5d5dac955ec544e94dc9f99993d335cccd8e2a81ab1792e81be45174e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2025-02-25","documentId":81347,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021343s056,021379s059,021488s053,021731s056lbl.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"52ca19a7cfc1f615023cb414fc0570b58707d55a63940e103ce1bd0d286151ac","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2025-02-25","documentId":81369,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s056,021379Orig1s059,021488Orig1s053,021731Orig1s056ltr.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e4944327a2a3aaedd6bd6072261548c11f0b894a5ed1d9b63cea65e76880a482","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2025-02-25","documentId":81370,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s056,021379Orig1s059,021488Orig1s053,021731Orig1s056ltr.pdf","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a1de684df0af66515a9a32efdb4f7c61a75b7dfd6179e4f114720ad7ee190fc0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2025-02-25","documentId":81371,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s056,021379Orig1s059,021488Orig1s053,021731Orig1s056ltr.pdf","submissionNumber":53,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3d07837500f355c1cae4504f8a60aa526ea9228a0d2014c78aa6e6f48156cbac","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2025-02-25","documentId":81372,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021343Orig1s056,021379Orig1s059,021488Orig1s053,021731Orig1s056ltr.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"55702d631614c58add3fc7eee020c68a8a88aad51838c7dbb400d51afbcd0ab6","publishedAt":"2026-08-24"},{"applicationNumber":"ANDA215503","documentDate":"2025-03-04","documentId":81436,"documentType":"Review","documentTypeId":3,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215503Orig1s000edt.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c04ea6f77a6c28bb37b0a1fe45c0f9a58f45c60f18abc0b2a57c336099c13514","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2025-03-18","documentId":81621,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/212097Orig1s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"905f59a8aa8d6078fc93e5b5dcaf896fb442404a8c0498b84f2076a300ac7411","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210134","documentDate":"2025-03-18","documentId":81629,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210134s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"940b308d2b2754a891dbac51b2f6ac18f82744e3e90fa364fb751f2dfe2bd216","publishedAt":"2026-08-24"},{"applicationNumber":"NDA210134","documentDate":"2025-03-18","documentId":81633,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/210134Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"42e75df67c0a1305ff752e7221ffbeaa9a3b6292459a94c9ed3913b1af471b8c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA212097","documentDate":"2025-03-18","documentId":81641,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212097s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b52b0e36d7036310ebfdfb95ed0a7808218d46b0d559b819063af306121553f1","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2025-03-26","documentId":81739,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9cd948b2d29c4ff8f7aa44c69d972511753c0fb6652d6e902118d54694017b58","publishedAt":"2026-08-24"},{"applicationNumber":"BLA022505","documentDate":"2025-03-27","documentId":81743,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tesamorelin"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022505Orig1s020ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b52e3768fe9878b45a0417d93ee217d967f37fb4e1deddc6fbf4c715399ce227","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2025-04-09","documentId":81894,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/208743Orig1s017ltr.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4bf27e20b60f9239aaed57366895cdc2f32c0170921e170f73f08c2d62621ebc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA214938","documentDate":"2025-04-10","documentId":81918,"documentType":"Review","documentTypeId":3,"peptideSlugs":["vosoritide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/214938Orig1s002.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"35f0f5d2eaf9b81962198f7aa8eca4aadec7d256803e1a485cc09f9f530b3bcd","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2025-05-08","documentId":82168,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213150Orig1s007ltr.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5f570a1a475fd68e69a9dc4fa5315907996fa137567103e2afe077ea049de1ee","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2025-05-27","documentId":82331,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/020263Orig1s056ltr.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"be5fc6feaaa6e1f6024f77ce683c07c3d44730576f5bc349ca7e9b87a66a542b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2025-05-29","documentId":82342,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021773Orig1s050ltr.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fa17da95448564d44e0e19848a2a1089767bd1f757cae010cbff8b86ace85169","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2025-05-29","documentId":82343,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022200Orig1s036ltr.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0912bc3e22cf2714021d39db8fddde5f4bd544c3ea48d3056cca16f398087a36","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2025-05-29","documentId":82344,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/125469Orig1s063ltr.pdf","submissionNumber":63,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e0de1dbc67a130c369424ed7ed21270e666131cdccb1b920a34c11195fc6834c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2025-05-29","documentId":82345,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/206321Orig1s020ltr.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fe6bda62175bc94b343810ad2e07e3b456ef3841321f20ecd61b36c97f6e3e5c","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2025-05-29","documentId":82346,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/208471Orig1s010ltr.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6f159b9e3925223a950f80eda8c86ed9b26130ffde09b15b54db5d6d4be3cd19","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2025-05-29","documentId":82349,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209210Orig1s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ddbc827a9894389a7b0a106a5860ce9c051037a822c1b20410aefa160bfe2203","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2025-05-29","documentId":82350,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215866Orig1s031ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da6db950dbbac68d6813b410dabd384a73fdd0206a0cdb423e35a20ec747fc52","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2025-05-30","documentId":82359,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s020lbl.pdf","submissionNumber":20,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"815c35fd2eaf6e2c819e7c015918068474d13d1be6a4b16d7816c2564fd9f7c1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2025-05-30","documentId":82371,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s044lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"370385461663d7e1ba92de5c58fbe04d90f6d59021a6d2c2feae9ca9cc7e25b0","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2025-06-02","documentId":82377,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125469s063lbl.pdf","submissionNumber":63,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5ca18f6ce9527aaf6ffd34d4482a838650d45f1904a21bac4c38e74eee9f7d86","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2025-06-02","documentId":82379,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s031lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f54e987ea5eaab3469709f220e7a8b3edf94c1f78e086392e49de8eeb7dcf065","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2025-06-02","documentId":82381,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021773s050lbl.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"941ed6b1078ace97bfe261a99f2fe8d96e42ece371af173624b4902b83c4fe1c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2025-06-02","documentId":82382,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021773s050lbl.pdf#page=33","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d4e8895198eb7c0948a60d914c60896c1a719607a8eac9121bd48c4445441ee","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2025-06-02","documentId":82383,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022200s036lbl.pdf","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"79bbc979c2bb63f09bc3dc70fe700825a237754e3e032df77f32536c45d512e6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022200","documentDate":"2025-06-02","documentId":82384,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022200s036lbl.pdf#page=38","submissionNumber":36,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"29fb07b7490001cab6bb7945d063690360aed0eb17856a8c5921b69b67bb573b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2025-06-02","documentId":82386,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209210s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d0904ce7d8b9ae9756293691e49e02b0f0f9e86ce5fff3936be70ebe23c74355","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209210","documentDate":"2025-06-02","documentId":82387,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209210s025lbl.pdf#page=37","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"63d43e7f2e06502fd7733f1a17dc889f234844674ffc87ec87c9647747e573dd","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2025-06-02","documentId":82390,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208471s010lbl.pdf","submissionNumber":10,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8cb5b8a077bcd5ab00b3922edf48ccd59584c52d087ea724e084f0c947ca7af1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2025-06-03","documentId":82447,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020263s056lbl.pdf","submissionNumber":56,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"eb5b18824675a76ffad3ce5d460de19287bc779a5a2b1139719811d59f6198f1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213224","documentDate":"2025-08-12","documentId":83095,"documentType":"Review","documentTypeId":3,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/213224Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"89e6fff2143cc3e4dbe4240e7cc0e437cb2071c5ddff01e97f5175b5328f32e1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2025-08-15","documentId":83106,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b4bbd183ec44dc3310b0a6cff325623806360f301baf966633f2620d7b6beb85","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2025-08-18","documentId":83118,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5a1023afa6f04df5696c9550cbac8350dbde7325308718e16610ea9cc66ecf57","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2025-08-19","documentId":83131,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/019732Orig1s050;%20020517Orig1s047ltr.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"166ad60427a9166dbb73e5b33323f49b0e6bf9500642c574b71611a7ef4d0944","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2025-08-19","documentId":83133,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/019732Orig1s050;%20020517Orig1s047ltr.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"098961d21cd34edb14131e8548ff39703671faa792216a0ad885455a29431de1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019732","documentDate":"2025-08-20","documentId":83146,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019732s050,020517s047lbl.pdf","submissionNumber":50,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"476d66ba6c4a05c73cbe97a737b4a79c349343db54d4784eed5d2cd8401a2a15","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020517","documentDate":"2025-08-20","documentId":83147,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019732s050,020517s047lbl.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7d60f116ef723fda13e4632b4cbcba8109b1f8f9932737711ab2f3892587a8f4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2025-08-25","documentId":83183,"documentType":"Label","documentTypeId":2,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213793Orig1s008lbl.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b9ca22b5c5e3499a57d28afa154084032d6251e000e1acd998a759b3d3e04674","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2025-08-25","documentId":83184,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213793Orig1s008ltr.pdf","submissionNumber":8,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0a5abf41b3afbbdd61b4e7832597710cd258d8ce3c1181b983f68c4d769b72f0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2025-09-03","documentId":83276,"documentType":"Label","documentTypeId":2,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021773Orig1s051correctedlbl.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e9ad1fcf04c0336bdc41b0daabafee6b2654f3dabaa879c8bba10a0c7faafb5a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021773","documentDate":"2025-09-03","documentId":83277,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["exenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021773Orig1s051correctedltr.pdf","submissionNumber":51,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2a69460b395c8942d88082aaed43cf1d1c063dcd7cc7c801e0e28bcbf5aee19c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2025-09-11","documentId":83321,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/019943Orig1s040,s041;020011Orig1s047,s048ltr.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d05bd990fea2244466359b616dbc842fb42e2973dd6cfe4736dd4f67db72eda6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2025-09-11","documentId":83322,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/019943Orig1s040,s041;020011Orig1s047,s048ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"749fe4a6ac04481fdeeab8af765fa5cec4b0bfe8c453a128162c0a8ef5c0f0c3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2025-09-11","documentId":83323,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/019943Orig1s040,s041;020011Orig1s047,s048ltr.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"85ef3b37a2737c7c1cbeb720908e75a8100e3773c6e4ab389c63e94f2ddfb108","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2025-09-11","documentId":83325,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/019943Orig1s040,s041;020011Orig1s047,s048ltr.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"60ae55a0bff5a2c41545f594a02f9758e98b9749b99feaaae5381d2aecabb920","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2025-09-11","documentId":83329,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/020708Orig1s040,s041ltr.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"01351d0dc14a0052c9ccad081055ceadd5f01e1f9f003e53aec72b18aa04d387","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2025-09-11","documentId":83330,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/020708Orig1s040,s041ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"25a459640141b7e56423ec606f4e862f94e2a4b9b251dac30f22ca500b29d460","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2025-09-11","documentId":83333,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020708s040s041lbl.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6bc4f7a6b1d32cda4e09a1114d3da544c501ab6b80dba627dfa560c4e0402461","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020708","documentDate":"2025-09-11","documentId":83334,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020708s040s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0401b74d450fbfaf95a687a6f03e2ea952df0a7d43fd88f15878b63fbd8dd147","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2025-09-11","documentId":83335,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019943s040s041,020011s047s048lbl.pdf","submissionNumber":40,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"41311f30b702ce7d1b602db2187e1ca12a5ce648b0336fda90771803546c430e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019943","documentDate":"2025-09-11","documentId":83336,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019943s040s041,020011s047s048lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e3d488434f2357706cbf3e82438577794550beeadf61222cb8a080c7613be22","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2025-09-11","documentId":83337,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019943s040s041,020011s047s048lbl.pdf","submissionNumber":47,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"83f678e1505b56b031b5bbc4fd965f95622838b50cb3b283f53e954572ed6a7e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020011","documentDate":"2025-09-11","documentId":83338,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019943s040s041,020011s047s048lbl.pdf","submissionNumber":48,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3f891ce72219d2731c3a3411ba1d583b5984a1b7abccedeb89e9cdadbc0d15e5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2025-09-17","documentId":83364,"documentType":"Label","documentTypeId":2,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/201849Orig1s024lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b41ec1191db19cbbe403bccb0be554cc3037c256fdf21d85e8ed3a09df9121e3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA201849","documentDate":"2025-09-17","documentId":83367,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["glucagon"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/201849Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1176e239269b199a8bcd49668c1c1d1a40fdee09bed64531af4bf234190f711c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2025-09-24","documentId":83424,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/020263Orig1s058ltr.pdf","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"31c1e7511bc3b685182b92b29cfb1bf31b074dbb03bd28e28bdf391c47c7f60f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2025-09-24","documentId":83428,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213150Orig1s011ltr.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e9f32bf958ae20cbeb9a1883dd827e6eadaa9c58aabd0cacd3a4b0ce69288245","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2025-09-25","documentId":83457,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020263s058lbl.pdf","submissionNumber":58,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7a0f6a3b92f247e5bdad55057ab8d090c289b23558bb74300b8f2ee1758520c8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2025-09-25","documentId":83470,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213150s011lbl.pdf","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0dfafa7ac2236c96e300b89a063c3efe197a6a646ecada4a1bb293a654585ee","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213150","documentDate":"2025-09-25","documentId":83471,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213150s011lbl.pdf#page=16","submissionNumber":11,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0e81288cc4c63290b5508ceb4b8a94a0dea1433cd7615fc1d596d1590d9b095d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2025-09-25","documentId":83475,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019010s043lbl.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"734e724ee0428e8a9ec053b79a332f2bc8e20a35b2510806d4b56d47bd86d69b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2025-09-26","documentId":83541,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215866Orig1s034ltr.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1ef06361c3497f6e5ba01beaa6fbd4095f395d94339b10ba46381ecb072f2f60","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2025-09-26","documentId":83542,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217806Orig1s031ltr.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7f4a9c9b10315449be1750363f44059bbce7c1c43850280e46e4096897dc24b9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2025-09-26","documentId":83555,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806s031lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e2b778d8df764ee29a772599f490ef058baa92dd41ea845b4923461b4731d39","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2025-09-26","documentId":83557,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s034lbl.pdf","submissionNumber":34,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c74885e70cfde993ef2aa18d2cc2b5084205b2b22cd20a4e5180541153372f97","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2025-09-30","documentId":83589,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/19010Orig1s043ltr.pdf","submissionNumber":43,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"566018e6d43763f879f7c74f449aeeb9a2af30afd427a55409227f5936e04989","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2025-10-01","documentId":83621,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/019010s042lbl.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"26d6d9d67b1b9938b55846bf62f1357e8230b16035ac728be0ef88bf1d85e68f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2025-10-02","documentId":83625,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/019010Orig1s042ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"26506c5d364aecb4d232bcb77fcfbe9d7e57c0f6bbfea590014c7b0ad3163d13","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2025-10-15","documentId":83771,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022341Orig1s046ltr.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"edb9873fffb2c9aa4827d980fb0f2a5de9b80bccf436e19e4a8131ae6e65090b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2025-10-15","documentId":83772,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/206321Orig1s022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"31f86d123e7c6aa0a3cddddaa7a3e7963442550f6d8a6731f885592f0926a746","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2025-10-15","documentId":83774,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s026ltr.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fddd53e1267ecfaff11894f6877254bd2c0fe92adee9768366e05da2e89499f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2025-10-15","documentId":83775,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209637Orig1s035,s037ltr.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f52699f071b85b042c2ee626b205ac1145254c50a650300be31891bc19872e41","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2025-10-15","documentId":83776,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209637Orig1s035,s037ltr.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"85ea73e94af3a48bbcb42037b62081429f130a19d874a0817d9d63a7bd09b69b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2025-10-15","documentId":83779,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s026lbl.pdf","submissionNumber":26,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2fdfe31a882ec774b3bf781b36aa5af11d30d94d322c394ccfc882f8d9ce76d8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2025-10-15","documentId":83781,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"87344f8d561a7b893c4a5f8881736ab900e2cce0d13e4da0ddda035b828144b0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2025-10-15","documentId":83782,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"61208ccc25aab0a5fcfdf8594f3d3e99e6cae5cd93c24cf6ea1ce98971f64b44","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2025-10-15","documentId":83783,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf#page=31","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8532591be9b150f6934e611d5b03d102f080f2631f9f6f8131d0eb53e204169a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2025-10-15","documentId":83786,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s046lbl.pdf","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"159e01aa67e38863b4d010bc473bf5863960640d7f4a203c0109804018afbb25","publishedAt":"2026-08-24"},{"applicationNumber":"NDA022341","documentDate":"2025-10-15","documentId":83787,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s046lbl.pdf#page=32","submissionNumber":46,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91fed9c3db0c542000926290da6c4d29be8eb55ec2e6fe37929aaf53706108b7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2025-10-15","documentId":83788,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s022lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7c160907e66bc6f7cc6132376c421453c976170a33687a263937bbb006df4b95","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2025-10-15","documentId":83789,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s022lbl.pdf#page=29","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8b32fff52a77e469c0dd1bef1247875061b4683d7ad4acf433049adc8d389997","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-20","documentId":83828,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024,s028s029lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32117e7c265adec8b99d511f03fc55d5002ee8cb872eb264b51b94f8aac750e3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-20","documentId":83829,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024,s028s029lbl.pdf#page=27","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6aad4ce7fee0543814288089005c7d7623e08e1c2d0034f045e07fae064152b9","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-20","documentId":83830,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024,s028s029lbl.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c986f074a9fd57a87c27e6e127a398a1aa09c2b6feea744c49739458d9d3a15","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-20","documentId":83832,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024,s028s029lbl.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2e1ed8ccca728427ef1b2b9ca4a1aa3e31f4643bf36c1a98acba29660dcca5c6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-21","documentId":83854,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213051Orig1s024,s028,s029ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"79d6059a7e0da44d2d57b341f90c49559f129208c13e5cd8fecd8fe48eaa6262","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-21","documentId":83855,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213051Orig1s024,s028,s029ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f78b136c46d6eecf2ffa3089d0c5fe88508323c1e1142e50c0eaa572de676eb7","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-21","documentId":83856,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213051Orig1s024,s028,s029ltr.pdf","submissionNumber":28,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8cf5845221b5581d66355c081732f13c8af50df8a802c1e6783dcac96a5fd96b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2025-10-21","documentId":83857,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/213051Orig1s024,s028,s029ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d9c25c9accb4544e1f7f311997598833101f1dcf0c39e05f52d02b860622c061","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2025-11-05","documentId":84064,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202811s022lbl.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0db43667b15cf7e97a8291c66b32ad06620392341297554ff34f3c4bc0b7ad89","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2025-11-05","documentId":84065,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202811s022lbl.pdf#page=26","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"67ed0d1ddff08734288a9030179550ecd00f2d70b7fa04664bb7adc2ee12ebc4","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2025-11-05","documentId":84071,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/202811Orig1s022ltr.pdf","submissionNumber":22,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7b5173f6414b24bfd6b67e9ff42ba3b81af28efc896746bd39cf05806d403813","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2025-11-17","documentId":84173,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020263s057lbl.pdf","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7e76378513f01941d5024de1427d9ed1147b35324185a0ebf0fdf746c2b368cf","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2025-11-17","documentId":84174,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020263s057lbl.pdf#page=26","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"36896535fcc6dc500aec98505a19ab7db1a1ea312881aa78d52dcc04fe9f55d5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA020263","documentDate":"2025-11-18","documentId":84181,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/020263Orig1s057ltr.pdf","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"91dc4f1bedd7d41aa35f2f4539f8af1a10678129f7a5f094bfab643847d601aa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2025-11-24","documentId":84279,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"daac800cd8d4279cf16bd4917f5828ae0dc7c572eb67d832fe0207e823fbc566","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2025-11-25","documentId":84296,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"150035c87b27b408bc7a06789260d30dbc4266ff923f0eb2921adb027d152f30","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2026-03-02","documentId":84393,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208743s017lbl.pdf","submissionNumber":17,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dd08e32aa435586864c9b9d1464341a266d6553e7235fb27a44cc5258a7e6b07","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2025-12-23","documentId":84499,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c72502b59957073d3af717a3be9e51c00d3bb67f1768de9524ef67f28adddd4f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2025-12-23","documentId":84507,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bb971ed53abd429858d52674af05e55c28dade83ba7c94be990bd235a36255f2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2025-12-23","documentId":84514,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215866Orig1s039ltr.pdf","submissionNumber":39,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c1c86e93bb20aef2e2dc3ee99e65f12f6bb40f749e9c0b39f548a57f508483e5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2025-12-23","documentId":84543,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218316Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c507ae6656f134c15b2e76e22d1539ffc6aba5ae6d00e209b81cb74c1f6ba1b6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-01-08","documentId":84715,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s037ltr.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4afd457206400f43d2fafa60786bb2d3f2210c43372f075922e99a78d833dde0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2026-01-08","documentId":84716,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s041ltr.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d76fe187e61d13b6e236d3d93f0f4a87e565fd74427f6eca786a765e62747c55","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2026-01-08","documentId":84721,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c05775ecae33b19c087bdeebcc7ae10fcc1cf1f6b52b40b9b8515ec4a34cc80e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2026-01-08","documentId":84722,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf#page=24","submissionNumber":41,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c15e154e328682c7ed0b0fd55cb4eab4c50f3702b0432f5f2718c2ad9737da56","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-01-08","documentId":84723,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6c9656b76257893dbaf0ab1e772f9854aa32befe4d23a57d82d17c14ca032a05","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-01-08","documentId":84724,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s037lbl.pdf#page=32","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f0c5eec1bdf2f7a2f22ebb3d804011dd8074e9234be1d7df0105b8e88f30347a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2026-01-21","documentId":84787,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"070c019b99b012d92da404ebbd175ae515c83b655215c9b0fa7ceafbcd1eb56d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2026-01-21","documentId":84788,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b84d28c848e813293781dc75c33f665efbe3413c40a3a24ee916dd9b6c330122","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-01-21","documentId":84790,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0ffc926724fd0c24599d658d6b7595e15091b4f15a734108590cfc97b09f07a2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-01-21","documentId":84791,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0ed6e242e763c9b06063fa1a5ce6de56049bbc7f46845179987b5df7b7b117e2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-01-21","documentId":84795,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"d40054ef875a43c02f13f4db86b320544ea61621186a3ea08485d9315565233d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-01-21","documentId":84796,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf#page=34","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5c9eab7f0b791fdcbd861d189dbfe73a7ca192ad35e238a5709cbb11f210398a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2026-01-21","documentId":84797,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"929a1255489b17709c20f8cd05ef158ecb66feb3567959ca0e7b8baaa4218bea","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215866","documentDate":"2026-01-21","documentId":84798,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf#page=25","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3751a664d91195222953f5623293b51bfe91041f179729f75b75d327b1aade35","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-01-30","documentId":84885,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215256Orig1s030;218316Orig1s002ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5b0e078c7f235f4703af2b08f70ddef35854575369b4a133cd521a6a5d2ad893","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-01-30","documentId":84886,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215256Orig1s030;218316Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"32c33909e65f9b53b584cdc7592ffbf91ca6e83652dcbbd98b287b1091432463","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2026-02-03","documentId":84895,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5d469e3a799f2aa797c26d3c0889beba5f3870c4cb8a770a8140b19e9734ae5b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-02-05","documentId":84941,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ed0c97727e5e26435bcdc09b1fa3b81d80e865cb48b9571c776a9e8d263d9325","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-01-29","documentId":84943,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s030lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"9a741973a72a1ab7865dd377b68b7f3c3c2a6e7be96a22268d261d08a4bed1e5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213051","documentDate":"2026-07-31","documentId":84949,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051Orig1s030lbl.pdf","submissionNumber":30,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cbd118e72797ee73d73405d92d9664dfcb4cc339a37ec3917de8fd58dfe4b88d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2026-02-24","documentId":85118,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/209637Orig1s032.pdf","submissionNumber":32,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"790df90fa34771a32038bfafe438f9f1930406f0bde960b0c86f17638f0a46d8","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2026-02-24","documentId":85119,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/209637Orig1s035.pdf","submissionNumber":35,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3227d58aae8a3eb0896b69d6ae4862736e435c93a2d3ec98f4a3f8611f169c9e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2026-02-24","documentId":85146,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/209637Orig1s037.pdf","submissionNumber":37,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"17316036be0bf466fb4f735f6b6062e14632090d04fe468237680a62916887b0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2026-02-27","documentId":85176,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/206321Orig1s025ltr.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a75f3018b6f4d51e3f3c38f3bc58c4fa8e0e31c739864ccd69af31bc5400222d","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-02-27","documentId":85178,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215256Orig1s033,218316Orig1s004ltr.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"baae01e851d983b746ab9db96f72bbc294f361621bc7bfe3ff408fbc70ab250a","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-02-27","documentId":85179,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215256Orig1s033,218316Orig1s004ltr.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"bccfa156aa436969993d17f46c48b83b815c4beb01f79a24b1b6b9f3c7a010c0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-02-27","documentId":85180,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s042ltr.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6a1498b11dfbbf9ff9903f3a8c002cfc3b19e1a524231bb74522426fdcb5f920","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2026-03-02","documentId":85188,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8e1cefdcbe378abf9d1336ab1f1f72854528087a786a5b39c565efca095b4fb2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-03-02","documentId":85190,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf","submissionNumber":33,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0bacf1b9fb6e1157a531a4ebd5a5f9ac2b46bcd8879d747e51065bec4a119db0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-03-02","documentId":85191,"documentType":"Label","documentTypeId":2,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf","submissionNumber":42,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"34d51c908908275a0b0ade622779d0caee75ec4e5d859e52efe00fc58739acc2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-03-02","documentId":85194,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s004lbl.pdf","submissionNumber":4,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ff438da1539003a0c8a07ca18292d367872881cede9054e634cc1e8081e667be","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2026-03-16","documentId":85373,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/125469Orig1s065ltr.pdf","submissionNumber":65,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7756b1a1e83c63d2ddce41e9cb14908a73c9e5b65506db128883637050ac737b","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2026-03-16","documentId":85374,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/208471Orig1s012ltr.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"256c279ab4dd17db7446d733af1928a1ec77b9a778cd1682042af8977ed9729b","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2026-03-18","documentId":85385,"documentType":"Label","documentTypeId":2,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125469s065lbl.pdf","submissionNumber":65,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a1efcdb90bb82566803a9ed56d10831ebf6a9f530f56919a6cc6f19b97759a84","publishedAt":"2026-08-24"},{"applicationNumber":"BLA125469","documentDate":"2026-03-12","documentId":85386,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["dulaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125469s065lbl.pdf#page=32","submissionNumber":65,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"78741d7377199fdc7746650526219a6ce379b928dedbbe11ace1e1c161abd9ff","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2026-03-18","documentId":85387,"documentType":"Label","documentTypeId":2,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208471s012lbl.pdf","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"15a2d7d719b064ab7d28ae8c0494d187a8c15e52914a456fb68d0c40b66c5aa3","publishedAt":"2026-08-24"},{"applicationNumber":"BLA208471","documentDate":"2026-03-12","documentId":85388,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["lixisenatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208471s012lbl.pdf#page=25","submissionNumber":12,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"21c095cbc59b55628e5719687f7b88548a9d2de6d4340e7d2128d8b46fa78a1c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2026-03-23","documentId":85450,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213793Orig1s009ltr.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"33d4aa844529dc3466d48b79aa394a0f7b1202893a9a7f1c3236058ca615bc9c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-03-23","documentId":85452,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215256Orig1s029;218316Orig1s005ltr.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"2ad66d0ae6a8162f75a30da6ea0b99e1acb7d3b0dd9813500f4d6f72ceacc224","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-03-23","documentId":85453,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215256Orig1s029;218316Orig1s005ltr.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"cbd66391102bc3cd7d774157ed15168b5a6c88a179369b6cf6f9da825283db58","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-03-24","documentId":85499,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ea93d93eb9f1d96b15c78a1e799c4995c04393e75b32fe4caec4dfd183a84158","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-03-24","documentId":85500,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s005lbl.pdf","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1ae0923801f2ef45c156d1a7bc84041e18b59e5ff6eb27e52c2f3a6b5620d73e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA213793","documentDate":"2026-03-24","documentId":85504,"documentType":"Label","documentTypeId":2,"peptideSlugs":["setmelanotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf","submissionNumber":9,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b3293042608bda1de5648be62eadb43b413a54557d3459f135b54edd903c2083","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-03-24","documentId":85515,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf#page=51","submissionNumber":29,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b91ed40083c89eee8dd6491c462c81719cc54aa323d35c83096b692f50145fd1","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-03-24","documentId":85516,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s005lbl.pdf#page=51","submissionNumber":5,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b7f81779340654c346480c8d376610e5b3c82413e6a0efd7f8cfdcb39e98d182","publishedAt":"2026-08-24"},{"applicationNumber":"BLA761412","documentDate":"2026-05-01","documentId":85798,"documentType":"Label","documentTypeId":2,"peptideSlugs":["insulin-glargine-aldy"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761412Orig1s000lbl.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"1024af5a86bdea3f642438e35957cbcaf58542fbec640d5490c35d1e1ffced08","publishedAt":"2026-08-24"},{"applicationNumber":"BLA761412","documentDate":"2026-05-01","documentId":85799,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["insulin-glargine-aldy"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761412Orig1s000ltr.pdf","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e6e97f11cc95bb08121976212981b5eeaeaaad33979ddbffb7fbca6717f7afe3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2026-05-08","documentId":85845,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/019010Orig1s044ltr.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0e42c8410756b0b8b4183c644749ecb50e9adbae84c7299e1159caf7aad67282","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2026-05-08","documentId":85852,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/021343Orig1s060,%20021379Orig1s065,%20021488Orig1s057,%20021731Orig1s062ltr.pdf","submissionNumber":60,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"471b86521e343cf4c7f16f1e03ca94d7a7358dda31231847563c43d3c39ee18b","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2026-05-08","documentId":85853,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/021343Orig1s060,%20021379Orig1s065,%20021488Orig1s057,%20021731Orig1s062ltr.pdf","submissionNumber":65,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"18bd39ed31fa60f2b46bae2386aeaa1a1df43661c60a72f29382939dcfe2d5c5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2026-05-08","documentId":85854,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/021343Orig1s060,%20021379Orig1s065,%20021488Orig1s057,%20021731Orig1s062ltr.pdf","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"46694022bcade44de8019324fdd8af711aa2e1a282444ed9cd81253f0a1ca2e3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2026-05-08","documentId":85855,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/021343Orig1s060,%20021379Orig1s065,%20021488Orig1s057,%20021731Orig1s062ltr.pdf","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"7c2e915544e4584600540f3c7b5359645b4082d1548702954f19f4e268196ad3","publishedAt":"2026-08-24"},{"applicationNumber":"NDA217806","documentDate":"2026-05-11","documentId":85860,"documentType":"Review","documentTypeId":3,"peptideSlugs":["tirzepatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/217806Orig1s013.pdf","submissionNumber":13,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e7d0fc7fa0852594743b4788f77c211568dfd4c561f65fb41fdb3667eaa80ebc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA019010","documentDate":"2026-05-12","documentId":85882,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/019010s044lbl.pdf","submissionNumber":44,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"da29055b282bebb62947fab3945c0e1ca392b6bf3d4c17f8dee76e9ccb5f2bee","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021343","documentDate":"2026-05-12","documentId":85887,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021343s060lbl021379s065lbl021488s057lbl021731s062lbl.pdf","submissionNumber":60,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"18d4efb2f2203a3d6b2e9d4cadaeadd9b87567de91a40100f4ab41d30487a80f","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021379","documentDate":"2026-05-12","documentId":85888,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021343s060lbl021379s065lbl021488s057lbl021731s062lbl.pdf","submissionNumber":65,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a6d0836c01bfa90525f6a3211915bb07bd7b41ed2d855bf0660e634082d2c75c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021488","documentDate":"2026-05-12","documentId":85889,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021343s060lbl021379s065lbl021488s057lbl021731s062lbl.pdf","submissionNumber":57,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"3009072b2cac75b4ca6a00181711668883ab445fce49d07dd29e95c6178763fa","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021731","documentDate":"2026-05-12","documentId":85890,"documentType":"Label","documentTypeId":2,"peptideSlugs":["leuprolide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021343s060lbl021379s065lbl021488s057lbl021731s062lbl.pdf","submissionNumber":62,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b7aae6aff0004bdd425007b965b6642562a10d0be175d0cf6fe63f389f482f4e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-05-12","documentId":85892,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"30e45c95ba036d1a5769b43c5e5e7f6a29f6c2be5cd8485d42690b4df7959246","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-05-12","documentId":85893,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf","submissionNumber":3,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"ccbf6500b8dcd4a0caabe49f48ac8b41ad1cf8ae4e768de14e5b12cfc928d85e","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2026-05-26","documentId":86021,"documentType":"Label","documentTypeId":2,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202811s023lbl.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c8c17c064cf9122467c5568f29cc60c4ec46a0506be3ddc7cc1e160097cc9d17","publishedAt":"2026-08-24"},{"applicationNumber":"NDA202811","documentDate":"2026-05-26","documentId":86022,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["linaclotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/202811Orig1s023ltr.pdf","submissionNumber":23,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"4a0a0b719d8b212a3fba097ba26efae70eb69c03b6e0be93ae34c3711f259583","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2026-06-02","documentId":86129,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/209637Orig1s038ltr.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b0ed3c4bb273436003b97ba10e077921278951c7b74b0c6eac013a4a773573f2","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2026-06-03","documentId":86137,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/206321Orig1s024ltr.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"f64749b856b9f470940c95f3d58b1505f43b2f929051188c71b3cdd4bfe0be21","publishedAt":"2026-08-24"},{"applicationNumber":"NDA206321","documentDate":"2026-08-19","documentId":86172,"documentType":"Label","documentTypeId":2,"peptideSlugs":["liraglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321Orig1s024lbl.pdf","submissionNumber":24,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b43b11851c21713165270edff075e9bcb5580b97026649d27b936d5bb01b11a5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA209637","documentDate":"2026-06-10","documentId":86202,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf","submissionNumber":38,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"418b3e88a0c15badfece7d018c6b0b4acac1cabfdf5102563c538900ec039eda","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-06-23","documentId":86339,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf","submissionNumber":25,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"fbe1dce5cff67557194de0073a853fa1bfa61154255dae9ccb4d6b44dcc39ce0","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218316","documentDate":"2026-06-23","documentId":86340,"documentType":"Label","documentTypeId":2,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf","submissionNumber":7,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"a3f0038d2fdc7c8444e40e77a632063fb64fa16d4c98f9c359ad659303dd6cf6","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208232","documentDate":"2021-03-11","documentId":86527,"documentType":"Review","documentTypeId":3,"peptideSlugs":["octreotide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/208232Orig1s000TOC.html","submissionNumber":1,"submissionType":"ORIG","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"b329359b1322c4db4fb55fd29bf4554f6df2baae57c4bdbc22d344ffae1fb161","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2026-08-06","documentId":86819,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/021318Orig1s059ltr.pdf","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"c0cf29fdfe4ec73715b0d74a380b248ae5759c4d4b8347bf1b22fd1fe03a4309","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2026-08-06","documentId":86821,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/208743Orig1s018ltr.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"110e98e7b7eb2bfb86f280b89d6ed431e0ded37ec47c9631d701d589720c193c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2026-08-06","documentId":86823,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/218771Orig1s002ltr.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"187575a60ad9c1404ed7bb98e970f67de43a4042cc1428d7e35e28050ecdf7f5","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2026-08-06","documentId":86825,"documentType":"Letter","documentTypeId":1,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/211939Orig1s021ltr.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e02b43d53237a3e2bb795c24227e91c7a17214a1b9820b15910a0afdc640620c","publishedAt":"2026-08-24"},{"applicationNumber":"NDA215256","documentDate":"2026-08-07","documentId":86830,"documentType":"Review","documentTypeId":3,"peptideSlugs":["semaglutide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/215256Orig1s031.pdf","submissionNumber":31,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"6d6501653a4cac86ddf243b497b85a82e72488c3aa56ac2c9c3475abbea9c1cb","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2026-08-11","documentId":86844,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021318Orig1s059lbl.pdf","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"68eb96f58a5e2e25d7e24bcafd5d39feb2f9d3b82dffee354fce113b84e95513","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2026-08-11","documentId":86852,"documentType":"Label","documentTypeId":2,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208743s018lbl.pdf","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"71422b8f9403cc3ea1bab5c7c6f72700f55c86f3c4e096c04914f85406c16029","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2026-08-11","documentId":86853,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211939s021lbl.pdf","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"e60ce0f3117f87b8d071f29fabcb09272b0f36bc15d2d16a0b70d7c62e5b85dc","publishedAt":"2026-08-24"},{"applicationNumber":"NDA021318","documentDate":"2026-08-11","documentId":86854,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021318s059lbl.pdf#page=17","submissionNumber":59,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"5163ab6247f289547bea91a6a296d6519895fd1c32129db289ca085b34a64963","publishedAt":"2026-08-24"},{"applicationNumber":"NDA208743","documentDate":"2026-08-11","documentId":86855,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["abaloparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208743s018lbl.pdf#page=22","submissionNumber":18,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"8089599bdcbb5fab5e094e780e97e88f32870eae22b24aab6bcb79264e7ccdac","publishedAt":"2026-08-24"},{"applicationNumber":"NDA211939","documentDate":"2026-08-11","documentId":86856,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211939s021lbl.pdf#page=22","submissionNumber":21,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"321b192d5c4be8f33fc7d3630a982147ae9b6546031425f27ec0b8c8de65f209","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2026-08-11","documentId":86857,"documentType":"Label","documentTypeId":2,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218771s002lbl.pdf","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"dafa4b4bd868a7687ea5cbf68f236f5fc4a6afc764133d6b7a35ee78b4028943","publishedAt":"2026-08-24"},{"applicationNumber":"NDA218771","documentDate":"2026-08-11","documentId":86858,"documentType":"Medication Guide","documentTypeId":8,"peptideSlugs":["teriparatide"],"schemaVersion":"tier-a-fda-regulatory-document/v1","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218771s002lbl.pdf#page=20","submissionNumber":2,"submissionType":"SUPPL","observedAt":"2026-08-24T21:23:49.000Z","recordSha256":"0f0ed12bb79ba85165bac5a3cf9ea4b31e3ce180ace10cc3ea9faffc210e5363","publishedAt":"2026-08-24"}],"urls":{"json":"https://peptidescanner.com/fda-regulatory-history/v1/history.json","markdown":"https://peptidescanner.com/fda-regulatory-history/v1/history.md"},"integrity":{"algorithm":"sha256","contentSha256":"801ff6a8bfaf4efc642cfac1da27da51a6b86f729530806c732b7cc32c06286f"}}